Improving the oral bioavailability of drugs through the design of modeled pre-systemic cytochrome P450 inhibitors by Fasinu, Pius Sedowhe
i 
 
IMPROVING THE ORAL BIOAVAILABILITY OF DRUGS 
THROUGH THE DESIGN OF MODELED PRE-SYSTEMIC 
CYTOCHROME P450 INHIBITORS 
 
 
Pius Sedowhe Fasinu 
 
A dissertation submitted to the Faculty of Health Sciences, 
 University of the Witwatersrand, in fulfillment of the requirements for the degree of 
Master of Science in Medicine  
 
 
 
 
Supervisor: 
Professor Viness Pillay, Department of Pharmacy and Pharmacology,  
University of the Witwatersrand, South Africa 
 
Co-Supervisor: 
Dr Yahya Essop Choonara, Department of Pharmacy and Pharmacology,  
University of the Witwatersrand, South Africa 
 
 
Johannesburg, 2010
  
i 
 
DECLARATION 
I, Pius Sedowhe Fasinu declare that this dissertation is my own work. It is being submitted 
for the degree of Master of Science in Medicine in the field of Pharmaceutics in the 
Faculty of Health Sciences at the University of the Witwatersrand, Johannesburg, South 
Africa. It has not been submitted before for any degree or examination at this or any other 
University. 
 
 
 
 
………………………………… 
Signature 
 
 
………………………………… 
Date 
  
ii 
 
RESEARCH PUBLICATION AND PRESENTATIONS 
PUBLICATIONS 
Review: Advances in the Approaches for Enhancement of Oral Drug Bioavailability. 
Pius Fasinu, Viness Pillay, Valence Ndesendo, Lisa du Toit and Yahya Choonara.  
Submitted to Biopharmaceutics and Drug Disposition, USA 
 
A  Study of the Novel Computationally Modeled Cytochrome P450 3A4 Inhibitors. 
Pius Fasinu, Viness Pillay, Yahya Choonara, Lisa du Toit and Riaz Khan. 
To be submitted 
 
Investigation of the Oral Bioavailability-Enhancing Property of 8-arm-poly(ethylene glycol), 
a Novel Computationally Modeled Cytochrome P450 3A4 Inhibitor 
Pius Fasinu, Viness Pillay, Yahya Choonara, Lisa du Toit and Leith Meyer. 
To be submitted 
 
 
  
iii 
 
PODIUM PRESENTATIONS 
A Novel Application of Computational Modeling in Biomodulation: Pharmaceutical Grade 
Polymers Inhibits In Vitro CYP3A4-Catalysed Felodipine Metabolism.  
Pius Fasinu, Viness Pillay, Yahya Choonara and Lisa du Toit  
The 2nd Annual Cross Faculty Postgraduate Research Symposium, University of the 
Witwatersrand, Johannesburg, South Africa, 20th -21st October, 2009 
 
An In Vitro Investigation of the Effects of CYP3A4 Inhibiting Flavonoids on CYP1A2-
catalysed Phenacetin O-deethylation Employing Human Liver Microsomes 
Pius Fasinu, Viness Pillay, Yahya Choonara and Lisa du Toit 
The Postgraduate Research Day, School of Therapeutic Sciences, University of the 
Witwatersrand, Johannesburg, South Africa, 12th August, 2009.  
  
iv 
 
POSTER PRESENTATIONS 
Optimization of the In Vitro Metabolism of Dihydropyridines by Human Liver Microsomal 
Enzymes. 
Pius Fasinu, Viness Pillay, Yahya Choonara and Lisa du Toit.  
The American Association of Pharmaceutical Scientists’ (AAPS) Annual Meeting and 
Exposition, 7th-12th Novermber, 2009. 
 
CYP1A2-Mediated O-deethylation of Phenacetin to Produce Paracetamol: In Vitro 
Optimization and Determination of Kinetic Parameters. 
Pius Fasinu, Viness Pillay, Yahya Choonara and Lisa du Toit. 
The 5th International Conference on Pharmaceutical and Pharmacological Sciences, 
North-west University, Potchefstroom, South Africa, 23th – 26th September, 2009. 
 
In vitro Investigation of the Effects of Quercetin, Naringin and Naringenin on the 
Metabolism of Felodipine by Human Liver Microsomes.  
Pius Fasinu, Viness Pillay, Yahya Choonara and Lisa du Toit. 
The 5th International Conference on Pharmaceutical and Pharmacological Sciences, 
North-west University, Potchefstroom, South Africa, 23th – 26th September, 2009. 
  
v 
 
PATENTS 
Improving the Oral Bioavailability of Drugs through the Design of Modeled Pre-Systemic 
Cytochrome P450 Inhibitors. 
Pius Fasinu, Viness Pillay, Yahya Choonara and Lisa du Toit, South Africa, Patent 
Application filed, awaiting priority date. 
 
  
vi 
 
ABSTRACT 
The poor bioavailability of drugs has been identified as the single most important 
challenge in oral drug delivery. Prominent among the factors responsible for this are the 
metabolic activity of the intestinal and hepatic cytochrome P450 enzyme family. This 
dissertation presents novel cytochrome P450 inhibitors generated through the application 
of computational modeling of known cytochrome P450-substrate and cytochrome P450-
inhibitor interactions. In vitro metabolism of felodipine by cytochrome P450 3A4-
expressed human liver microsomes was optimized yielding a typical Michaelis-Menten 
plot through the application of Enzyme Kinetic Module software from where the enzyme 
kinetic parameters were determined. Quercetin, naringin and naringenin which are the 
major phytochemical component of grapefruit juice, a well known cytochrome P450 3A4 
inhibitor, were separately incubated in human liver microsomes together with felodipine at 
concentration equivalent to the determined Michaelis-Menten Constant (Km) value. 
Compared to verapamil, a known competitive inhibitor of cytochrome P450 3A4, all three 
flavonoids inhibited felodipine metabolism with IC50 values of 208.65, 177.81 and 
121.97µM respectively confirming earlier suggestions that the flavonoid contents of 
grapefruit juice are responsible for known grapefruit-drug interactions. Following a 
detailed study of the quantitative structure-activity relationship of these flavonoids and 
verapamil, their binding properties with cytochrome P3A4, the amino acid sequence and 
binding affinity of cytochrome P3A4, computational modeling software on a non-silicon 
graphic system was employed to generate pharmaceutical grade and commercially 
available polymers based on activity prediction aided by computational biomimetism and 
simulations. Thus grapefruit-felodipine interaction (a typical cytochrome P3A4 inhibitor-
substrate interaction) served as the basis for the computational modeling where several 
modeled compounds including 8-arm-poly(ethylene glycol), o-(2-aminoethyl)-o-methyl 
poly(ethylene glycol), 4-arm-poly(ethylene glycol) (MW=10000g/mol and 20000g/mol) and 
poly (L-lysine) were generated and investigated for inhibitory activity against felodipine 
metabolism by human liver microsomes and human intestinal microsomes where 8-arm-
poly(ethylene glycol) demonstrated the highest inhibitory potency with an IC50 value of 
7.22µM. An ex vivo method employing freshly excised pig intestinal tissue was developed 
and validated to investigate the inhibition of cytochrome P450-induced drug metabolism in 
living tissues. Both naringenin and 8-arm-poly(ethylene glycol) exhibited significant 
inhibitory effects against felodipine metabolism in pig intestinal tissues. The ex vivo 
studies yielding IC50 values of 179.88 and 487.75µM for naringenin and 8-arm-
poly(ethylene glycol) respectively demonstrated a promising in vivo inhibitory activity 
against intestinal cytochrome P450 3A4. The potential utility of 8-arm-poly(ethylene 
glycol) in oral drug delivery was investigated by assessing its influence on the formulation 
and behavior of tablet matrices. Results showed that 8-arm-poly(ethylene glycol) 
possessed satisfactory compressional, binding and friability characteristics with 
acceptable drug release profiles. In vivo studies of the effects of 8-arm-poly(ethylene 
glycol) on the oral bioavailability of felodipine were performed on the Large White pig 
model. Compared to controls, a >100% increase in plasma felodipine levels was 
observed. The outcome of this research presents 8-arm-poly(ethelyne glycol) as a 
promising oral bioavailability enhancer. 
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CHAPTER ONE 
INTRODUCTION AND MOTIVATION FOR STUDY 
 
 
1.1. Background of this Study  
 
The desired site of drug action, systemic or localized, is a major factor for consideration in 
deciding the route of drug administration. Systemic routes of drug administration are 
traditionally classified into enteral and parenteral routes (Hughes et al., 2005). Enteral 
routes are those involving the gastrointestinal tract (GIT) which include oral ingestion, 
sublingual, buccal and rectal administration while parenteral drug delivery routes include 
intra-arterial, intravenous, intrathecal, intramuscular, intracardiac, cutaneous and 
subcutaneous injections, surgical site-specific implantations, and inhalational routes 
(Yadav and Prakashan, 2008). Drugs intended for local actions are administered through 
topical application on the skin and mucosal membranes of the eye, ear, rectum and the 
anus. The choice of route of drug administration is decided by a number of factors 
including the physicochemical properties of the drug, biopsychosocial condition of the 
patient, the desired site and onset of drug action, dosage frequency as well as ease and 
convenience of administration (Strang et al., 2006). For toxicological considerations, the 
possibility of reverse administration like gastric lavage and stimulation of emesis are 
extreme considerations in the choice of route of drug administration (Rathbone et al., 
1994). The choice of route of drug administration has a significant influence on patient 
compliance, therapeutic efficacy and manifestation of side-effects (Liu et al., 1997; 
Sterling et al., 1997; Schwartzman and Morgan, 2004). 
 
Oral drug delivery remains the most favorable and preferred route of drug administration 
both by patient and physicians (Wong et al., 2006). Oral administration is generally 
accepted, easy and convenient; and offers the patient the possibility of self administration 
requiring no expertise (De Jong et al., 2007). Compared to injectables and implants, 
pharmaceutical products intended for oral administration are cheaper and currently >60% 
of drugs are marketed as oral products (Pretorius and Bouic, 2009). Researchers and 
pharmaceutical companies are increasingly aware of the need for earlier assessment of 
new drug entities for their potential as oral candidates (Davis and Wilding, 2001). The 
merits of new drugs are measured in their delivery convenience in addition to their 
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therapeutic efficacy (Breimer, 1999). The possibility of self-administration, patient 
compliance and less risk of irreversible side-effects has placed the oral route as a 
standard in drug delivery (Sastry et al., 2000; Tong, 2007). 
 
1.1.1. Barriers to oral drug administration 
The most significant limitation to oral drug administration is the resulting poor systemic 
bioavailability of various drugs as a result of first-pass metabolism (DeMario and Ratain, 
1998; Veber et al., 2002). In numerous instances, significant allowances are made for 
pre-systemic drug loss in the design of the dosage regimen and the drug delivery system. 
Previous studies on structurally diverse drugs have also revealed that subject 
variableness in bioavailability was indirectly proportional to the extent of bioavailability 
which implies higher subject variability for poorer bioavailable drugs (Hellriegel et al., 
1996; Gidal et al., 2000; Ezzet et al., 2005). This variation and the resulting poor control of 
plasma drug concentrations would particularly be of concern for drugs that have a narrow 
therapeutic window or a precipitous dose-effect profile (Aungst, 2000). Prominent among 
impediments to oral absorption are intestinal efflux proteins (Chan et al., 2004; Takano et 
al., 2006; Yamagata et al., 2007), physicochemical stability of the drug in the various 
compartments of the gastrointestinal tract (Tong, 2007), insufficient contact time in transit 
(Severijnen et al., 2004), poor permeability across the gastrointestinal mucosa (Thanou et 
al., 2001; Wu and Benet, 2005) and digestive and metabolic enzyme activity (Jeong et al., 
2005; Cao et al., 2006). The extremely poor solubility of certain drugs such as the 
bisphosphonates can make their oral delivery difficult. This challenge is even greater 
when the required dose is high (Veber et al., 2002; Hu et al., 2004).  
 
In addition to digesting and absorbing nutrients, the GIT wall forms a physiological barrier 
against the invasion of foreign substances including pathogens, antigens, toxins and 
poisons (Brenchley and Douek, 2008). This barrier comprises the cell membranes, tight 
junctions between adjacent epithelial cells, the mucus layer, catabolic enzymes and the 
efflux proteins that propel molecules back into the GIT lumen after oral administration 
(Wang et al., 2005). Drug molecules are often recognized as foreign substances and 
therefore, the absorption of drug is also inhibited (Hamman et al., 2007). Overcoming 
these challenges in oral drug delivery has been one of the most challenging endeavors 
facing the pharmaceutical industry for decades.  
 
When drugs are administered orally, apart from their exposure to possible physical 
degradation, chemical inactivation or microbial biotransformation, the anatomical 
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proximity of the liver to the GIT necessitates the passage of absorbed drug through the 
liver where drugs are metabolized to varying degrees by a process known as the first-
pass effect (Gibaldi et al., 1971; Kwan, 1997; Back and Rogers, 2007). The most 
important of all the factors responsible for poor oral drug bioavailability is the cytochrome 
P450 (CYP)-mediated first-pass metabolism. In a few cases, >90% of administered drug 
is lost to pre-systemic metabolism (Ghilzai, 2004; Hamman et al., 2005; Leonard et al., 
2006; Majumdar and Mitra, 2006). The human CYP enzyme system present in the 
intestines and liver is responsible for the metabolism of a wider range of drugs (Fang and 
Xiao-yin, 2005). A sub-family of this enzyme system CYP 3A is responsible for the 
metabolism of >50% of marketed drugs to a large extent (Rendic, 2002). The ability of 
CYP3A to metabolize numerous structurally unrelated compounds apart from being 
responsible for the poor oral bioavailability of numerous drugs is responsible for the large 
number of documented drug-drug and drug-food interactions (Quintieri et al., 2008). 
Successful inhibition of the metabolic activity of these enzymes on orally administered 
drug may enhance the drug oral bioavailability.  
 
Various strategies have been employed to improve the systemic availability of orally 
administered drugs (Gomez-Orellana, 2005). The principles are generally based on the 
modification of the physicochemical properties of the drug (Delie and Blanco-Prieto, 
2005), addition of novel functionality to the molecular structure of the drug to enhance 
intestinal wall penetration (Hajduk and Greer, 2007) and modification of pharmaceutical 
formulation technology by the use of novel drug delivery carrier systems such as 
microparticles (Muhrer et al., 2006; Ozeki et al., 2005), nanoparticles (Moharanj and 
Chen, 2006; Bawarski et al., 2008) and dry emulsions (Morishita and Peppas, 2006). 
 
Due to changes in the composition and thickness of the GIT mucus layer, the GIT 
regional pH as well as the surface area and enzyme activity, certain drugs undergo site-
specific absorption (Hamman et al. 2005). The most significant site of GIT drug absorption 
is the small intestine (Lacombe et al. 2004, Masaoka et al., 2006). Although the small 
surface area and short residence time of most drugs in the stomach limits gastric 
absorption, gastro-retentive drug delivery systems have been used to enhance the local 
action of drugs in the stomach such as anti-diarrheals (Connor et al., 2001), antacids 
(Fabregas et al., 1994), anti-ulcer agents like misoprostol (Oth et al., 2004), and to 
facilitate absorption of furosemide in the stomach and the upper small intestine (Streubel 
et al. 2006). Gastroretentive drug delivery systems are also crucial for drugs such as 
captopril and ranitidine that are unstable in the intestine and colon (Drummer and Jarrott, 
2006), and diazepam that exhibits low solubility at high pH values (Castrol et al. 1999). 
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Site specificity in drug absorption also involves the use of enteric coating to delay the 
release of drug until it reaches the small intestine. Various polymers which dissolve at a 
pH range of 5-7 have been used to target the delivery of drug to the intestines while those 
that degrade above a pH value of 7 have been used to target colonic drug delivery in 
diseases such as colitis (Rubinstein, 2005). Colonic absorption may be enhanced due to 
a reduced concentration of enzymes such as peptidases that degrade peptide drugs, long 
residence times, high sensitivity to absorption enhancers, natural absorptive 
characteristics and the abundance of lymphoid tissue follicles in the colon (Yang et al., 
2002). 
 
Most of these various approaches have been successfully employed to improve oral drug 
delivery which has often translated in enhanced drug absorption. The challenges of poor 
oral bioavailability are still prominent despite these breakthroughs. This is because CYP-
induced metabolism is the single most important of all the factors responsible for poor oral 
bioavailability of drugs (Benet and Cummins, 2001) and to date, no commercially 
available formulation is known to inhibit CYP-induced first-pass metabolism. 
 
1.1.2. Specific cytochrome P450 enzymes involved in drug metabolism 
The CYP superfamily is generally involved in oxidative, peroxidative and reductive 
biotransformation of xenobiotics and endogenous compounds (Nebert and Russell, 2002). 
It is conventionally divided into families and subfamilies based on nucleotide sequence 
homology (Zeldin and Seubert, 2008). There is a high degree of substrate specificity 
among the various families. CYP belonging to the families 1, 2 and 3 are principally 
involved in xenobiotic metabolism while others play a major role in the formation and 
elimination of endogenous compounds such as hormones, bile acids and fatty acids 
(Hedlund et al., 2001; Norlin and Wikvall, 2007). The most important CYP subfamilies 
which are majorly responsible for drug metabolism in humans are 1A2, 2A6, 2C9, 2C19, 
2D6, 2E1, 3A4 and 3A5 (Ono et al., 1996).  
 
CYP1A1 and 1A2 are the two major members of the human CYP1A subfamily. CYP 1A1 
is mainly expressed in extra-hepatic tissues such as the kidney, the intestines and the 
lungs while CYP1A2 constitutes about 15% of total hepatic CYP. CYP2B6 is involved in 
drug metabolism while most other members of the CYP2B subfamily play less significant 
metabolic roles. The subfamily 2C is the second most abundant CYP after 3A 
representing over 20% of the total CYP present in the human liver. It comprises three 
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active members: 2C8, 2C9 and 2C19 all of which are also involved in the metabolism of 
some endogenous compounds including retinol and retinoic acid.  
 
Few clinically relevant drugs including paracetamol, chlorzoxazone and enflurane are 
metabolized by CYP2E1, the most active of the 2E subfamily. CYP3A subfamily 
constitutes over 30% of the total CYP in the human body (although the levels may vary 
40-fold among individuals) with CYP3A4 being the most abundant of all isoforms highly 
expressed in the liver and the intestines and participates in the metabolism of about half 
of drugs in use today (Taavitsainen, 2001; Nelson et al., 2009). The specificity and 
selectivity of substrates and inhibitors for these enzymes are particularly useful in 
pharmacokinetic and toxicological studies. 
 
1.1.3. Known cytochrome P450 inhibitors 
As seen in Table 1.1, various drugs are able to inhibit the activities of the different CYP 
subfamilies. This explains the reason for many clinically known drug-drug interactions 
following competitive substrate binding and inhibitory actions of drugs on CYP enzymes. 
Other chemical compounds have been documented to exert inhibitory actions on CYP.  
 
Table 1.1: A list of common substrates and inhibitors of major CYP isoforms (Flockhart, 
2009). 
1A2  2C9  2D6  3A4  
Substrates Inhibitors Substrates Inhibitors Substrates Inhibitors Substrates Inhibitors 
 
Amitriptyline 
 
Mibefradil 
 
Diclofenac 
 
Fluconazole 
 
Carvedilol 
 
Quinidine 
 
Quinidine 
 
Indinavir 
Caffeine Cimetidine Ibuprofen Amiodarone Metoprolol Paroxetine Midazolam Nelfinavir 
Clomipramine Interferon Naproxen Fenofibrate Timolol Bupropion Felodipine Ritonavir 
Clozapine Furafylline Tolbutamide Fluvastatin Desipramine Duloxetine Nifedipine Itraconazole 
Olanzepine Ciprofloxacin Glipizide Isoniazid Imipramine Amiodarone Ritonavir Ketoconazole 
Estradiol Fluvoxamine Losartan Lovastatin Paroxetine Cimetidine Indinavir Saquinavir 
Fluvoxamine Amiodarone Irbesartan Probenecid Haloperidol Sertraline Tacrolimus Aprepitant 
Haloperidol Methoxsalen S-warfarin Sertraline Thioridazine Celecoxib Cisapride Verapamil 
Imipramine Enoxacin Torsemide Teniposide Fluoxetine Cinacalcet Astemizole Diltiazem 
Mexiletine Caffeine Tamoxifen Zafirlucast Flecainide Citalopram Verapamil Cimetidine 
Naproxen Echinacea Rosiglitazone Voriconazole Alprenolol Clemastine Simvastatin Amiodarone 
Olanzapine Verapamil Glyburide Flavonoids Lidocaine Cocaine Amlodipine Fluvoxamine 
Ondasetron Zileuton Fluvastatin Flavones Bufuralol Doxepin Quinine Gestodine 
Phenacetin Flavonoids Fluoxetin Fenofibrates Atomoxetine Hydroxyzine Estradiol Imatinib 
Propranolol Flavones Celecoxib Fluvastatins Codeine Ritonavir Lovastatin Milbefradil 
Riluxole  Amitriptyline Isonizid Tramadol Ranitidine Alfentanyl Mifepristone 
Ropivacaine  Phenytoin Sertraline Tamoxifen Methadone Cafergot Norfloxacin 
Tacrine  Meloxicam teniposide Sparteine Midodrine Buspirone Voriconazole 
Theophylline  Suprofen  Propanolol Ticlopidine Cocaine Quercetin 
Tizanidine  Glimepiride  Phenformin Haloperidol Dapsone Bergapten 
Verapamil  Glibenclamide  Oxychodone  Fentanyl Piperine 
Warfarin  Glimepiride  Ondasetron  Docetaxel Star fruit 
Zileuton  Lornoxicam  Nebivolol  codeine Efavirenz 
 
Bailey and co-workers (1998) reported an unexpected increase in plasma felodipine 
levels in a felodipine-alcohol interaction studies. Subjects had been given grapefruit juice 
to obscure the obnoxious taste of ethanol. This observation, on a further investigation was 
6 
 
absent with other common fruit juices. The pharmacokinetic profile of parenteral felodipine 
was not altered following concomitant consumption of grapefruit juice. It was thus 
concluded that certain phytochemical contents of grapefruit juice could have inhibited the 
CYP3A4-dependent pre-systemic metabolism of the dihydropyridine. Grapefruit juice 
produces similar effects with other CYP3A4 substrates including midazolam, testosterone, 
statins, nisoldipine, cisapride, cyclosporine, triazolam and nifedipine. It has been 
suggested also that the flavonoid and the furanocoumarins found in grapefruit juice are 
capable of modulating cytochrome-dependent metabolism (Hertog and Feskens, et al., 
1993; Ho, P. and Saville, D. 2001; Bailey et al., 1998; Kolars et al., 1991; Lown et al., 
1997 and Paine et al., 2008). 
 
Rotenone, a naturally occurring phytochemical used in insecticide formulations is known 
to inhibit CYP activity by interfering with the electron transfer of the heme iron (Sanderson 
et al., 2004). Photo-products of nitrobenzene, which are substrates to CYP3A4, have also 
been reported to competitively inhibit the metabolism of other substrates (Paula and 
Douglas, 1996). Other CYP3A4 inhibitors are resveratrol, a natural polymer, and 
tryptophan, an amino acid (Chun et al., 1999; Rannug et al., 2006).  
 
1.2. Rationale and Motivation for this Study 
 
The ability of administered drug to elicit the desired pharmacologic response and reverse 
or modify a disease condition is the ultimate goal of drug therapy (Chan and Holford, 
2001). Serum drug concentration determines the availability of drug molecules at their 
receptor site (Hammett-Stabler et al., 2002). Thus, the rate and extent of drug absorption 
(bioavailability) from the GIT is an important factor that determines the plasma 
concentrations of orally administered drug. With a general preference for the oral route of 
drug administration, first-pass drug metabolism has become one of the most singularly 
important considerations in drug delivery. Drug loss due to poor absorption and/or pre-
systemic metabolism is significant in certain cases such that oral delivery is practically 
impossible (Majumdar and Mitra, 2006). This has left researchers with two options: a 
search for new drugs capable of bypassing impediments of oral delivery or development 
of novel delivery systems to enhance the oral bioavailability of poorly bioavailable drugs. 
 
The search for new drug candidates is a lengthy, complex and usually an expensive 
adventure. Much success is reported for most new drug candidates in the processes of 
identification, synthesis, characterization, screening and assaying for therapeutic efficacy 
(Ulrich and Friend, 2002; Angell, 2005). These successes are however short-lived in most 
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cases as the drug development stage often reveals poor drug delivery properties, the 
same challenges with older drugs that prompted such researches. At this stage of new 
drug molecule development, an average expenditure of between US$802 million and 
US$1.9billion is incurred, lasting 10-15 years (Dimasi et al., 2003; Adams and Brantner, 
2006; Woodcock and Woosley, 2008).  
 
The development of novel drug delivery systems typified by recent breakthroughs in drug 
delivery (Kondoh et al., 2006; Liu et al., 2007) has further strengthened the belief that new 
drug candidates, most of which end up with similar delivery challenges might not offer all 
the desired solutions to the challenges encountered with the old ones (Lichtenberg, 
2001). Research attention therefore, in recent times is geared towards developing old 
drugs with emphasis on improvement on their delivery challenges (Gabizon, 2001).  
 
With regard to CYP3A4 substrates, the abundance of CYP3A4 in the intestines and the 
liver makes the oral bioavailability of its substrates extremely poor. An average of 80% of 
administered CYP3A4 substrates including dihydropyridines and statins are lost to first-
pass metabolism (Cockcroft and Wikinson, 2000). The choice of parenteral route for these 
drugs is more challenging especially in chronic use. In the particular case of felodipine, 
85% of the administered dose is lost to CYP3A4 mediated pre-systemic metabolism 
(Joseph, et al., 2003). Thus, successful inhibition of their pre-systemic activity presents 
the potential for improved oral bioavailability of drugs. In addition, the required oral 
dosage may be greatly reduced, thus enhancing patient convenience and compliance. 
This would translate in the reduction of production costs to manufacturers and a 
transferred economic and further medical benefit to the patient in terms of affordability 
and a lower manifestation of side-effects with more predictable drug outcomes and 
pharmacokinetic properties. 
 
Studies in this area have shown that certain chemical compounds including therapeutic 
agents, herbal extracts and phytochemicals are capable of inhibiting the metabolic activity 
of CYP3A4 (Table 1.1). This has been useful for understanding food-drug and drug-drug 
interactions. The ability of CYP inhibitors to also exert pharmacological action, however, 
limits their application in drug formulations for the sole aim of inhibiting CYP3A4. 
Grapefruit juice and its flavonoid contents are herbal products with non-uniform 
standards. Though commercially available, they exhibit various physiological actions 
including their antioxidant activity and are not approved by the United States Food and 
Drug Administration (FDA) for use in pharmaceutical formulations (Pietta, 2000). 
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Therefore, the novelty of this study is its intention to model pharmaceutical grade 
compounds on the chemical structure, structure-activity relationship and molecular 
binding properties of grapefruit flavonoids taking into consideration the amino acid 
sequence and binding properties of CYP3A4, with the aid of HyperChem 7.5 software 
(HyperCube Inc. Gainesville, FL, USA). The focus is to generate commercially available, 
USFDA-approved chemical substances which are physiologically inactive for possible 
inclusion in oral formulations with the aim of inhibiting the metabolism of CYP3A4 
substrates (Figure 1.1). The success of this study promises a breakthrough in improving 
the oral bioavailability of drug substrates of CYP3A4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Schematic illustrating a) the pre-systemic fate of drug administered via the 
oral route and b) an expanded intestinal view, with both showing the proposed sites of 
action of the modeled pre-systemic CYP inhibitors. 
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1.3. Aim and Objectives of this Study 
 
The overall aim of this study is to generate Modeled Pre-systemic CYP Inhibitors (MPCI) 
that are biocompatible, biodegradable and can be combined with various drugs in a single 
drug delivery system in order to improve the oral bioavailability of the drug. With a 
detailed study of the structure and the Qualitative Structure-Activity Relationship (QSAR) 
of flavonoids and verapamil, pharmaceutical grade and USFDA-approved compounds are 
intended to be computationally modeled through computational simulation and 
biomimetism, and screened for inhibitory activity against CYP3A4. This study considers 
the possibility of designing a commercializable drug-MPCI combination that will deliver 
drug to the systemic circulation with increased bioavailability. In order to achieve this aim, 
the specific objectives of this study would include: 
 
1. To optimize and validate an in vitro method of metabolism of CYP-specific substrates 
such as felodipine (CYP3A4-dependent) and phenacetin (CYP 1A2-dependent) 
employing Human Liver Microsomes (HLM) and to determine their enzymatic kinetic 
parameters. 
 
2. To verify the in vitro inhibitory activity of quercetin, naringin and naringenin on the 
metabolism of CYP-specific substrates such as felodipine and phenacetin by HLM in 
comparison to that of verapamil. 
 
 
3. To model pharmaceutical entities (MPCI) with the potential of inhibiting the pre-
systemic metabolic activity of CYP3A enzymes. 
 
4. To investigate the ability of the MPCI to inhibit the in vitro CYP3A4-dependent 
felodipine metabolism employing CYP3A4 expressed HLM and Human Intestinal 
Microsomes (HIM). 
 
5. To formulate an oral tablet matrix comprising felodipine and an MPCI and assess the 
influence of the MPCI on the formulation properties including felodipine release 
profiles. 
 
6. To perform in vivo animal studies using an oral tablet matrix developed in 5 above in a 
Large White Pig model in order to assess the influence on improving bioavailability. 
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1.4. Technology Applied in this Study 
 
1.4.1. Ultra Performance Liquid Chromatography (UPLC) 
UPLC is a highly sensitive quantitative and qualitative analytical technique that allowed 
samples to be detected and analysed with the shortest run-time. It functioned on the 
principles of High Performance Liquid Chromatography (HPLC) with in-built software for 
inter-method conversions compatible with modern auto-analytical systems that 
demonstrated high sensitivity. It employed porous sub-2µm particles at high linear 
velocities for analyte separation (Waters, 2008). Analytical determinations were achieved 
with optimized methods that usually involved standard parameter settings including pH, 
flow-rate, column type, column length and the choice of mobile phase. Its sensitivity 
allowed the identification and quantification of a wide range of non-volatile compounds at 
extremely low (nano-range) concentrations.  
 
A Waters® Acquity UPLC™ System (Milford, MA, USA) was used in this study and it 
possessed the following features: 
 
 Comprehensive system components, including an Acquity UPLC® Sample 
Organizer, Column Manager and Column Heater/Cooler, Binary Solvent Manager 
and Sample Manager, for customized throughput and condition requirements 
 HPLC to UPLC method conversion with the Acquity UPLC console calculator 
 Support for existing HPLC methods 
 Predictive system support with Connections Insight® remote intelligent services 
 Chemistries and formats to suit specific analytical tasks, including Acquity UPLC 
1.7μm columns, VanGuard pre-columns or Acquity UPLC HSS and HSS T3 1.8μm 
columns 
 Extended detection capabilities with Acquity UPLC Fluorescence (FLR), Tunable 
UV (TUV), Photodiode Array (PDA), and Evaporative Light Scattering (ELS) 
detectors to single, tandem, and time-of-flight mass spectrometers 
 Compatible with third-party MS solutions  
 
The UPLC was coupled with a Photodiode Array (PDA) detector that was responsible for 
filtering samples through wavelengths of absorption. It identified the wavelength (ʎmax) 
where maximum light absorption or transmission occurred. It allowed for the detection and 
quantification of lower concentrations of sample analytes and compared spectra across 
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wavelengths and broad concentration ranges. Data rates of up to 80 Hz, noise 
specifications of 10 µAU, and an extended linear range was used. It provided flexibility for 
simultaneous 2D and 3D analysis (Waters, 2008). The PDA detector (Waters® Acquity 
UPLC PDA Detector, Milford, MA, USA) used in this study possessed the following 
features: 
 
 The ability to quantitate trace impurities at levels as low as 0.004% with low signal-
to-noise ratios, high optical and digital resolution, and library matching which 
helped in accurate determinations of analytes 
 The ability to achieve UPLC/PDA separations with flexible parameter control and 
sampling rates for accurate, reproducible integration 
 Efficient light transmission for maximum sensitivity 
 Provided simultaneous 2D and 3D operations for more reliable determinations 
 Wavelength range of 190-500 nm and up to 2.0 Area Under the Curve (AU) 
without compromising linearity; 
 
o 1.3% deviation at 2.0 AU 
o 5.0% deviation at 2.8 AU 
which was employed in determining ƛmax and confirming complete separation of 
analyte without interference. 
 
1.4.3. Computational modeling of pre-systemic CYP3A4 inhibitors  
A detailed study of the structure of the amino acid sequence of CYP3A4 was performed 
simultaneously with the QSAR of its known inhibitors. This involved computational 
modeling employing Hyperchem 7.5 modeling software on a non-silicon graphics system 
(HyperCube Inc. Gainesville, FL, USA). The templates derived from the known substrate 
(felodipine) was step-wise modified as a single variant within the CYP3A4-felodipine 
complex taking into consideration the overall electronegativity/total charge density, dipole 
moment, bond length, bond angle, stereo-orientation and effective geometry. The most 
stable form of the resulting compounds was determined by estimation of the hydration 
energy and the energy of conformation. This approach generated a number of potential 
pre-systemic CYP3A4 inhibitors. 
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1.4.4. Tissue incubation and drug metabolism studies 
Felodipine was incubated in simulated intestinal fluids along with freshly excised intestinal 
tissues employing a modified method of de Kanter and co-workers (2005) in order to 
assess the drug-metabolizing ability of freshly excised intestinal tissue and the influence 
of MPCI on such metabolic activity. This was applied to ascertain a closer extrapolation of 
the in vitro results with the MPCI. The employment of Galaxy
®
 R Series CO2 incubator 
(Galaxy Incubators, RS Biotech Laboratory Equipment (Pty) Ltd. Ayrshire, Scotland, UK) 
enhanced tissue viability. 
 
The Galaxy incubator created a precise environment for tissue propagation and cellular 
metabolic activity. It offered a temperature range of 25-50°C, a CO2 range of 0.3-19.9% 
and an O2 control of 1-95%. A refrigerated centrifuge (Xiang Yi L-535R
TM Centrifuge, 
Changsha, China) was employed to precipitate denatured enzyme proteins. The 
temperature-regulator feature of the centrifuge makes it suitable for final termination of 
enzyme activity. Refrigerated centrifugation not only terminated enzyme action, but also 
facilitated the separation of the components of the incubation mixture preparatory to 
further analysis. 
 
1.5. Potential Benefits of this Study 
 
The novel MPCI intended developed in this research has the potential of solving the 
CYP3A4-dependent oral bioavailability related problems. The successful incorporation of 
MPCI into oral formulations of drugs which normally undergoes significant CYP3A4-
induced pre-systemic intestinal and hepatic metabolism may significantly enhance the 
oral bioavailability of the CYP3A4-substrates. The resulting enhanced oral bioavailability 
may help in reducing the required doses and frequency of dosing of such drugs, thus 
saving cost and enhancing compliance. Such MPCI may also make oral administration 
possible for a wide range of drugs that are traditionally administered parenterally due to 
CYP3A4-induced poor oral bioavailability. 
 
1.6. Overview of this Dissertation 
 
Chapter One provides a background to this study. The factors influencing oral drug 
bioavailability including GIT barriers, CYP-induced pre-systemic drug metabolism are 
discussed along with the need to enhance oral drug bioavailability. It outlines the 
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rationale, motivation, aim and objectives of the study, the technology used and the 
potential benefits of the study. 
 
Chapter Two reviews relevant literature on various approaches applied to enhance oral 
drug bioavailability. It explains preferences for oral drug delivery and the attendant 
challenges involved. Manipulation of intestinal physiology including the inhibition of pre-
systemic activity of CYP and efflux proteins is discussed. Site-specific drug delivery for 
regional drug absorption including gastroretentive systems and enteric coating for small 
intestinal drug targeting as an option for improved oral drug delivery and enhanced 
bioavailability is explored. Other methods for improving oral drug bioavailability discussed 
include modification of formulation techniques including solid dispersion systems, lipid 
suspensions, solutions, emulsions and nanotechnology. 
 
In Chapter Three, an optimized method for in vitro metabolism of CYP substrates namely 
felodipine and phenacetin are described. The effects of grapefruit juice flavonoids; 
naringin, naringenin and quercetin on CYP3A4 and CYP1A2 are also reported and 
discussed. UPLC analytical methods developed, validated and applied for the 
quantification of both substrates are also presented. 
 
Chapter Four focuses on the application of computational modeling to generate MPCIs. It 
reports the effects of co-incubation of felodipine with the various MPCI on the rate and 
extent of metabolism of the latter. 
 
Chapter Five presents the detailed study of 8-arm-PEG and its ability to enhance oral 
bioavailability of felodipine. An ex vivo study of the metabolism of felodipine by freshly 
excised pig intestinal tissue supplemented with a biomimetic environment is presented. 
The influence of 8-arm-PEG on the intestinal tissue metabolism of felodipine is also 
presented. Felodipine tablet matrices incorporating varying concentration of 8-arm-PEG 
were administered to Large White Pigs and the observed changes in plasma felodipine 
levels attributable to the presence of 8-arm-PEG is discussed. 
 
Chapter Six provides the conclusions and recommendations for further study in this field. 
A list of references used in this study is finally presented. 
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CHAPTER TWO 
ADVANCES IN THE APPROACHES FOR ENHANCEMENT OF ORAL DRUG 
BIOAVAILABILITY: A LITERATURE SURVEY 
 
 
2.1. Introduction 
 
In conscious and co-operating patients, oral drug delivery remains the preferable route of 
drug administration. However, not all drugs possess the desirable physicochemical and 
pharmacokinetic properties which favor oral administration resulting in poor bioavailability. 
This has in some cases led to the choice of other routes of administration, which may 
compromise the patient comfort and convenience, with increasing risk of non-compliance. 
Poor bioavailability has necessitated the administration of higher than normally required 
oral doses which often leads to economic wastages, risk of toxicity, erratic and 
unpredictable responses. The challenge over the years has been to design techniques 
that will allow oral administration of most drugs, irrespective of their properties and yet 
achieve a therapeutic systemic availability. This will be a worthy achievement since over 
90% of therapeutic compounds are known to possess oral bioavailability limitations.  
 
In this chapter therefore, an attempt is made to survey the literature on the various 
approaches that have been explored in the recent years to improve oral drug 
bioavailability, including physical and chemical means. Design of pro-drugs to bypass 
metabolism or enhance solubility as well as modification of formulation techniques such 
as the use of additives, permeation enhancers, solubilizers, emulsifiers and non aqueous 
vehicles are discussed. Pharmaceutical application of nanotechnology, which is an 
emerging area in drug delivery, has also been addressed. This review sought to assess 
each method aimed at enhancing the oral bioavailability of drugs in terms of the purpose, 
scientific basis, limitations, commercial application as well as the areas for further 
research improvement. 
 
2.1.1. Factors that influence gastrointestinal drug absorption and oral 
bioavailability 
The fate of orally administered drugs is determined by a number of factors. These include 
chemical degradation, physical inactivation through binding or complexation, 
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biotransformation induced by GIT microflora and idiosyncratic behavior among others. 
The fraction of the dose that survives these initial impediments is available for absorption. 
Of this fraction, some may be metabolized in transit through the GIT wall while unchanged 
fraction that reaches the hepatic portal vessels may undergo further extraction through 
CYP-catalyzed metabolism or hepatobiliary excretion (Figure 2.1). Thus, the fraction (F) 
of administered dose that reached the general circulation unchanged (bioavailability) is 
the product of the fraction (Fx) of drugs absorbed, the unmetabolized fraction (Fg) after a 
single passage through the gut wall and the fraction (FH) that survives first passage 
through the liver as represented by Equation 2.1.  
 
F = FxFgFH              Equation 2.1 
 
 
 
Figure 2.1: Factors influencing the oral bioavailability of drugs (Source: Gobin et al., 
1985). 
 
These factors that influence oral bioavailability can thus be broadly classified into three 
categories. These include features due to 1) the drug 2) the patient and 3) the physiology 
of the gastrointestinal tract (GIT). Drug properties include the dosage form, solubility, 
acid-base characteristics, partition and aqueous ionization potentials. The dosage form of 
Dosage forms pass down the 
esophagus often unhindered 
Absorbed drugs are subjected to 
hepatic extraction by cytochrome 
P450 enzymes 
The hepatobiliary excretion 
contributes to fecal drug loss 
Interaction with gastric and 
intestinal contents, and metabolism 
by cytochrome P450 enzymes in 
the gut wall can greatly reduce the 
fraction of drug that reaches the 
systemic circulation 
Gastrointestinal motility significantly 
contributes to fecal loss of orally 
administered drugs 
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an active ingredient can have a great effect on its solubility and permeability, thereby 
influencing its absorption and bioavailability. The Biopharmaceutics Classification System 
classifies drugs into four groups: Class 1: high permeability, high solubility; Class 2: high 
permeability, low solubility; Class 3: low permeability, high solubility; and Class 4: low 
permeability, low solubility (van de Waterbeemd, 2000). Low bioavailability is often 
associated with oral dosage forms of Class 2-4 drugs, i.e., drugs with low solubility, low 
permeability, or both. 
 
While the GIT forms a barrier to absorption, the presence of metabolizing enzymes and 
efflux proteins in the GIT lumen, the physicochemical properties of the GIT fluids and the 
irreversible removal by first-pass organs including the intestine, liver and lungs, are 
additional factors influencing oral bioavailability (Pang, 2003). The necessary passage of 
orally administered drugs through various tissues and organs, as illustrated in Figure 2.1, 
contributes greatly to the resulting poor oral bioavailability. Although most of these factors 
affect the oral bioavailability of different drugs to a varying extent, the single most 
important cause of poor oral bioavailability is the CYP-induced first pass metabolism. 
Table 2.1 illustrates typical examples of extremely poor bioavailable drugs and factors 
responsible for this feature. 
 
In order to improve oral bioavailability therefore, a strategy that will achieve any of the 
following must be adopted: 1) the modification and manipulation of the physicochemical 
properties of the drug molecule, 2) the addition of a novel functionality (e.g. receptor 
recognition or cell permeability and 3) design of novel drug delivery systems that can 
bypass the impediments or interfere with these physiological barriers. This is a more 
promising approach to pharmaceutical research in pharmacotherapy than development of 
new drug entities as most new drug candidates face similar problems (Morishita and 
Peppas, 2006).  
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Table 2.1: Some poorly bioavailable (≤ 20%) drugs and drug classes in accordance with 
BCS classification.  
Drugs Bioavailability 
(%) 
Reported Reasons Reference 
 
Allendronate 
 
0.59-0.78 
 
Poor solubility, poor absorption 
 
Cremers et al., 20005  
Atorvaststin 14 CYP450 and P-gp activity Reinoso et al., 2002 
Bromocriptine 5-10 Extensive first pass effect Turner et al., 2003 
Clodronate 1 Poor solubility, poor absorption Lambrinoudaki, et al., 2006 
Cytarabine 20 Intestinal and hepatic first pass Joseph and Sharma, 2007 
Domperidone 15 First pass effect, liver and gut wall Ahmad et al., 2006 
Doxorubicin 5 Intestinal and hepatic metabolism Sturgill et al., 2000 
Etidronate 5 Poor solubility, poor absorption Cremers et al., 2005 
Felodipine 15 CYP450 and P-gp activities Dorne et al., 2003 
Isradipine 15 CYP450 and P-gp activities Tse and Jaffe, 1987 
Nimodipine 13 CYP450 and P-gp activities Choi and Burm, 2006 
Fluvastatin 20 CYP450 and P-gp activities Garcia et al., 2003 
Hyoscine 20 Hepatic metabolism Bennett et al., 2002 
Ketamine 20 Intestinal and hepatic metabolism Kharasch and Labroo, 1992 
Lovastatin <5 CYP450 and P-gp activities Buse, 2003 
Morphine 20-33 liver and gut first pass Manoir et al., 2006 
Pyridostigmine 14 Poor absorption Aquilonius et al., 1980 
Naloxone 2-10 90%absorption, extensive first pass Kleiman-Wexler et al., 1989 
Naltrexone 5-40 Enterohepatic recycling, first pass Buse, 2003 
Pamidronate 1 Poor solubility, poor absorption Cremers et al., 2005 
Pravastatin 17-34 CYP450 and P-gp activities Reinoso et al., 2002 
Prochlorperazine 20 Intestinal and hepatic first pass Finn et al., 2005 
Risedronate <1 Poor solubility, poor absorption Cremers et al., 2005 
Selegiline 20 Extensive first pass Clarke and Jankovic 2006 
Simvastatin 5-48 CYP450 and P-gp activities Buse, 2003 
Sumatriptan  20 Hepatic first pass effect Cossons and Fusseau, 
1999 
Tacrine 10-30 Hepatic first pass effect Jann et al., 2002 
Terbutaline 9-21 Poor absorption, first pass Nakhat et al., 2007 
Tiludronate 6 Poor solubility, poor absorption Cremers et al., 2005 
Lidocaine 3 Hepatic first pass effect Isohanni et al., 2006 
Budesonide 11
2
 Hepatic first pass effect Dorne et al., 2003 
Zoledronic acid 0.9-1.8 Poor solubility, poor absorption Lambrinoudaki, et al., 2006 
    
Class II compounds  High permeability, low solubility van de Waterbeemd, 2000 
amiodarone HCl, atazanavir sulfate, atorvastatin,  azithromycin,  benazepril HCl, bicalutamide, candesartan 
cilexetil, carbamazepine, carisoprodol, carvedilol, celecoxib, clarithromycin, diazepam, divalproex sodium, 
docetaxel, donepezil HCL, efavirenz, etodolac, ezetimibe, fenofibrate, finasteride, gemfibrozil, glimepiride, 
glyburide, ibuprofen, indapamide, indomethacin, irbesartan, ketoconazole, lansoprazole, loratadine, lovastatin, 
meclizine HCL, metaxalone, moxifloxacin HCl, mycophenolate mofetil, nabumetone, nelfinavir mesylate, 
olmesartan medoxomil, pioglitazone HCl, prednisone, raloxifene HCl, risperidone, ritonavir, rofecoxib, 
simvastatin, spironolactone, tacrolimus, temazepam, valdecoxib, valsartan, ziprasidone HCl. 
 
Class III compounds
  
 Low permeability, high solubility   van de Waterbeemd, 2000 
albuterol, alendronate sodium, amlodipine besylate, amoxicillin, atenolol, baclofen, buspirone HCl, captopril, 
carboplatin, ceftriaxone, ciprofloxacin, ciprofloxacin HCl, colchicine, fluconazole, folic acid, gabapentin, 
gemcitabine HCl, granisetron HCl, hydrochlorothiazide, hyoscyamine sulfate, lamivudine, lamotrigine, 
levetiracetam, levofloxacin, lisinopril, metformin HCl, metronidazole, minocycline HCl, morphine sulfate, niacin, 
oxaliplatin, oxycodone HCl, oxycontin, penicillin VK, progesterone, ranitidine, risedronate sodium, rosiglitazone, 
sumatriptan, terazosin HCl, thalidomide, timolol maleate, topiramate, valacyclovir HCl, zoledronic acid, zolpidem. 
 
Class IV compounds  low permeability, low solubility van de Waterbeemd, 2000 
acyclovir, allopurinol, aspirin, cefdinir, cefprozil, cephalexin, clindamycin HCl, doxycycline hyclate, famotidine, 
felodipine, furosemide, glipizide, linezolid, meloxicam, mesalamine, methocarbamol, methotrexate, nifedipine, 
nitrofurantoin, olanzapine, oxcarbazepine, phenobarbital, sildenafil citrate, tadalafil, temozolomide, tetracycline, 
theophylline. 
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2.2. Manipulation of Gastrointestinal Physiology 
 
2.2.1. Inhibition of pre-systemic metabolic enzymes  
Cytochrome is the main oxidative drug metabolizing enzyme family (Guéraud et al., 1999; 
Glue and Clement, 2004). It is highly expressed in the liver and intestines and as a result 
of this, it is responsible for most pre-systemic metabolism of orally administered drugs, in 
humans (Glue and Clement, 2004). By anatomical design, blood circulation of the 
intestine is unique due to the fact that the intestine is the portal tissue that regulates the 
flow of substrates to the liver. The majority of blood supply to the liver, about 75%, is from 
intestinal venous pool (Pang, 2003). Thus, all absorbed drugs are subjected to passage 
through the hepatic system (Figure 2.1).  
 
Cytochrome consists of approximately 12 families and 17 subfamilies (Nelson et al., 
1993), but it is only a small number of these enzyme families that is responsible for the 
majority of drug oxidation (Quintieri et al., 2008). This is the human cytochrome P450 
(CYP3A) subfamily which is responsible for the metabolism of more than 50% of currently 
marketed drugs (Quintieri et al., 2008). It is also known from the literature that there is a 
large inter-individual variability in cytochrome P450 (CYP) 3A expression as already 
determined with the erythromycin breath test (Guengerich, 1998). CYP3A4 is the major 
isoform, largely expressed in human liver and occupy more than 70% of gastrointestinal 
cytochrome expression and catalyzes the oxidative metabolism of most clinically 
important drugs including statins, and dihydropyridines (Figure 2.2). CYP3A5 is a 
polymorphic isoform, present in significant amounts in 20-60% of human livers 
(Guengerich, 1998). When present however, it accounts for at least 50% of total CYP3A. 
CYP3A enzymes metabolize numerous structurally unrelated compounds, a property that 
is said to be responsible for the large number of documented drug-drug and drug-food 
interactions (Quintieri et al., 2008).  
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Figure 2.2: A schematic showing the structural characteristics and the mechanism of 
action involved in the pre-systemic metabolism of Simvastatin by cytochrome P450 
(Source: Reinoso et al., 2002). 
 
Interactions between grapefruit juice and clinically used drugs have been reported in 
recent years (Bailey et al., 1998). The drugs include cyclosporine, midazolam, triazolam 
and calcium channel blockers such as felodipine and nisoldipine (Bailey et al., 1998). All 
of these drugs are substrates for CY3A4 and undergo extensive metabolism by intestinal 
CYP3A4 (Kolars et al., 1991; Lown et al., 1997; Paine et al., 2008). Various researchers 
have suggested that flavonoid contents of grapefruit juices could be responsible for the 
inhibition of the cytochrome enzymes (Hertog et al., 1993; Ho and Saville, 2001; Paine et 
al., 2008). Flavonoids are polyphenolic compounds with antioxidant properties and are 
widely distributed in foods of plant origin such as vegetables, fruit, tea and wine (Hertog et 
al., 1993). When administered orally, natural flavonoids such as flavone, tangeretin and 
nobiletin can activate rat and human benzopyrene hydroxylase and some other CYP 
activity (Ho and Saville, 2001). Flavonoids are believed to exert various other 
physiological actions. This limits their commercial use in pharmaceutical preparations in 
enhancing oral bioavailability. In this regard, no commercialized technique of inhibiting 
pre-systemic metabolism as a way of enhancing oral bioavailability has been reported. 
Further exploitation of this approach is anticipated. 
6´β-hydroxymethyl 
simvastatin 
6´β-carboxy 
simvastatin 
Simvastatin 6´β-exomethylene 
simvastatin 
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2.2.2. Inhibition of efflux pumps to enhance drug bioavailability 
Efflux transporters such as P-glycoprotein (P-gp) and the multidrug resistance related 
protein (MRP), which have been known for decades to be over-expressed in tumor cells, 
are also widely distributed throughout normal tissues in humans, including the liver, 
kidney, intestinal mucosa and endothelial cells of the brain (Gupta, 1995; Ambudkar et al., 
1999; Hugger et al., 2002a). Tumor cells often become resistant not only to the drugs 
which have been used during the treatment but also to other drugs which are structurally 
and functionally unrelated. This is called multidrug ‘resistance’ (MDR). MDR is frequently 
associated with decreased drug accumulation resulting from enhanced drug efflux. This is 
correlated with the presence of a membrane protein, P-glycoprotein, which pumps a wide 
variety of drugs out of cells (Borrel et al., 1994).  
 
P-gp is a type of ATPase, and an energy-dependent transmembrane drug efflux pump 
which belongs to members of ATPase Binding Cassette (ABC) transporters (Juliano and 
Ling, 1976). It is a 1280 long amino acid glycoprotein with a molecular weight of 170kDa, 
expressed as a single chain containing two homologous portions of equal length, each 
containing six membrane domains and two ATP binding regions separated by a flexible 
linker polypeptide region between the Walker A and B motifs (Schinkel et al., 1993; 
Pokharkar et al., 2006). Immunohistochemical analysis using monoclonal antibodies 
provided evidence for localization of P-gp in a wide range of tissues, particularly in 
columnar epithelial cells of the lower GIT, capillary endothelial cells of brain and testis, 
canalicular surface of hepatocytes and apical surface of proximal tubule in the kidney 
(Thiebut et al., 1987). Due to selective distribution at the port of drug entry and exit, P-gp 
has been speculated to play a major physiological role in absorption, distribution and 
excretion of xenobiotics. Drug efflux pumps like P-gp have been identified recently to play 
a major role in altering the pharmacokinetics of various drugs and are particularly 
associated with poor bioavailability in co-ordination with gut wall metabolism. Though 
much research has been carried out in the process of establishing the role of P-gp in 
multidrug resistance in cancer cells, it is only recently that it is gaining importance in 
absorption enhancement due to its selective distribution at the sites of drug absorption as 
depicted in Table 2.2 (Varma et al., 2003; Varma et al., 2006). 
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Table 2.2: Distribution of metabolic enzymes and transporters in the liver and small 
intestine.  
Enzymes and 
transporters 
Duodenum Jejunum Ileum Liver Reference 
 
Cytochrome P-450 (rat, 
humans) 
 
Higher 
 
Lower 
 
Lowest 
 
Highest 
 
Bergheim et al., 
2005; Pang et al., 
2007 
UDP-
Glucuronosyltransferase 
(rat) 
Higher  Lowest Highest Li et al., 2002 
Sulfotransferase (guinea 
pig) 
Higher  Lowest Highest Heydel et al., 2001 
Glutathione S-
transferase (rat) 
Highest  Lowest  Dooley, 1998 
Sulfatase (rat) Highest  Lowest  Hayes et al., 1989 
Oligopeptide transporter 
1 - PEPT1 (rabbit) 
Highest    Miki et al., 2002; 
Ziegler et al., 2002 
Apical sodium-
dependent bile acid 
transport - ASBT 
(hamster, rat) 
Lowest  Highest  Botka et al., 2000 
Monocarboxylic acid 
transporter 1 - MCT1 
(rat) 
Lower Highest Lowest  Shneider et al., 1995 
Organic anion 
transporting polypeptide 
3 - Oatp3 (rat) 
Lower 
 
 
Higher Lower  Cong et al., 2001 
Multidrug resistance  
protein MDR1 or Pgp (rat) 
Lowest Higher Highest  Chen and 
Pang, 2005 
Multidrug resistance-
associated protein 2 - 
MRP2 (rat) 
High Highest Lowest  Liu et al., 2006 
Multidrug resistance-
associated protein 3 - 
MRP3 (rat) 
Lowest Higher Highest  Mottino et al., 2000; 
Gotoh et al., 2000 
 
 
The motivation for the search and use of modulators of P-gp and other efflux proteins in 
bioavailability enhancement and in improving pharmacokinetic properties include the 
following (Varma et al., 2006): 
 
(i) Products of histochemical researches have given evidences of the presence 
of high concentrations of P-gp in the absorbing surfaces of the 
gastrointestinal tract. 
(ii) P-gp acts as barrier to intestinal absorption of a number of clinically 
significant drugs. Further, these drugs induce P-gp expression, which may 
lead to inefficient therapy on chronic use. 
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(iii) Concert role of P-gp and CYP further limits bioavailability of orally 
administered drugs due to a great overlap between substrate specificity and 
intestinal distribution of both proteins (Table 2.2). 
(iv) Distribution of P-gp extends to the major excretory organs like kidney and 
liver leading to change in distribution and elimination kinetics of administered 
drugs  (Table 2.2)  
 
Studies have identified a number of clinically important drugs as P-gp substrates, which 
include anthracyclins (doxorubicin, daunorubicin), alkaloids (reserpine, vincristine, 
vinblastine), specific peptides (valinomycin, cyclosporine), steroid hormones (aldosterone, 
hydrocortisone) and local anesthetics (dibucaine) (Schuetz et al., 1996; Fromm, 2002; Hu, 
2004a). Even dye molecules (Rhodamine123) and some pharmaceutical excipients have 
been found to exhibit P-gp substrate activity (Lin et al., 2007). The identification of few 
substrates of P-gp as inhibitors set off an opportunity in multidrug resistance reversal 
(Johnson, 2002). Improved clinical efficacy of various drugs observed by P-gp inhibition, 
especially conditions subjected to multidrug resistance, led to the design and 
development of modulators, which specifically block P-gp efflux and improve the toxicity 
profiles (Johnson, 2002). P-gp inhibitors are gaining recognition to improve bioavailability 
by inhibiting P-gp in intestine, brain, liver and kidneys as has been observed by many 
researchers in recent years (Eytan et al., 1996; van Asperen et al., 1997; Breedveld et al., 
2006). 
  
Borrel and co-workers (1994) reported that mobile ionophores such as valinomycin, 
nonactin, nigericin, monencin, calcimycin, and lasalocid inhibit the efflux of anthracycline 
by P-gp whereas channel forming ionophores such as gramicidin do not. Cyclosporine 
which is also a strong calcium chelating agent was reported to inhibit the P-gp-mediated 
efflux of anthracycline. P-gp inhibitors are traditionally classified into three generations 
based on specificity and affinity. First generation inhibitors are pharmacological actives, 
which are clinically used for other indications but have been shown to inhibit P-gp. These 
include calcium channel blockers (e.g. verapamil) and immunosuppresants (e.g. 
cyclosporine A); alkaloids (e.g. reserpine; quinidine, yohimbine) and antiestrogens (e.g. 
tamoxifen and toremifen). The ability of risperidone and its major active metabolite, 9-
hydroxy-risperidone (paliperidone) to inhibit P-gp activity in vitro where both compounds 
significantly increases the intracellular accumulation of Rhodamine 123 and Doxorubicin 
in a concentration-dependent manner, has also been reported (Zhu et al., 2007). The 
usage of these compounds is limited by their toxicity due to the high serum concentrations 
achieved with the dose that is required to inhibit P-gp. Further research directed at 
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improving the toxicity profile resulted in second and third-generation inhibitors that 
specifically modulate P-gp (Breedveld et al., 2006). Second-generation modulators are 
agents that lack the pharmacological activity of the first generation compounds and 
usually posses a higher P-gp affinity. However, inhibition of two or more ABC transporters 
leads to complicated drug-drug interactions by this class of compounds, which include 
non-immunosuppressive analogues of cyclosporine A, PSC 833; D-isomer of verapamil, 
and dexverapamil; and others such as biricolar (VX-170), elacridar (GF120918), 
zosuquidar (LY335979), tariquidar (XR9576) and MS-209 (Zhu et al., 2007). On the other 
hand, several other novel third-generation P-gp blockers are under development primarily 
aimed at improving the treatment of multidrug resistant tumours and to inhibit P-gp with 
high specificity. Modulators such as LY335979, OC144093 and XR9576 have been 
identified to be highly potent and selective inhibitors of P-gp with a potency of about 10-
fold more than the first- and second-generation inhibitors (Breedveld et al., 2006). 
 
Generally, P-gp can be inhibited by: 1) blocking drug binding site either competitively, 
non-competitively or allosterically; 2) interfering with ATP hydrolysis; or 3) altering the 
integrity of cell membrane lipids. Although most of the drugs inhibit P-gp function by 
blocking drug binding sites, presence of multiple binding sites complicate understanding 
as well as hinder developing a true, conclusive structure-activity relationship for 
substrates or inhibitors. However the mode of handling of substances and inhibitors is the 
same for P-gp if the protein transport and/or inhibition are mediated only through binding 
sites. The point of great concern which therefore needs to be addressed is establishing 
why, down to the molecular level, substrates and inhibitors are discriminated. In this 
regard, Eytan and co-workers (1996), proposed a plausible explanation that the modulator 
or inhibitor ‘flipped’ by P-gp can ‘flop’ back into the inner leaflet of the membrane, for 
further transport, which rapidly creates a big difference between the rate of efflux of the 
substrate and inhibitor. Thus the P-gp modulator is cycled repeatedly, preventing efflux of 
substrates, which depends on the hydrophobicity of the compound. This concept has 
been proved from the drug delivery point of view that the absorption of high affinity drugs 
to proteins need not necessarily be limited by P-gp (e.g. verapamil), if they are highly 
permeable whereas less permeable drugs (though may be weak substrates) may undergo 
a substantial extrusion mediated by P-gp, e.g. tanilol (Doppenschmitt et al., 1999). 
Compounds that inhibit ATP hydrolysis could serve as better inhibitors since they are 
unlikely to be transported by P-gp. These kinds of agents will require a low dose which is 
desirable for local use in the gut lumen. Quercetin is a naturally occurring flavonoid which 
has been proposed to block the P-gp function by an unknown mechanism, possibly by 
interfering with ATPase activity (Shapiro and Ling, 1997). Since none of the substrates 
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have been found to interact with the nucleotide binding site thereby interfering P-gp 
ATPase catalytic cycle, further research to explore the detailed mechanism of inhibition of 
ATP hydrolysis would provide new and better inhibitors with potent and specific activity. 
 
2.2.2.1. Pharmaceutical surfactants used as P-gp inhibitors 
The commonly used pharmaceutical surfactants are emerging as a different class of P-gp 
inhibitors, which act by altering integrity of membrane lipids (Hugger et al., 2002b). The 
change in secondary and tertiary structure is found to be the reason for loss of P-gp 
function due to disturbance in hydrophobic environment by surfactants (Hugger et al., 
2002a). In a series of studies by Hugger and co-workers (2002a), it was observed that 
excipients such as poly(ethylene) glycol (PEG)-300, Cremophor® EL, and Tween® 80 
inhibit P-gp activity in epithelial colorectal adenocarcinoma (CaCO-2) cell monolayers. 
Surfactants seem to be a better choice since they have already been approved for routine 
use in pharmaceutical formulations. However, they have only been tested at the in vitro 
level to date, which therefore necessitates a further evaluation in animal or human 
subjects. Likewise, the clinical hypothesis that P-gp inhibitors interfere with ATP 
hydrolysis and catalytic cycle is hampered by lack of understanding of the exact mode of 
inhibition which therefore posses to be another potential area for further research. 
 
2.3. Application of Site-Specific Drug Delivery 
 
2.3.1. The significance of regional drug absorption 
The differences in the composition and thickness of the mucus layer, pH, surface area 
and enzyme activity of the GIT is responsible for the possibility of site-specific absorption 
(Hamman et al., 2005). The most important site for GIT drug absorption is the small 
intestine due to the large absorptive surface area as a result of the presence of villi and 
microvilli (Lacombe et al., 2004). Drug absorption is generally believed to be higher in the 
upper region of the small intestine compared to the lower parts due to higher permeability 
(Masaoka et al., 2006). Esophageal absorption is usually negligible due to short transit 
time of the passing drug. The stomach is responsible for initial digestion. The small 
surface area and short residence time in the stomach limits gastric absorption. 
 
2.3.2. Gastroretentive systems for the enhancement of site-specific absorption 
Gastroretentive systems have been designed to enhance local action in the stomach for 
drugs such as antacids, misoprostol, certain antidotes and antibiotics (Ali et al., 2006). 
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Furthermore, gastroretentive systems have been employed to improve the bioavailability 
of drugs such as captopril and ranitidine which have been found to be unstable in the 
intestine and the colon (Drummer and Jarrott, 2006).  Furosemide is absorbed mainly in 
the stomach and upper small intestine (Streubel et al., 2006) due to its weak acidic 
properties (pKa 3.9). This narrow absorption window of furosemide is the major cause of 
its low oral bioavailability (Klausner et al., 2003). The feasibility of widening the absorption 
window for furosemide has been demonstrated by controlling the pH in the distal portions 
of the GIT through the co-administration of Eudragit® L100-55 (Terao et al., 2001).  Drugs 
like diazepam, which exhibit low solubility at high pH are best absorbed in the stomach 
(Castrol et al., 1999). 
 
Gastroretentive systems employed in pharmaceutical formulations for drugs that are 
preferentially absorbed in the stomach may be bioadhesive (Rosa et al., 1994), swelling 
and expanding (Deshpande et al., 1996; 1997), floatable (Menon et al., 1994; Whitehead 
et al., 1998), delayed gastric emptying (Singh and Kim, 2000; Chawla and Bansal, 2003), 
simplex lattice (Patel et al., 2001), high density (Shine and More, 2008), modified shape 
(Garg and Sharma, 2003), super porous hydrogels, or magnetic systems (Bardonnet et 
al., 2005). 
 
It is, however, pertinent to note that an effective gastroretentive drug delivery system must 
be able to withstand the peristaltic forces, constrictions, grinding and churning 
mechanisms in order to resist premature gastric emptying. Novel gastroretentive drug 
delivery systems combined with a timed release mechanism holds the promise of a future 
once-a-day regimen for a wide range of drugs. However, as promising as gastroretentive 
drug delivery system appears, it must be pointed out that it is not suitable for drugs that 
may cause gastric irritation or those unstable in acidic medium. Examples of commercially 
available gastroretentive formulations are Valrelease®, a diazepam floating capsule; 
Madopar®, a combination formulation of benserazide and levodopa; Topalkan®, an 
aluminium-magnesium antacid, liquid Gaviscon®; a floating liquid alginate preparation; 
and Almagate Flot-Coat®, an antacid preparation (Shinde and More, 2008). 
 
2.3.3. Enteric coating technology for small intestinal drug targeting 
The technology of enteric coating has been used for many years effectively to delay the 
release of active ingredients in drug formulation until it reaches the small intestine 
(Marvola et al., 1999; Ho and Saville, 2001; Atyabi et al., 2005). Targeting drug release in 
the small intestine by employing a pH-dependent coating is required principally to prevent 
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drug destruction by gastric enzymes or gastric fluids, as well as to prevent nausea and 
vomiting caused by the irritation of the gastric mucosa. However, absorption from enteric 
coated tablets is erratic and to a high degree dependent on the gastric emptying time 
(Zeitoun et al., 2006). For example, erythromycin is administered either in an enteric 
coated dosage form or in the form of a less soluble salt or as a pro-drug since it is thought 
that it has low bioavailability due to the hydrolysis caused by the acidic environment of the 
stomach (Somogyi et al., 1995). Specific bioadhesive drug delivery systems using lectins 
have been proposed to improve the oral bioavailability of poorly absorbed drugs such as 
peptides and proteins through prolonged and/or intensified contact with the intestinal 
mucosa (Lehr et al., 1992). Various polymers have been used as enteric coatings which 
breakdown to release the active ingredient within the pH range of 5-7 (Aungst, 2000; 
Cremers et al., 2005). Thus synthesizing polymers that are soluble only at the intestinal 
pH may be a useful approach to improve the oral bioavailability of drugs that are not 
stable at the gastric pH. 
 
Drugs are generally absorbed to a smaller extent in the colon than in the small intestine 
(Atyabi et al., 2005; Chourasia and Jain, 2003; 2004; Laila et al., 2006). Both nisoldipine 
and dilazep hydrochloride, are known to be preferentially absorbed in the colon (Antonin, 
1993). Such drugs have to be protected through coating to delay their release from the 
formulation matrix until they reach their site of absorption. In certain pathological 
instances, such as in the treatment of inflammation of the colon where local action is 
desired, it is expedient to target drug release in the colon. This helps to prevent the 
absorption of the drug before it reaches the colon. In addition, for drugs such as peptides, 
which are metabolized by the endogenous enzymes of the small intestine, colonic 
targeting for absorption becomes favorable since the colon exhibits a relatively low 
digestive enzyme activity. It should also be noted that drugs generally have relatively long 
contact times with the absorbing surface of the colon (Rouge et al., 1996). Several 
physiological factors such as the regional pH, gastrointestinal transit time and colonic 
microflora are the major considerations in targeting the release of orally administered 
drugs to the colon. Reduced concentration of enzymes such as peptidases that degrade 
peptide drugs in the colon, long residence time, enhanced sensitivity to absorption 
enhancers, demonstration of natural absorptive characteristics and the abundance of 
lymphoid tissue follicles are some of the factors that favor drug absorption in the colon 
(Hamman et al., 2007). Some delayed-release units with a gastroresistant film use the 
relatively constant small intestine transit time.  
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Gazzaniga and co-workers (1994), described a system consisting of a drug-containing 
core coated with two or three polymeric layers. The outer layer dissolves at a pH greater 
than 5 when the system has left the stomach. The intestinal layer which is made of 
hydrophilic swellable polymers is the one responsible for the lag phase that favors the 
protection of the core drug during the transit through the small intestine. An inner layer 
composed of an enteric film soluble at a pH greater than 6.5-7 may be added as a further 
control element. Polymers such as USP methacrylic acid copolymer type B (Eudragit® S, 
Rohm and Haas, Philadelphia, USA) that degrade above a pH of 7 have been used for 
colonic drug delivery in diseases such as colitis (Gibaldi, 1984). 
 
The number of microorganisms is significantly higher in the colon (Wahlqvist and Ball, 
2002). According to Ashford and Fell, (Ashford et al., 1994) two main classes of enzymes 
that are produced by the microbial population in the colon, namely azoreductase and 
polysaccharidases, are considered reproducible enough to be exploited in drug targeting. 
The use of pro-drugs such as azo, glucuronide and dextran conjugate compounds has 
been proposed to target drugs to the colon (McLeod et al., 1994). This approach seems, 
however, to be limited to only specific drugs. Thus, it is considered that a more promising 
approach would be to coat the dosage form with agents resistant to gastric and intestinal 
fluid, but susceptible to bacterial degradation such as azo-linked coatings or lauric acid 
dextran esters (Gazzaniga et al., 1994; Kesslhut and Bauer, 1994; Rouge et al., 1996). 
Matrices made of polysaccharides comply with these biodegradation requirements, but 
they are soluble in water and therefore have to be transformed into water-insoluble 
products. This has been achieved by pectin (by forming the calcium salt or by selecting a 
high methoxypectin) or by chondroitin sulphate (by cross-linking) (Rouge et al., 1996). It 
should be noted that the drug has to be released by erosion and simple diffusion must be 
prevented. Therefore, these matrices are only valuable for insoluble drugs (Rouge et al., 
1996). Thus, it can be concluded that targeting specific regions of the GIT through coating 
techniques, may render it possible for drugs to be delivered to sites where their 
absorptions is most favored thereby leading to the improvement of  their bioavailability.  
 
2.4. Modification of Formulation Techniques for Oral Bioavailability Enhancement 
 
Drug dosage forms and formulation design can be modified to improve oral bioavailability 
of drugs. Conventional approaches to enhancing the solubility properties and oral 
bioavailability of hydrophobic drugs include the following (van den Mooter et al., 1994): 
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 Synthesis of molecular species such as salts to facilitate dissolution e.g. addition of 
hydrochloride, sulphate or phosphate moieties. 
 Drug particle size reduction by physical grinding and milling to improve the surface 
area and improve membrane permeability as often employed in formulating 
griseofulvin, a poorly water-soluble drug. 
 Use of amorphous crystal formation for production of solid/resin dispersions: typically 
melt extrusion technology, in which spectra-melt temperatures are used to produce a 
more soluble amorphous dispersion of chemical drug molecules in a polymer diluent 
such as polyethylene glycol (PEG). 
 Use of surfactants/emulsifiers, for example in self-emulsifying/micro-emulsifying 
systems: anhydrous lipid-based formulations containing water-insoluble drug 
dissolved in oil/s, together with surfactants and co-solvents; generally administered in 
soft gel capsules for spontaneous emulsion formation on contact with gastrointestinal 
fluids. 
 Conjugation/derivation of delivery system including integration of two or more different 
delivery systems e.g. formulation of effervescent tablets and encapsulation of 
emulsions. 
 
Two transport routes, namely transcellular and paracellular are responsible for the 
passage of drugs through the GIT lumen and into the blood stream (Figure 2.2). In the 
transcellular transport, compounds cross the epithelial cells by crossing the intestinal cell 
membrane, generally by passive diffusion. In the small intestine, drugs with structures 
similar to those of nutrients may be taken up by facilitated diffusion or by active transport 
both of which represent carrier-mediated transport (Figure 2.2). The absorption of drugs 
which are poorly absorbed because of their hydrophilic character can be influenced either 
by manipulating the drug, the dosage form or the intestinal membrane. Therefore, most 
strategies for absorption enhancement either change the permeability properties of the 
enterocytes or alter the physico-chemical properties of the compound (Ezra and Golomb, 
1999). 
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Figure 2.3: A schematic depicting the a) transcellular and paracellular transport routes b) 
active transport c) passive transport and d) facilitated transport of compounds across the 
GIT lumen (Adapted from: Matheny et al., 2009). 
 
 
In order to lower the physical barrier function of structural elements of the intestinal 
mucosa towards poorly absorbed drugs, the potentials of co-administration of absorption 
enhancing agents have been extensively investigated (van Hoogdalem et al., 1989; 
Takatsuka et al., 2006). The absorption enhancers used belong to widely differing 
chemical entities and it appears that the only common characteristic they share is their 
ability to promote absorption. Desired effect for an absorption enhancing formulation 
includes the absence of toxic manifestation, the potential of which must be evaluated. 
Unfortunately, toxicity is probably often closely related to the mechanism of intestinal 
permeation enhancement. Some mechanisms may inherently have lower potential to 
cause toxicity than other mechanisms just as a transient opening of tight junctions would 
seem less damaging than a disruption of cell membrane structure. 
 
The main classes of enhancers of intestinal drug absorption are surfactants, fatty acids, 
medium chain glycerides, steroidal detergents, acyl carnitine and alkanoyl-cholines, N-
acetylated non-α-amino acids, chitosan and other mucoadhesive polymers, bile salts and  
its analogues, chelating agents, salicylates and phosphonate derivatives (Kawahara et al., 
2000). According to an investigation undertaken by Janner and co-workers (1991), the 
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absorption of Alendronate which is a bisphosphonate without EDTA was at a range of 1-
3% while the addition of EDTA increased its absorption about ten-fold at an allendronate 
dose of 0.6mg/kg and about two-fold at lower doses of 0.1 and 0.3mg/kg (Gibaldi, 1984). 
EDTA was also reported to increase the absorption of Clodronate (Legen et al., 2006). 
Similarly, in a screening evaluation of some pharmaceutically acceptable excipients as 
permeation enhancers for amoxicillin, Legen and co-workers (2006), reported that sodium 
lauryl sulphate (0.2mg/mL) increased the intestinal permeability of amoxicillin in the 
mucosa-to-serosal direction. Likewise, Sodium caprate, a medium chain fatty acid, is 
known to enhance the transport of drugs across the intestinal mucosa in cell culture 
systems and small animal species (Legen et al., 2006). It has also been demonstrated 
that it can improve the oral absorption of two chemically modified antisense 
oligonucleotides ISIS 2503 (phosphorothioate) and ISIS 104838 (methoxyethyl modified 
phosphorothioate) when studied in an intra-intestinal catheterized pig model (Raoof et al., 
2002). However, it is apparent that many, if not most of the compounds examined as 
membrane permeation enhancers in vitro cause cytotoxicity or membrane damage. The 
dilemma is whether the concentrations associated with membrane permeation 
enhancement are different from concentrations causing membrane damage. Most studies 
however suggested that enhancers often have steep concentration versus effect profiles 
in vitro, with relatively small safety margins (Kawahara et al., 2000). Either, it has been 
demonstrated through in vitro investigation that papain which is a proteolytic enzyme can 
serve as an effective permeation enhancer for orally administered low molecular weight 
heparin (Grabovac et al., 2007).  It has further been argued that most likely papain lacks 
the toxicity associated with oral absorption enhancers due to its presence in fruit such as 
papaya, and in over-the-counter products as well as in drugs such as Wobenzym N® 
(MucosPharma GmbH & Co, Gretsried, Germany) (Raoof et al., 2002). 
 
2.4.1. Modification of drug solubility properties 
Another alternative for altering the permeability characteristics of a drug molecule is to 
modify the solubility properties. In order for a drug to be absorbed into the systemic 
circulation following oral administration, the drug must be dissolved in the gastrointestinal 
fluids. For hydrophobic drugs, it is this dissolution process which acts as the rate-
controlling step and therefore, determines the rate and extent of absorption. One of the 
major challenges to drug development today is poor solubility. It has been estimated that 
40% of all newly developed drugs are poorly soluble or insoluble in water (Watt and 
Morrison, 2001; Payghan, 2008). In addition, up to 50% of orally administered drugs 
suffer from formulation problems related to their high lipophilicity (Naseem et al., 2004; 
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Gursoy and Benita, 2004). One of the methods that has often been employed in 
pharmaceutical practice to improve solubility properties, and hence bioavailability is 
mechanical micronization through milling. However, the major disadvantage of milling is 
the limited opportunity to control important characteristics of the final particle such as size, 
shape, morphology, surface properties and electrostatic charge (Ward and Schultz, 
1995). Milling also causes disruption in the drugs crystal lattice resulting in the presence 
of disordered or amorphous regions in the final product which make such particles 
thermodynamically unstable and render them susceptible to recrystallization on storage 
(Ward and Schultz, 1995). Alternatives to milling are spray drying, solvent-diffusion and 
supercritical fluid technology (Quintanar-Guerrero et al., 1998; Hu, 2004a). One of the 
advantages of these methods is the possibility of designing the formulation with certain 
beneficial characteristics such as enhancing dissolution rate by inclusion of surfactant or 
increasing the stability of amorphous material by incorporation of sugars. Poloxamer 407, 
a hydrophilic surfactant, has been used to improve the particle wetting and dissolution 
rate, via spray drying so as to improve the oral absorption of griseofulvin which is known 
to have poor solubility properties (Wong et al., 2006). 
 
2.4.2. Solid dispersion systems for bioavailability enhancement of poorly water-
soluble drugs 
Solid dispersion is another promising method for improving the oral bioavailability of 
poorly water-soluble drugs. Reduction of the particle size of a drug to an absolute 
minimum improves the wettability which may significantly improve the bioavailability. Solid 
dispersions usually present as amorphous products and are mainly obtained by two 
different methods, such as melting and solvent evaporation. Recently, surfactants have 
been included into solid dispersions to avoid recrystallization and also to potentiate their 
solubility (Vasconcelos et al., 2007). The success that has been recorded with the 
application of solid dispersions has been largely due to the use of polymeric carriers since 
they can give rise to amorphous solid dispersions. Polymeric carriers are either synthetic 
or natural product-based macromolecules. Synthetic polymers include povidone, 
poly(ethylene glycol) and polymethacrylates. Natural product-based polymers are mostly 
synthesized from cellulose derivatives, such as hydroxymethylpropylcellulose, 
ethylcellulose, hydroxypropylcellulose or starch derivatives like cyclodextrins. A higher 
efficiency is expected from solid dispersions than solubilization and particle size reduction 
techniques because of the particle size reduction limit of between 2 and 5 microns in the 
latter methods. This particle size range is frequently not enough to considerably improve 
the drug solubility or drug release in the small intestine and consequently the 
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bioavailability (Karavas et al., 2006; Muhrer et al., 2006). However, despite extensive 
expertise that exists regarding solid dispersions, they are not broadly used in commercial 
preparations mainly due to the possibility that during processing (mechanical stress) or 
storage (temperature and humidity stress), the amorphous state may undergo 
crystallization (Pokharkar et al., 2006). Another drawback associated with solid 
dispersions is their poor scaling-up possibility for manufacturing purposes (Vasconcelos 
et al., 2007). An improvement to these problems might be the development of a dry 
emulsion which does not require any milling or chemical modification as a useful delivery 
approach. For example, Jang and co-workers (2006), reported an improved photostability 
and oral bioavailability of amlodipine using a redispersible dry emulsion method.  
 
2.4.3. Lipid suspensions, solutions and emulsion systems for bioavailability 
enhancement of poorly water-soluble drugs 
Recently, there has been an increasing interest in formulations of poorly water-soluble 
drugs in lipid vehicles as a means of enhancing drug solubilization and absorption in the 
GIT (Pouton, 2006; Porter et al., 2007) due to some findings which have demonstrated 
that the oral bioavailability of certain poorly water–soluble drugs, as well as lipophilic 
drugs may be enhanced when co-administered with a fat-rich meal (Welling, 1996; 
Sunesen et al., 2005). As a result, lipid suspensions, solutions and emulsions have all 
been employed to enhance the oral bioavailability of poorly water-soluble drugs and more 
recently, there has been an increase in the utility of self-emulsifying lipid-based 
formulations (Sunesen et al., 2005). In formulating lipid solutions however, digestive lipids 
such as soybean oil, corn oil or olive oil are often preferred. The enhanced drug 
solubilization in the colloidal species formed by digestion of these lipid vehicles and the 
resultant intercalation of the lipid digestion products into endogenous bile salts and 
phosphatidylcholine micellar structures, have been reported to be responsible for the 
observed improved bioavailability (Porter et al., 2008). However, despite the proven utility 
of self-emulsifying lipid-based formulations, relatively few lipid-based products have been 
scaled up and made available commercially. The existing few examples include Neoral® 
(cyclosporine, Novartis Pharma, Basel, Switzerland), Norvir® (ritonavir, Abbott 
Laboratories, Abbott Park, Illinois, USA), Fortovase® (saquinavir, Roche Laboratories, 
Basel, Switzerland), Agenerase® (amprenavir, Glaxosmithkline, Uxbridge, Middlesex, UK), 
cholecalciferol lipid solution (Vitamin D) and other lipid soluble vitamins. It has often been 
observed that the formulation is as important as the active drug. Thus, proper 
manipulation of drug formulation technologies has great potential for improving the oral 
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bioavailability of drug compounds, and therefore solving the array of drug delivery 
problems to a degree. 
 
2.5. Nanotechnology Approaches for Bioavailability Enhancement of Poorly Water-
Soluble Drugs 
 
Nanotechnology offers a means of providing novel formulations for existing marketed 
drugs and new drug candidates with poor water solubility. Nanocrystal formulations shrink 
the drug’s particle size thereby increasing the surface area and enhancing dissociation 
(du Toit et al., 2007) (Table 2.3). Pharmaceutical application of nanoscience seems to 
have evolved from observed increase in solubility of chemical substances after size 
reduction. When the size of material is reduced to less than 100nm, the principles 
inherent in quantum physics increasingly apply and materials begin to demonstrate 
entirely new properties such as enhanced solubility which is helpful in increasing the oral 
bioavailability of poorly water-soluble drugs (du Toit et al., 2007). This has therefore led to 
a number of nano-based drug delivery systems being developed. These systems serve as 
drug carriers and include micelles, nanoparticles, nanogels, nanoemulsions, liposomes, 
nanofibres, polymer therapeutics and nanodevices, examples of which are represented in 
Figure 2.4.  
 
Figure 2.4: Representative nano-based pharmaceutical carriers employed for the 
enhancement of the oral bioavailability of poorly water-soluble drugs (Kaparissides et al., 
2006). 
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Elan Pharma (Pty) Ltd. (Dublin, Ireland), is one of the first companies to nanosize drugs, 
and currently boasting of four products on the market. Its first nanotechnology based 
formulation of Wyeth’s Rapamune (sirolimus which is an immunosuppressant to prevent 
organ transplant rejection, was developed and approved by US Food and Drug 
Administration in 2000 and has become the fastest selling drug in the transplant market. 
Some of the key nanotechnology-based approaches for the enhancement of drug 
solubility and oral bioavailability according to Saffie-Siebert and co-workers (2005) are 
highlighted in Table 2.3. There is a high expectation and possibility that nanotechnology 
will find useful application and provide a lasting solution to many challenges in 
pharmaceuticals and medicine as the natural biological (cellular) interface operates at the 
nanoscale level (i.e. 1-100nm). However, as promising as it appears to be, together with 
its multifaceted applications including developments in drug delivery, advancement in 
nanotechnology has raised safety concerns (Sun et al., 1999; Filho et al., 2007; Ahamed 
et al., 2008;). Known properties of some familiar materials can change when they enter 
the nanometer range (Filho et al., 20070). The fact that exposure of animals to 
nanoparticles can lead to neurological damage as well as respiratory and circulatory 
problems, has driven governmental research into the safety of these new technologies 
(Saffie-Siebert et al., 2005; Oberdoster et al., 2005).  
 
Other issues that need attention for a wider acceptance of nanoparticle-mediated delivery 
of biologicals include low incorporation efficiency of hydrophilic drugs, precise control of 
drug release and avoidance of particle aggregation (Morishita and Peppas, 2006). With a 
responsible research and development strategy, including early consideration of public 
safety concerns, significant therapeutic advances are to be expected from this growing 
field within the next few years.  
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Table 2.3: Diverse nanotechnology-based approaches employed by various 
pharmaceutical companies.  
Company Nanotechnology-based 
formulation approach 
Example Description and 
Reference 
 
Elan Pharma 
International  
(Dublin, Ireland) 
 
Nanocrystal drug particles 
(<1,000nm) production by wet-
milling and stabilised against 
agglomeration through surface 
adsorption of stabilizers, applicable 
to new molecular entities like 
aprepitant, also for reformulation of 
existing drugs e.g. sirolimus 
  
Nanocrystal drug 
particle 
(Physorg.com, 2005) 
Eurand 
Pharmaceuticals 
(Vandalia, Ohio 
USA) 
Nanocrystal/amorphous drug 
production by physical breakdown 
of the crystal lattice and stabilised 
with biocompatible carriers 
(swellable microparticles or 
cyclodextrins) 
 Cyclodextrin 
nanoparticle (Bean, 
2006) 
SkyePharma 
Plc, (Piccadily, 
London, UK) 
Use of high shear, cavitation or 
impaction forming micro-nanomicro 
particulate/droplet water insoluble 
drug core stabilized by 
phospholipids, applicable for 
insoluble drug delivery 
 A polymer stabilizing 
nano reactor with the 
encapsulated drug 
core (Kaparissides et 
al., 2006) 
BioSante 
Pharmaceuticals 
(Lincolnshire, 
Illinois, USA) 
Formation of nanoparticles that are 
Calcium Phosphate-based for 
improved oral bioavailability of 
hormones/proteins such as insulin; 
also as vaccine adjuvants 
 Calcium phosphate 
nanoparticles (Loher 
et al., 2005) 
American 
Biosciences 
(Blauvelt, NY, 
USA) 
Nanoparticle albumin-Bound 
technology: Injectable suspension 
of biocompatible protein with drug 
improves solubility/removes need 
for toxic solvents; e.g. paclitaxel-
albumin nanoparticles 
 Paclitaxel albumin 
nanoparticles (Lvov 
et al., 2008) 
Baxter 
Pharmaceuticals 
(Deerfield, 
Illinois, USA) 
Nanoedge technology: drug particle 
size reduction to nano range by 
platforms including direct 
homogenisation, microprecipitation, 
lipid emulsions and other dispersed-
phase technology 
 
 
 
 
 
 
 
Nano lipid emulsion 
(Miller et al., 2006) 
pSivida Ltd. 
(Watertown, 
MA, USA) 
Structuring of drug particles within 
the nano-width pores of 
biocompatible BioSilicon 
nanoparticles, membranes or fibres; 
which gives controlled release and 
improves the solubility and 
bioavailability of hydrophobic drugs 
 Silicon nanoparticles 
(Physorg.com, 2005) 
iMEDD Inc 
(Burlingame, 
CA, USA) 
Use of silicon membrane with nano-
width pores (10-100nm) used as 
part of an implantable system for 
drug delivery and biofiltration 
 
 
 
 
 
 
 
 
Stretchable silicon 
nanomembrane 
(Physorg.com, 2008) 
PharmaSol 
GmbH (Berlin 
Germany) 
Nanostructured lipid carriers: 
nanostructured lipid particle 
dispersions with solid contents 
produced by high-pressure 
homogenisation; lipid-drug 
conjugate nanoparticles provide 
high-loading capacity for hydrophilic 
drugs for oral delivery 
 Drug encapsulated in 
lipid nanoparticles 
[(Kaparissides et al., 
2006) 
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2.6. The Pro-drug Approach for Overcoming Poor Bioavailability and Chemical 
Instability 
 
Classical pro-drug design often represents a non specific chemical approach to mask 
undesirable drug properties such as limited bioavailability, lack of site specificity and 
chemical instability (Patel, 2008; Xu et al., 2009). Although there is no strict universal 
definition for a pro-drug itself, and the definition may vary from author to author, pro-drugs 
can be generally defined as pharmacologically inert chemical derivatives that can be 
converted in vivo to the active drug molecule, enzymatically or non-enzymatically, to exert 
a therapeutic effect (Han and Amidon, 2000). Pro-drug design can be very effective in 
solving many of the stability, solubility, permeability and targeting problems that plague 
drug delivery and bioavailability.  
 
Pro-drugs are made from several pro-moieties of various functional groups, including acyl, 
alkyl, alkanoic, and alkanoate groups. The principle behind this is that the chemical 
conversion into the active compound takes place once the stage for the unwanted 
property has been surpassed (Meyers and Borch, 2000; Napier et al., 2000; Rautio et al., 
2008). The chemical stability of pro-drugs may be different under enzymatic conditions 
(Meyers and Borch, 2000). Pro-drugs of simple alkyl esters, cyclic carbonate esters and 
acyclic double esters often present their own advantages and disadvantages. Simple alkyl 
esters are not usually substrates of human blood esterases. They tend to rely on hepatic 
hydrolysis, and have been used successfully for many ACE inhibitors like enalapril which 
is converted to the active enalaprilat in vivo (Pang et al., 1984). Cyclic carbonate esters 
and acyclic double esters can be activated by human blood borne esterases and have 
been used successfully for antibiotics, antivirals, and angiotensin II antagonists (Rautio et 
al., 2008). Generally, esters are the most common type of pro-drugs and are converted 
back to the active parent via the ubiquitous esterases present in blood, tissues and 
organs. Levodopa, a drug used in the management of Parkinsonism, is a pro-drug that is 
converted to dopamine by DOPA-decarboxylase in the body. Dopamine itself is easily 
metabolized by aminases and hardly crosses the blood-brain barrier (Hall et al., 2007). 
Gabapentin is an anticonvulsant used for the treatment of epilepsy and post-herpetic 
neuralgia, but suffers from suboptimal pharmacokinetic properties including saturable 
absorption, high inter-patient variability, lack of dose proportionality and short half life (Hu, 
2004a). To improve on these shortcomings, XP-13512 was developed by XenoPort, Inc, 
(Santa Clara, CA, USA) as an oral pro-drug. XP-13512 is a substrate of MCT-1, a 
monocarboxylate transporter (MCT) which is highly expressed in all segment of the colon 
as well as upper GIT, and is a sodium-dependent transport system responsible for 
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transfer and distribution of multiple vitamins from the various absorptive tissues (Cundy et 
al., 2004). Oral bioavailability increased from 25% for gabapentin to 85% for XP-13512 in 
monkeys, and no saturation was observed for increasing pro-drug doses (Cundy et al., 
2004; Hu, 2004b). XP-13512 is cleaved to gabapentin by non specific esterases in the 
intestine, liver, and blood with low pro-drug exposure (<2%) in human clinical trials, while 
the tablet formulation of the pro-drug allows twice daily dosing. XP-13512 is currently in 
phase II clinical trials for post-herpetic neuralgia and restless legs syndrome (Wittmaack-
Ekbom's syndrome) (Cundy et al., 2004; Hu, 2004b).  
 
A pro-drug strategy was also found to overcome P-glycoprotein (P-gp)-mediated efflux by 
utilizing nutrient transporters expressed on the outer leaflet of cellular membranes (Hu, 
2004a). Quinidine which is well known substrate of P-gp, was conjugated to valine in the 
form of an ester. Valine-quinidine does not interact with P-gp even at high concentrations. 
As reported by Hu (2004b), pro-drug design can effectively enhance oral bioavailability. A 
few examples of the successful application of pro-drug design are discussed in the 
following sub-sections.  
 
2.6.1. Ximelagran as a pro-drug of melagran 
Melagatran was identified in the 1990s as a potent direct inhibitor of thrombin and platelet 
aggregation. Its oral bioavailability was only about 5% which was further reduced when 
dosed with food due to the presence of two strongly basic groups and one carboxylic acid 
group. It is present as a zwitterion at intestinal pH. Ximelagatran is a pro-drug of 
melagatran designed by AstraZeneca Pharma (London, UK) to increase its permeability 
while maintaining its beneficial pharmacological properties. The carboxylic acid of 
melagatran was converted to an ester and the imidine was hydroxylated to reduce its 
basicity, leading to a compound that is not charged at intestinal pH, 170-fold more 
lipophilic and 80-fold more permeable than the parent. Ximelagran is virtually inactive 
towards thrombin and is rapidly converted to the active melagatran in vivo across a wide 
range of patient populations, leading to a much improved bioavailability of about 20% for 
the active melagran. 
 
2.6.2. Fosamprenavir as a pro-drug of amprenavir 
The HIV protease inhibitor amprenavir was approved by FDA in 1999 for use in adults 
and children with HIV infection, but its limited water solubility requires the use of softgel 
formulation for delivery and multiple pills for a single dose. Fosamprenavir calcium is a 
pro-drug of amprenavir developed by GlaxoSmithKline (Uxbridge, Middlesex, UK) with 
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improved aqueous solubility. After screening 60 pro-drugs through in vitro and in vivo 
assays, the phosphate pro-drug, fosamprenavir calcium (GW433908), was selected for its 
high water solubility, solution and solid-state stability, as well as its rapid conversion to the 
parent drug on the apical side of epithelium. The pro-drug is designed as a solid dosage 
form in such a way that the amount of pills required to be taken is significantly reduced, 
two tablets replacing eight amprenavir softgels. Fosamprenavir calcium was approved in 
October 2003 for use in combination with other antiretroviral agents for the treatment of 
HIV infection in adults (Hester et al., 2006). 
 
2.6.3. Development of ampiroxicam to overcome gastric irritation associated with 
piroxicam 
Piroxicam is an NSAID that can cause serious gastrointestinal perforation, ulceration, and 
bleeding. Ampiroxicam which is a pro-drug for Piroxicam was developed by Pfizer 
International (NY, USA) to reduce gastric irritation associated with piroxicam. Over 225 
piroxicam derivatives were synthesized and screened for COX inhibition, bioavailability in 
the rat, solid state stability, and absorption in dogs. In a preclinical ulcerogenic study in 
rat, UD50 for ampiroxicam was 38.6mg/kg while for piroxicam UD50 was 17.9mg/kg. Also 
in clinical trials, ampiroxicam also showed comparable therapeutic efficacy. 
 
2.6.4. Development of tenofovir disoproxil fumarate as a pro-drug to improve the 
permeability of tenofovir across biological membranes 
Tenofovir is an acyclic nucleoside phosphonate that undergoes phosphorylation to form 
tenofovir diphosphonate, a potent inhibitor of viral reverse transcriptase. However, 
tenofovir is a dianion at physiological pH with a low partition coefficient, leading to low and 
erratic oral bioavailability. Tenofovir disoproxil fumarate has been developed as a pro-
drug to improve the permeability of tenofovir across biological membranes. Tenofovir 
disoproxil, the bis-isopropoxyl carbonate, was the most stable of several evaluated 
phosphonate pro-drugs and was quickly converted back to the parent tenofovir in the 
presence of tissue homogenates. Oral bioavailability of tenofovir in beagle dogs is about 
30%. Tenofovir disoproxil fumarate is chemically stable in solid state, is non-hygroscopic 
up to 93% relative humidity at room temperature and shows relatively, rapid dissolution. 
More important is that it has an oral bioavailability of about 43% in humans which 
therefore can allow only a once-daily dose (Cundy et al., 2004). Thus, the pro-drug design 
approach can be applied to enhance intestinal permeation of pharmaceuticals, to inhibit 
degradation by gastrointestinal and hepatic enzymes and to reduce the incidence of 
unwanted effects. 
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2.7. Concluding Remarks 
 
Despite sophisticated new drug delivery systems, the development of satisfactory oral 
formulations remains a challenge since adequate drug delivery for most formulations has 
not been attained. This is in part a consequence of low bioavailability presented by 
numerous orally administered drugs. Notably, this is particularly so for peptides, proteins 
and nucleic acid molecules, due to their sensitivity to chemical and enzymatic hydrolysis 
as well as a poor cellular uptake. This low bioavailability implies a large variation in 
absorption/plasma levels as well as high manufacturing costs which are both 
unacceptable for drug development. It should be acknowledged that various novel drug 
delivery designs have tremendously improved drug absorption. Micronization and 
nanopharmaceutical application have to a large extent broken the barriers of poor GIT 
penetration while various novel formulation techniques have aided drug dissolution and 
absorption across the GIT wall. Significantly however, increased rate of absorption has 
not always translated into higher extent of absorption. This is due to exposure of 
absorbed drugs through the gut wall and the liver to CYP-induced pre-systemic 
metabolism. Thus, more strategies should be put forward if the improvement in oral 
bioavailability is to be attained. Among the possible strategies is the design and 
application of CYP inhibitors, the actions of which will be transcient to allow the normal 
course of drug elimination. In this case, competitive inhibition of the metabolic enzymes 
will be a preferable mechanism. This allows the utilization of the inhibitors while the drug 
escapes the first-pass. This is an exciting approach towards the enhancement of uptake 
and transport of orally administered molecules, leading to the requirement of relatively 
lower doses and decreasing incidences of adverse effects.  
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CHAPTER THREE 
IN VITRO INVESTIGATION OF THE EFFECTS OF GRAPEFRUIT FLAVONOIDS ON 
THE METABOLISM OF FELODIPINE AND PHENACETIN EMPLOYING HUMAN LIVER 
MICROSOMES 
 
 
3.1. Introduction 
 
Multiple drug administration is often necessary in clinical practice for desirable therapeutic 
synergies and especially in the presence of co-morbidity. Major concerns however arise 
with the administration of drugs that share similar pharmacokinetic pathways. The 
resulting drug-drug interaction could produce unwanted side-effects, toxicological 
manifestations or therapeutic failure. The most significant mechanism of such interaction 
is the induction or inhibition of metabolic enzymes usually responsible for the systemic 
clearance of the drugs. This is the basis for most drug-drug contra-indications in 
pharmacotherapy (Lin and Lu, 1998; Thummel, 1998; Lin, 2003). 
 
Recently, food-drug interaction has also become an important consideration in oral drug 
delivery (Sorensen, 2002; Dahan and Altman, 2004). The desirability of fed-state or fasted 
conditions for oral drug administration is often determined by considerations for food-drug 
interaction (Williams et al., 1993; Schmidt and Dalhoff, 2002). Elemental components of 
proteinaceous and fatty food substances are known to chelate a few drugs. A typical 
example is the formation of insoluble complexes between polyvalent metals and some 
antibiotics including tetracyclines and penicillins which significantly reduces the oral 
absorption and bioavailability of the latter (Gu, 2005). Bailey and co-workers (1998), 
reported an unexpected observation of increased plasma felodipine levels in a drug 
interaction study between the calcium channel antagonist, felodipine and ethanol where 
subjects were given grapefruit juice to obscure the taste of ethanol. A marked increase in 
oral bioavailability has been reported in various other CYP3A4 substrates including 
nisoldipine, nifedipine, midazolam, triazolam and cyclosporine following concurrent 
grapefruit consumption (Soons, et al., 1991; Hollander et al., 1995; Josefsson et al., 1996; 
Kupferschmidt et al., 1997; Andersen et al., 2002). The inability of other common fruit 
juices to exert the same effect has led to conclusions that certain components unique to 
grapefruit juice might be responsible for this observation. Grapefruit juice did not change 
the pharmacokinetic profile of felodipine which suggests the inhibition of pre-systemic 
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metabolism as its mechanism of action (Bailey et al., 1993). Grapefruit juice contains a 
range of flavonoids and furanocoumarins including naringin, naringenin, quercetin, 
kaempferol and bergapten. Further studies have suggested these phytochemical 
constituents could be responsible for the inhibitory effects on intestinal CYP3A4 enzymes 
(Minicalo, et al., 1992; Ho and Saville, 2001; Choi and Burm, 2006; Quintieri et al., 2008). 
Consequently, the consumption of grapefruit juice has been listed in most CYP3A4 
substrates’ monographs as being contra-indicated. This is for the concerns of increased 
bioavailability with possible toxicological consequences. 
 
Research in drug metabolism has attracted more attention in recent times not only 
because it forms the basis for understanding pharmacotoxicology but for its growing 
influence and application in drug delivery and pharmacotherapy (Davila et al., 1998; 
Cross and Bayliss, 2000; Ekins et al., 2000; Ehrhardt and Forbes, 2005). Inhibition of first-
pass drug metabolism is desirable in order to improve oral drug bioavailability and clinical 
outcomes (Agoram et al., 2001; Breedveld et al., 2006) while the induction of enzymatic 
metabolic activity may be applicable in clinical toxicity (Uwe, 2000). The human CYP 
enzyme system present in the liver and intestine is responsible for the metabolism of a 
wide range of xenobiotics (drugs, carcinogens, pesticides) and endobiotics 
(prostaglandins, bile acids, steroids) (Zhang and Benet, 2001; Handschin et al., 2002; 
Guengerich, 2003; Gonzalez, 2005; Fang and Xiao-yin, 2005; Nebert and Dalton, 2006). 
It is the ability of CYP to metabolize numerous structurally unrelated compounds (Chapter 
two, Section 2.2) that is responsible for the poor oral bioavailability of many drugs as they 
are subjected to pre-systemic CYP-mediated metabolic activity (Dresser et al., 2000; 
Quintieri, et al., 2008). The large number of documented drug-drug and drug-food 
interactions has also been attributed to intestinal and liver microsomal CYP activity (Wang 
et al., 2000; Ohyama et al., 2000; Obach et al., 2006). 
 
3.2. In Vitro Drug Metabolism Techniques 
 
One of the major steps involved in the development of new drug candidates is the 
verification of their potential for oral bioavailability and interaction with other drugs (Veber 
et al., 2002). Various challenges are experienced in extrapolating the results of animal 
studies to humans, and as a result, various in vitro methods have been developed 
employing human tissue-derived systems. In vitro investigations of drug metabolism 
provides information regarding the metabolic stability of the test drug, its potential for 
possible interactions with other compounds that have affinity for the same drug-
42 
 
metabolizing enzymes, and indication of its oral bioavailability and toxicological 
tendencies (White, 2000; Masimirembwa et al., 2001; Veber et al., 2002). 
 
One of the best characterized and validated models for drug metabolism studies is the 
use of microsomes fractionated from the human liver subcellular organelles by differential 
ultracentrifugation (Wrighton et al., 1993; Ekins et al., 2000). A human liver microsomal 
fraction contains a full complement of CYP which makes it a suitable tool for studying 
CYP-catalyzed metabolite formation and inhibitory interactions. In addition to reliability 
and reproducibility of in vitro data generated from their use, human liver microsomes are 
relatively easy to prepare, commercially available and stable on prolonged storage. This 
has made the application of liver microsomes the most widely used in metabolic and 
toxicological studies (Taavitsainen, 2001).  
 
Other in vitro methods for drug metabolism studies include the utilization of human 
primary hepatocytes. Human hepatocytes are difficult to preserve and their preparation 
requires a large number of liver samples (Gomez-Lechon, 2003). These factors have 
greatly restricted the use of primary hepatocytes for in vitro studies. The use of permanent 
cell lines expressing one or more drug-metabolizing enzymes has also been described 
but with limited utilisation due to the lack of the complement of metabolizing enzymes 
present in vivo (Pelkonen and Raunio, 2005). As valuable alternatives to human liver 
microsomes for drug metabolic studies, cDNA-expressed enzymes produced in the 
endoplasmic reticulum of an eukaryote host-cell including bacteria, yeast, baculovirus 
systems and mammalian cell lines have also been described. A few researchers however 
have expressed reservations on the utilization of cDNA-expressed enzymes and the in 
vivo correlative value of the data generated because the enzymes lack the whole 
complement of hepatic metabolic enzymes and are studied in isolation (Taavitsainen, 
2001; Plant, 2004).  
 
In most studies therefore, the search for a suitable CYP enzyme inhibitor for oral 
bioavailability enhancement has involved the utilisation of HLM, the results of which are 
closer to in vivo studies. Such in vitro investigations are optimized by either measuring the 
rate of disappearance of substrates in incubation mixtures or the rate of formation of a 
specific metabolite.  
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3.3. Felodipine and Phenacetin as Probe Substrates for CYP-Mediated Metabolism 
 
A list of recommended probe substrates and inhibitors for studies of drug metabolism by 
various CYP isozymes is presented in Table 3.1. Felodipine, a typical probe substrate is a 
dihydropyridine calcium channel blocker which has been effective in the management of 
cardiovascular diseases including hypertension, angina pectoris, arrhythmias and 
congestive heart failure. It is highly lipophilic and exhibits excellent tissue penetration but 
with a mean systemic oral bioavailability of 15% independent of the oral formulation used, 
due to CYP-induced pre-systemic metabolism (Dresser et al., 2000). Its primary route of 
inactivation is the oxidation of the dihydropyridine ring to the inactive dehydropyridine 
metabolite, a reaction mediated by CYP3A4 (Bailey et al., 1995). The pre-systemic 
abundance of CYP3A4 in the intestines and the liver is therefore responsible for the poor 
oral bioavailability of all the dihydropyridines. 
 
 
Table 3.1: A list of recommended in vitro probe substrates and inhibitors for CYP 
isozymes (Source: Taavitsainen 2001 and Bjornsson et al., 2003). 
CYP Substrate Specific reaction Inhibitor 
 
1A2 
 
Ethoxyresorufin 
Phenacetin 
 
O-deethylation 
O-deethyaltion 
 
furafylline 
2A6 Coumarin 7-hydroxylation 8-methoxypsoralen 
2B6 S-mephenytoin N-demethylation Orphenadrine 
Sertraline 
2C8 Paclitaxel 6α-hydroxylation Quercetin 
2C9 Tolbutamide 
 
Diclofenac 
S-warfarin 
Methyl hydroxylation 
Hydroxylation 
7-hydroxylation 
Sulfaphenazole 
2C19 S-mephenytoin 
omeprazole 
4’-hydroxylation 
oxidation 
Ticlopidine 
2D6 Dextromethorphan 
Debrisoquine 
Bufuralol 
O-demethylation 
4-hydroxylation 
1-hydroxylation 
Quinidine 
2E1 Aniline 
Chlorzoxazone 
4-hydroxylation 
6-hydroxylation 
Pyridine 
Clomethiazole 
3A4 Midazolam 
 
Testosterone 
Felodipine 
Nifedipine 
1’- and 4 
hydroxylation 
6ß-hydroxylation 
Dehydrogenation 
Dehydrogenation 
 
Ketoconazole 
Verapamil 
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Phenacetin is an analgesic that was popular in the 70s and 80s (Sanerkin, 1971; Clissold, 
1986). It is a pro-drug known to be converted in vivo to acetaminophen, the active 
metabolite. Following oral absorption, phenacetin is completely absorbed but undergoes 
favorable pre-systemic metabolism in the liver. Its first metabolic step is CYP1A2-
catalyzed o-deethylation. This makes phenacetin a suitable probe substrate for CYP1A2 
metabolic activity. Further metabolism of phenacetin usually includes phase two reactions 
of metabolite conjugation with glucuronide, sulfate or glutathione to form soluble 
complexes that are ultimately excreted in the urine.  
 
The aim of the present study was therefore to optimize and validate in vitro techniques for 
drug metabolism employing CYP1A2- and CYP3A4-expressed HLM. In this study the rate 
of felodipine consumption was explored as the determinant of CYP3A4 metabolism while 
the rate and extent of paracetamol formation was used to measure CYP1A2-catalyzed o-
deethylation of phenacetin. The present study also investigated the effect of quercetin, 
naringin and naringenin on CYP3A4-dependent metabolism of felodipine and formation of 
paracetamol, a specific and measurable product of CYP1A2-catalyzed o-deethylation of 
phenacetin. The effect of these flavonoids on felodipine metabolism was compared to that 
of verapamil, a known competitive inhibitor of CYP3A4.  
 
3.4. Materials and Methods 
 
The strategies employed in this study are outlined in Figure 3.1. Detailed description of 
the steps outlined follows in the subsequent sections. 
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Development of assay 
methods for felodipine 
and phenacetin 
Development and 
optimization of in vitro 
technique of drug 
metabolism employing HLM 
Investigation of the 
inhibitory effects of 
grapefruit flavonoids on 
felodipine and 
phenacetin metabolism 
Quantitative analysis of 
felodipine and phenacetin 
employing the UPLC 
Profiling the analyte 
concentrations against AUC 
ratio to yield standard 
calibration curves 
Preparation of HLM mixtures, 
felodipine and phenacetin 
dilutions, NADP-regenerating 
system and potassium 
phosphate buffer 
Separate incubation of felodipine 
and phenacetin in HLM, buffer and 
NADP-regenerating system 
employing the shaking orbital 
incubator 
Termination of metabolism with 
ice-cold acetonitrile, 
refrigerated centrifugation to 
precipitate HLM proteins and 
filtration of supernatants 
Addition of Internal Standard and 
quantitative determination of 
felodipine, phenacetin and their 
metabolites employing the UPLC 
Preparation of graded 
concentrations of quercetin, 
naringin, naringenin and 
verapamil for metabolism 
inhibition study 
Co-incubation of each of 
quercetin, naringin, 
naringenin and verapamil with 
metabolism incubation 
mixture separately containing 
felodipine and phenacetin 
Termination of metabolic 
reactions with ice-cold 
acetonitrile, refrigerated 
centrifugation to precipitate 
HLM proteins and filtration of 
the supernatant 
Addition of Internal Standard and 
quantitative determination of 
felodipine, phenacetin and their 
metabolites employing UPLC 
 
Analysis and determination of 
enzyme kinetic parameters 
employing the Enzyme Kinetic 
Module software 
Analysis of the effects of 
quercetin, naringin and naringenin 
on the metabolism of felodipine 
and phenacetin compared to 
verapamil, a known CYP3A4 
inhibitor 
Figure 3.1: A schematic representation of the techniques employed in the current study.  
a) b) c) 
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3.4.1. Materials 
Pooled mixed gender human liver microsomes (HLM) expressing CYP3A4, CYP2C9, 
CYP4A11, CYP4F2, CYP2E1 and CYP2A6 were purchased from BD Biosciences (Pty) 
Ltd. (Woburn, MA, USA) and stored at -70ºC until used. Supply information indicated that 
microsomes were prepared from donor human livers (16 male, 14 female; 26 Caucasians, 
2 African-American and 2 Hispanics; age range 24-78 years; non-smokers, non-drinkers 
with non-liver related cause of death with no significant medical history). Felodipine 
(C18H19Cl2NO; MW=384.26g/mol), verapamil hydrochloride (C27H38N2O4.HCl; 
MW=491.08g/mol) loperamide (C29H34Cl2N2O2; MW=477.04g/mol), phenacetin (C10H13NO2; 
MW=179.22) and sodium citrate (C6H5Na3O7.2H2O; MW=294.1g/mol; molecular biology 
grade) were purchased from Merck Chemicals (Pty) Ltd. (Darmstadt, Germany). 
Quercetin (C15H10O7; MW=302.236g/mol), naringin (C27H32O14; MW=580.54g/mol), 
naringenin (C15H12O5; MW=272.25g/mol), D-glucose 6-phosphate monosodium (G6P), 
glucose 6-phosphate dehydrogenase (G6PDH) and nicotinamide adenine dinucleotide 
phosphate (NADPH, reduced form) were purchased from Sigma-Aldrich (Pty) Ltd. (St 
Louis, MO, USA). Molecular biology grade potassium phosphate monobasic (KH2PO4, 
MW=136.1g/mol) and dibasic (K2HPO4, MW=228.2g/mol) were purchased from EMD 
Chemicals (Pty) Ltd. (Gibbstown, NJ, USA). All other chemicals and reagents were of 
standard guaranteed reagent grade and used as received under stringent bio-analytical 
protocols. 
 
3.4.2. Assay method development for felodipine, phenacetin and paracetamol 
analysis 
3.4.2.1. Quantitative analysis of felodipine concentration 
A method of quantitative determination of felodipine was developed using the UPLC. 
Standard curves were yielded with isocratic baseline separation of felodipine and 
loperamide (internal standard) using UPLC technology (Waters® Acquity UPLC™ System, 
Milford, MA, USA) comprising a binary solvent and a sample manager; a BEH C18 column 
(1.7µm; 2.1x50mm) and a Photodiode Array (PDA) detector set at 200nm. Felodipine 
solutions were prepared in acetonitrile with concentrations ranging from 31.25-
1000µmol/L. The mobile phase comprised 0.025M KH2PO4 buffer (pH 2.5) and 
acetonitrile (50:50) with a flow-rate of 0.2mL/min (7000psi, delta ˂20) while 1.7µL equal 
volume of sample and 50µmol/L loperamide was injected on to the column at 25ºC. 
Double-deionized water obtained from a Milli-Q water purification system (Milli-Q, 
Millipore, Billerica, MA, USA) was used for all aqueous dilutions. Loperamide eluted at 
1.48±0.02 minutes while felodipine eluted at 5.1±0.02 minutes. Complete separation of 
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the sample and the internal standard were confirmed by two- and three-dimensional 
chromatographic separation. 
 
3.4.2.2. Quantitative analysis of phenacetin and paracetamol 
Using techniques similar to the one described in Section 3.4.2.1., a method of 
chromatographical separation and quantitative determination of paracetamol and 
phenacetin was developed. A complete separation was obtained by injecting 1.7µL of 
sample containing equal volume of 0.05M loperamide (internal standard) through a BEH 
phenyl column (1.7µm; 2.1x100mm) in a gradient binary mobile phase comprising 0.025M 
KH2PO4
 (pH 2.5) and acetonitrile (Table 3.2) at a flow-rate of 0.25mL/min absorbing at 
200nm (7000psi, delta<20). Three-dimensional chromatography was used to confirm 
complete separation of phenacetin, metabolites and the internal standard. 
 
Figure 3.2: The gradient composition of the mobile phase for the separation of 
paracetamol, phenacetin and loperamide by UPLC. 
Time (Minutes) Flow-rate (mL/min) K2PO4 (%) Acetonitrile (%) 
 
Initial 
 
0.25 
 
90 
 
10 
3 0.25 60 40 
4 0.25 20 80 
5 0.25 10 90 
 
 
3.4.3. Optimization of in vitro felodipine and phenacetin metabolism employing 
human liver microsomes 
3.4.3.1. Preparation of co-factor and NADP-regenerating solutions 
Co-factor concentrates containing 400mg each of reduced NADP+ and G6P; and 0.1M of 
magnesium chloride pentahydrate was prepared in deionized water to make a 20mL 
solution and stored at -20ºC until further use. G6PDH (40U/mL) was prepared in 5mM 
sodium citrate solution and stored at -20⁰C until further use. The NADP-Regenerating 
system (NRS) comprised 130µL G6PDH, 650µL co-factor stock solution and made up to 
4.42mL with 1.3mL 0.5M phosphate buffer (pH 7.4) and deionized water. The preparation 
of the NRS was completed immediately before use. It was prepared such that on addition 
to the incubation mixture, it contained 2.6mM NADP+, 6.7mM G6P, 6.6mM magnesium 
chloride and 0.8units/mL G6PDH. 
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3.4.3.2. Preparation of felodipine, phenacetin and microsomal dilutions for 
incubation 
Felodipine and phenacetin solutions were prepared over a range of 0.01-100.0mM in 
acetonitrile. Frozen HLM (-70⁰C) was thawed in water at room temperature (25C⁰) and 
500µL (5mg protein/mL) measured with a micropipette was diluted in 0.5M phosphate 
buffer (pH 7.4) to produce a final protein concentration of 0.5mg/mL. This was kept on ice 
until further use. 
 
3.4.3.3. In vitro metabolism of felodipine and phenacetin in human liver 
microsomes 
In 24-well plates, 5µL felodipine and phenacetin solutions in duplicate were separately 
pre-warmed with 250µL 0.5mg/ml HLM for 5 minutes in a orbital shaking incubator 
(Labex, Stuart SBS40®, Helsingborg, Sweden) set at 100rpm and 37°C followed by the 
addition of 245µL NRS to initiate enzymatic metabolic reactions and a further incubation 
for 10 minutes. The reaction was halted by a stop solution comprising ice-cold acetonitrile 
(-20°C).  
 
3.4.3.4. Analysis of felodipine, phenacetin and metabolites post-incubation 
The 24-well plates were transferred to a refrigerated centrifuge (Xiang Yi L-535RTM 
Centrifuge, Changsha, China) and the incubation mixtures were centrifuged at 4°C at 
4000g for 30 minutes to precipitate the HLM proteins. The supernatants were filtered 
through a 0.22µm Cameo Acetate membrane filters (Millipore, Billerica, MA, USA) and 
analyzed by UPLC as described in Sections 3.4.2.1 and 3.4.2.2 in order to quantify the 
extent of felodipine and phenacetin metabolism. The procedures are summarized in 
Figure 3.2. The rate of felodipine metabolism was determined as the rate of 
disappearance of felodipine from the CYP3A4-dependent reaction mixture while the rate 
of paracetamol formation was used as the determinant of CYP1A2-catalyzed o-
deethylation of phenacetin. The rate of metabolism and the enzyme kinetic parameters for 
felodipine and phenacetin were determined employing the SigmaPlot Enzyme Kinetic 
Software (SigmaPlot: Enzyme Kinetic Module, Systat Software Inc., Chicago, IL, USA). 
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Figure 3.2: A schematic depicting the in vitro felodipine metabolism techniques employed 
that involved: a) incubation with HLM in 24-well plates placed in an orbital shaking 
incubator; b) refrigerated (4°C) centrifugation of the incubation mixture to precipitate HLM 
proteins; c) filtration of the supernatant through 0.22µm Cameo Acetate membrane filter; 
and d) chromatographic analysis of the filtered supernatant for substrate and metabolite. 
 
3.4.4. Investigation of the effects of grapefruit flavonoids and verapamil on the 
metabolism of felodipine and phenacetin by HLM 
Felodipine and phenacetin at their determined Michaelis-Menten constant (Km) (Section 
3.4.3.4) were incubated in HLM as described in Section 3.4.3 except for the addition of 
verapamil, and the grapefruit flavonoids. Verapamil, naringin, naringenin and quercetin 
solutions were prepared in solutions at graded concentrations ranging from  30-1000µM. 
Using a multi-channel micropipette, 5µL of each test solution was added to a 250µL 
diluted HLM solution (0.5mg/ml) using 24-well plates and pre-warmed for 5 minutes in a 
shaking incubator (100rpm; 37ºC). With the addition of the NRS, microsomal activity was 
initiated and the well plate incubated for 10 minutes. This was followed by the addition of 
5µL of felodipine and phenacetin into each corresponding well and a further incubation for 
 24-well plate 
Orbital shaking incubator 
Refrigerated 
centrifuge 
UPLC 
Membrane filter 
50 
 
10 minutes. The incubation time of 10 minutes was selected such that a significant 
fraction of felodipine and phenacetin was metabolized. Supernatants were analysed with 
UPLC method described in Section 3.4.2. To quantify the rate and extent of felodipine and 
phenacetin metabolism, control samples incubated with 0.05mg/mL microsomal proteins 
without co-factors and NRS were subjected to a similar procedure. Positive control 
incubations without test compounds allowing for maximum metabolism were also 
employed. 
 
All the test compounds investigated were poorly water-soluble except for verapamil. 
Acetonitrile is the preferred solvent for poorly water-soluble compounds in in vitro 
determinations involving subcellular fractions (Celsis, 2009) thus, the flavonoids were 
dissolved in acetonitrile. At high concentration, the effect of acetonitrile on enzymatic 
activity could be significant (Celsis, 2009). Therefore the final concentration of acetonitrile 
in the incubation mixture was ˂1%.  
 
3.5. Results and Discussion 
 
3.5.1. Assay method development 
3.5.1.1. Chromatographic separation and quantitative determination of felodipine 
Felodipine and loperamide (internal standard) were eluted after 1.464±0.02 and 
5.037±0.02 minutes, respectively (Figure 3.3). At the retention time and wavelength 
employed (200nm), no interfering peaks were noted as confirmed by three-dimensional 
chromatographical analysis (Figure 3.4).  The assay method yielded a linear calibration 
curve through the origin with the relationship y=0.0158x where ‘x’ variable represented 
felodipine concentration and ‘y’ the chromatographic felodipine/internal standard Area 
Under the Curve (AUC) ratio (Figure 3.5). Assay method validation analysis revealed 
satisfactory intra and inter-day precision and accuracy (R2=0.99).  
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Figure 3.3: UPLC chromatograms showing the retention time of felodipine (5.037 
minutes), the appearance of its metabolite (3.542 minutes) and the internal standard 
(1.434 minutes). 
 
 
 
 
 
 
Figure 3.4: A three-dimensional chromatogram showing a complete separation of 
felodipine and loperamide 
1.
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Figure 3.5: A standard calibration curve for the quantitative analysis of felodipine 
concentration by UPLC (N=3; S.D.<0.002 in all cases). 
 
3.5.1.2. Chromatographic separation and quantitative determination of phenacetin 
and paracetamol 
Paracetamol, phenacetin and loperamide (internal standard) were eluted after 
1.672±0.02, 2.400±0.02 and 3.595±0.02 minutes respectively (Figure 3.6). Complete 
separation of sample components with no interfering peaks was confirmed through a 
three-dimensional chromatographic analysis (Figure 3.7). The method was validated 
yielding a linear standard curve through the origin with the relationships y=0.0031x 
(R2=0.99) and y=0.002x (R2=0.99) for phenacetin and paracetamol, respectively. The ‘x’ 
and ‘y’ variables represented the phenacetin/paracetamol concentrations and the ratio of 
the AUCs respectively (Figure 3.8).  
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Figure 3.6: UPLC chromatograms showing the retention time of phenacetin (2.488 
minutes), the appearance of paracetamol, its metabolite (1.672 minutes) and the internal 
standard (3.595 minutes). 
 
 
 
Figure 3.7: A three-dimensional chromatogram showing a complete separation of 
phenacetin, paracetamol and loperamide. 
 
1
.6
7
2
2
.4
8
8
3
.5
9
5
A
U
0.00
0.10
0.20
0.30
0.40
0.50
0.60
Minutes
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00
-0.10
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
1.10
1.20
1.30
A
U
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00
Minutes
200.00
220.00
240.00
260.00
280.00
300.00
320.00
340.00
360.00
380.00
400.00
Paracetamol 
Phenacetin 
Loperamide 
Minutes 
ƛ (nm) 
AU 
Loperamide 
Phenacetin 
Paracetamol 
54 
 
y=0.002x
R
2
=0.99
Paracetamol Concentration (µM)
0 200 400 600 800 1000
A
U
C
 R
a
ti
o
0.0
0.5
1.0
1.5
2.0
 
Figure 3.8: A standard calibration curve for the quantitative analysis of paracetamol 
concentration by UPLC (N=3; S.D.<0.002 in all cases) 
 
3.5.2. Determination of enzyme kinetic parameters for in vitro felodipine and 
phenacetin metabolism  
Decrease in felodipine concentration in the incubation mixture as determined by UPLC 
was used as evidence of enzymatic activity while the appearance and increase in 
concentration of paracetamol was used as evidence of CYP1A2-mediated o-deethylation 
of phenacetin. Similar results were obtained when the rate of phenacetin metabolism and 
rate of paracetamol formation were used as evidence of CYP enzymatic activity. By 
comparing the felodipine concentration in the metabolized mixture with the control, the 
difference represented the quantity of substrate metabolized.  
 
In most enzymatic reactions, the Michaelis-Menten principle holds. According to this 
postulation, the initial rate of enzymatic reactions is directly proportional to the substrate 
concentration. It describes how the initial reaction rate, V0 depends on the position of the 
substrate-binding equilibrium and the rate of metabolite formation (Kou et al., 2005). 
There is a substrate concentration where reaction rate is maximal (Vmax) and beyond 
which the rate of metabolite formation is independent of further increase in substrate 
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concentration [S]. The substrate concentration corresponding to half the Vmax is referred to 
as the Michaelis-Menten constant (Km) (Hsu et al., 2001). The Michaelis-Menten equation 
as expressed in Equation 3.1 is the basis for most single-substrate enzyme kinetics. 
 
𝑉0 =
𝑉𝑚𝑎𝑥 [𝑆]
𝐾𝑚 +[𝑆]
                           Equation 3.1 
 
Where V0=the initial rate of metabolism, Vmax=the maximum rate of metabolism, [S]=the 
substrate concentration and Km=the Michaelis-Menten Constant 
 
The rate of product formation depends on both the enzyme and substrate concentrations 
reaching its peak at equilibrium where the saturation of the enzyme binding site yields the 
highest rate of product formation. A typical Michaelis-Menten curve is therefore non-linear 
and various attempts have been made to modify it in a way that enzyme kinetic 
parameters can be estimated at a glance. One of the most common linearized 
modifications to the Michaelis-Menten curve is the Hanes-Woolf Plot. It is based on the 
rearrangement of Michaelis-Menten equation as depicted in Equation 3.2. 
 
[𝑆]
𝑉
=
[𝑆]
𝑉𝑚𝑎𝑥
+
𝐾𝑚
𝑉𝑚𝑎𝑥
               Equation 3.2 
 
As presented in Equation 3.2, a plot of the ratio of the initial substrate concentration to the 
reaction velocity ([S]/V) against [S] will yield a linear graph with 1/Vmax as the slope, a y-
intercept of Km/Vmax and an x-intercept of –Km.  Hanes-Woolf Plot has been used for rapid 
and easy determination of major kinetic parameters such as the Km and the Vmax. 
 
The metabolic behavior of felodipine and phenacetin were characterized by Enzyme 
Kinetic Software capable of applying various enzyme kinetic principles including 
Michaelis-Menten and Hanes-Woolf in order to determine the enzyme kinetic parameters. 
A typical Michaelis-Menten curve yielding a Vmax of 634.1nmol/min/mg HLM and Km of 
7.4µM (Figure 3.9a) was generated on profiling the initial rate of felodipine metabolism 
against concentration. A similar curve characterized the rate of paracetamol formation 
from phenacetin as presented in Figure 3.9b yielding a Vmax of 12.7nmol/minute/mg and a 
Km of 12.2µM. 
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Figure 3.9: Michaelis-Menten Plot depicting the enzyme kinetic parameters of a) 
CYP3A4-catalyzed felodipine metabolism and b) CYP1A2-catalyzed phenacetin o-
deethylation generated by Enzyme Kinetic Software (SigmaPlot: Enzyme Kinetic Module) 
(N=3; S.D.<0.005 in all cases). 
 
Further analysis employing the Enzyme Kinetic Software was performed applying the 
Hanes-Woolf Plot. The plots generated confirmed the kinetic parameters obtained as 
depicted in Figure 3.10. Hanes-Woolf Plot has been used extensively for accurate and 
faster determination of enzyme kinetic parameters (Grace et al., 1994; Vatamaniuk et al., 
2000; Lu et al., 2004). Although literature values vary widely due to inter-laboratory 
differences and environmental conditions, kinetic parameters obtained through this 
method were reproducible, thereby validating the method for further analytical enzymatic 
determinations. 
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Figure 3.10: Hanes-Woolf Plots depicting the enzyme kinetic parameters of a) CYP3A4-
catalyzed felodipine metabolism  and b) CYP1A2-catalyzed phenacetin o-deethylation, 
generated by Enzyme Kinetic Software (SigmaPlot: Enzyme Kinetic Module) (N=3; 
S.D.<0.005 in all cases). 
 
a) b) 
a) b) 
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There is a direct correlation between in vitro and in vivo metabolism of xenobiotics by 
human liver and intestinal microsomal cytochromes (Moltke et al., 1999; Martinez et al., 
1999; Schmider et al., 1999). As a result of this, new drug candidates are usually 
subjected to in vitro microsomal reactions to determine their susceptibility to pre-systemic 
metabolism, mode of elimination from the body and interaction with other drugs. Thus 
results obtained from standardized and validated in vitro techniques are useful indicators 
of in vivo behavior. 
 
Standardization of laboratory techniques is often necessary in order to obtain reliable and 
reproducible results, and to determine best substrate concentration for optimal metabolic 
activity. HLM are sub-cellular fractions of the liver containing CYP enzymes, flavin 
monooxygenases and UDP glucuronyl transferases. HLM therefore, requires stringent 
and fastidious conditions for optimal in vitro activity. Incubation in buffer solutions (pH 7.4) 
at 37ºC, with co-factor solutions and NADP generating system has been demonstrated to 
enhance in vitro metabolic activity of HLM comparative to in vivo behavior (Yan and 
Caldwell, 2005).  
 
The Michaelis-Menten plot and its linearized forms have remained the most reliable 
mechanism of evaluation of enzyme activity. An optimal metabolic concentration for 
felodipine was predetermined in accordance with Michaelis-Menten principle. The Km 
value corresponding to the addition of 5µL of 0.75mM felodipine to a total incubation 
mixture of 0.5mL with 0.25mg/ml microsomal protein concentration as performed in this 
study agrees with earlier determinations (Miniscalo et al., 1992). Felodipine was the 
choice substrate in this study due to the initial observation of the influence of grapefruit 
juice on oral bioavailability in patients on felodipine therapy and concomitant grapefruit 
ingestion (Miniscalo et al., 1992). The predominant metabolic inactivation of the 
dihydropyridines (DHP) is the oxidation of the DHP ring to form the pharmacologically 
inactive pyridines (Figure 3.11). This step is mediated by CYP3A4 (Cardoza and Amin, 
2002). The initial assumption therefore, was the modulation of CYP3A4 by chemical 
constituents of grapefruit juice.  
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Figure 3.11: Oxidation of a) felodipine to the pharmacologically inactive b) 
dehydrofelodipine. 
 
3.5.3. Assessment of the inhibitory effects of flavonoids on felodipine metabolism 
in HLM incubation mixtures 
The flavonoids co-incubated with felodipine in HLM mixtures demonstrated an initial 
concentration-dependent inhibition of the rate and extent of felodipine metabolism. 
However, at higher concentrations, metabolism inhibition approached 100% (Figure 3.12). 
This result is in agreement with earlier determinations suggesting that flavonoids and 
furanocoumarins present in grapefruit juice are responsible for the observed increase in 
plasma felodipine concentration following a concomitant ingestion of grapefruit juice by 
patients on felodipine therapy (Miniscalo et al., 1992; Bailey et al., 1998). With IC50 values 
of 0.0631, 0.1032 and 0.0332µM respectively for quercetin, naringin and naringenin, all 
three test flavonoids compare closely to verapamil (IC50=0.0310µM) in CYP3A4 inhibition. 
Naringenin appeared more potent than naringin. This further suggested that the aglycone 
portion of the naringin glycoside exerts the inhibitory activity while the presence of the 
sugar moiety may not be necessary for inhibitory activity. With this, naringin will have to 
be hydrolyzed to its aglycone, naringenin which explains why naringenin appeared more 
potent. 
Felodipine 
Dehydrofelodipine 
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Figure 3:12: Profile of the inhibitory effects of flavonoids and verapamil on CYP3A4-
dependent felodipine metabolism (N=3; S.D.<0.004 in all cases). 
 
3.5.4. Assessment of the effects of flavonoids on the CYP1A2-catalyzed o-
deethylation of phenacetin 
All three flavonoids inhibited the rate and extent of paracetamol formation from 
phenacetin with IC50 values of 625.71, 831.43 and 8.88µM respectively for quercetin, 
naringin and naringenin. A steady concentration-dependent inhibition was observed with 
naringin and quercetin while naringenin appeared the most potent exhibiting enzyme 
inhibition tending towards 100% at a relatively low concentration (Figures 3.13). 
Compared to the effects on felodipine metabolism, the flavonoids exhibited less inhibitory 
activity against paracetamol production from CYP1A2-catalyzed phenacetin metabolism 
as demonstrated by the IC50 values. The influence of the flavonoids on the metabolic 
activity of CYP1A2 and CYP3A4 is compared in Table 3.3. 
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Figure 3:13: The effects of varying concentrations of a) naringenin, b) naringin and c) 
quercetin, on phenacetin metabolism by HLM (N=3; S.D.<0.005 in all cases). 
 
Table 3.3: Comparison of the inhibitory properties of grapefruit flavonoids against 
felodipine and phenacetin metabolism by HLM. 
Inhibitor IC50 (µM) (felodipine) IC50 (µM) (phenacetin) 
 
Naringin 
 
0.1032 
 
831.43 
Naringenin 0.0332 8.8800 
Quercetin 0.0631 625.71 
IC50=the concentration of test flavonoid that exhibit 50% inhibition of metabolism 
 
Quercetin is a phytochemical often used as a nutritional supplement. It forms part of the 
coloring found in a wide range of fruits. Although it has been widely used and promoted 
as being effective against various of diseases including cancer (Gulati et al., 2006), there 
is no clinical evidence that quercetin can prevent or treat cancer. Studies have shown that 
a) b) 
c) 
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quercetin has anti-inflammatory and anti-oxidant properties which explain its use in 
cardioprotection (Guardia et al., 2001; Kahraman et al., 2003). It has also been suggested 
to have ameliorating effects on obesity and other metabolic syndromes (Rivera et al., 
2008). However, despite these indications of possible health benefits, quercetin has not 
been confirmed by any regulatory agency as a specific therapy for any pathological 
condition in man. It is known to competitively bind bacterial DNA gyrase and therefore 
contra-indicated with certain antibiotics especially fluoroquinolones (Plaper et al., 2003). 
 
Ingested quercetin is extensively metabolized into non-active phenolic acids with >96% of 
the ingested dose excreted within 72 hours (Meng et al., 2004; Graf et al., 2006). The 
extensive first-pass metabolism of quercetin and its ability to inhibit in vitro CYP-catalyzed 
metabolism of felodipine and phenacetin as shown in this study further suggests its strong 
affinity for CYP enzymes. Competitive molecular binding may thus explain its mechanism 
of inhibitory action. Thus in addition to known interactions between grapefruit juice and 
CYP3A4 substrates, grapefruit juice and other quercetin-containing fruits have the 
potential of interacting with CYP1A2 substrates as the results of this investigation shows. 
 
Naringin, which is a flavonoid glycoside and a conjugate of naringenin and a sugar 
molecule, is present in grapefruit and is responsible for its bitter taste. It is metabolized 
into naringenin in the body. Some of the reported pharmacologic effects of naringin 
include its antioxidant, blood lipid-lowering, antifungal and anticancer properties (Manthey 
et al., 2001). Naringenin also possesses antioxidant properties, and in addition is known 
to exert anti-inflammatory actions, modulate the immune system and enhance 
carbohydrate metabolism. It is a free radical scavenger and has been shown to reduce 
the hepatitis virus production by infected hepatocytes in cell culture and suppresses 
HMGCoA and ACAT in rats fed a high cholesterol diet (Zbarsky et al., 2005). Both 
naringin and naringenin demonstrated potent inhibitory effects against paracetamol 
production from CYP1A2-induced phenacetin metabolism. The IC50 values showed that 
naringenin is about 100-fold more potent than its glycoside naringin in its inhibitory activity 
against CYP1A2 (Table 3.2). This further suggests that the aglycone portion of naringin is 
the active inhibitor against CYP1A2. 
 
The ability of the grapefruit flavonoids to inhibit CYP-catalyzed metabolism, apart from 
toxicological implications, can be applicable in drug delivery. Pre-systemic CYP inhibition 
can greatly improve oral drug bioavailability. Flavonoids being physiologically active 
compounds may not be useful in this regard but their intrinsic chemical and structural 
properties that enhance their binding affinity to CYP enzymes can be employed to model 
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pre-systemic CYP modulators that are physiologically inert and pharmaceutically 
acceptable. 
3.6. Concluding Remarks 
 
This chapter has been able to establish optimal in vitro conditions for assessing the 
metabolic activity of CYP-expressed HLM on felodipine and phenacetin. The flavonoids 
naringin, naringenin and quercetin inhibited the metabolism of felodipine and phenacetin. 
This confirmed that flavonoid contents of grapefruit juice are responsible for its inhibitory 
activity on CYP3A4. It also suggested that the effect of grapefruit juice is not limited to 
CYP3A4 inhibition as the study has demonstrated that the flavonoids also inhibited 
CYP1A2-dependent phenacetin o-deethylation. This further implied a potential interaction 
of grapefruit juice with drugs other than CYP3A4 substrates. In the search for a suitable 
pre-systemic metabolism inhibitor, the study of these flavonoids can be employed as 
leads for the design of suitable oral bioavailability enhancers. Since binding affinity to 
receptor sites and subsequent interaction are largely dependent on chemical structure, 
the parent structure of flavonoids and their structure-activity relationships with CYP can 
therefore be explored for further studies including modeling and design of pharmaceutical 
alternatives for CYP inhibition. 
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CHAPTER FOUR 
THE GENERATION OF CYTOCHROME P450 3A4 INHIBITORS THROUGH A NOVEL 
APPLICATION OF COMPUTATIONAL MODELING  
 
 
4.1. Introduction 
 
In chapter three, the ability of grapefruit flavonoids to inhibit CYP3A4-induced metabolism 
of felodipine was demonstrated. Considering the magnitude of the influence of CYP3A4 
on oral drug delivery (Chapter two, Section 2.8), pre-systemic enzymatic modulation may 
greatly enhance the oral bioavailability of drugs. The search for an effective pre-systemic 
enzyme inhibitor is therefore an important component of the earnestly sought solution to 
the many challenges of effective oral drug delivery. It is important that an effective pre-
systemic metabolism inhibitor should be inert, biocompatible and biodegradable. Such 
compounds should also exert temporary and/or reversible inhibition on metabolic 
enzymes to allow systemic drug clearance and prevent drug accumulation. As described 
in Chapter three, Section 3.4, naringin, naringenin and quercetin exert various 
pharmacological effects and are therefore not ideal for inclusion in pharmaceutical 
formulations to enhance oral bioavailability. 
 
Recent advancement in computer-based simulations has opened the possibility of 
exploring computational modeling in predicting natural and biological activities given 
specific sets of input parameters. Computational modeling simulates natural phenomena 
and can be employed to predict the relationship between xenobiotics and biological 
enzymes (Long and Walker, 2003). Understanding the complex nature of biochemical and 
pharmacological reactions at a cellular level which hitherto has been unexploited, has 
now been made possible through computational molecular and structural rationalization 
techniques (Ironi and Tentoni, 2003; Sibeko et al., 2009). Quantitative structure-activity 
relationships (QSAR) of CYP substrates, their pharmacophoric units and the distinct 
amino acid sequences of CYP enzymes, their molecular binding sites and overlapping 
substrate specificity are some of the inputs required to understand the biochemical basis 
of enzymatic reactions, predictability of outcomes on parameter variation and a deeper 
understanding of cellular reactions. Initial studies have reported the successful application 
of two-dimensional and three-dimensional QSAR, pharmacophoric mapping and ligand-
64 
 
based computational modeling in predicting the affinity of structurally diverse compounds 
to CYP2C9 and other CYPs (Rao et al., 2000; Rieko, 2006). 
 
A little is known of the crystal structure of mammalian CYPs due to their membrane-
bound nature (Ekins et al., 2001). Computational modeling has therefore become a useful 
tool to understand the structure and the active sites of these enzymes. Understanding the 
substrate specificity of the CYPs is essential because of their clinically important roles in 
the metabolism of drugs. It has been shown that various three-dimensional QSAR (3D-
QSAR) models can be generated and may be employed to classify molecules for their 
likely capability to be CYP substrates or inhibitors. Computational modeling and 3D-
QSAR provide a visual description of how molecules may bind to CYPs as either 
substrates or inhibitors.  
 
Lewis and co-workers (1996) had suggested structural requirements of CYP3A4 
substrates to include a hydrogen bond acceptor atom 5.5-7.8Å from the site of 
metabolism and 3Å from the oxygen associated with the heme. Ekins and co-workers 
(1999a; 1999b and 2001) employed the Catalyst software programme (Model ChemLab, 
Fulton, NY, USA) to build 3D-QSAR pharmacophoric models to reveal the structural 
features common to competitive-type CYP3A4 inhibitors. The substrate model was 
described to include a hydrogen bond acceptor 5.5-7.8Å from the site of metabolism and 
3Å from the oxygen molecule associated with the heme, while the inhibitor 
pharmacophores included three hydrophobes at distance ranging from 5.2-8.8Å from a 
hydrogen bond acceptor, three hydrophobes at distance of 4.2-7.1Å from a hydrogen 
bond acceptor and an additional 5.2Å from another hydrogen bond acceptor or one 
hydrophobe at distance 8.1-16.3Å from the furthest of three hydrogen bond acceptors 
(Ekins et al., 2001). It is believed that this molecular understanding can be explored to 
generate useful Modeled Pre-systemic CYP Inhibitors (MPCI) in order to improve the oral 
bioavailability of drug. 
 
The aim of the present study was therefore to apply the parameters involved in flavonoid-
CYP and verapamil-CYP binding and interaction as a blueprint for computational 
modeling to generate MPCIs and to investigate the ability of the modeled compounds to 
inhibit in vitro CYP3A4-induced felodipine metabolism. The use of verapamil and 
grapefruit flavonoids (established CYP3A4-inhibitors) as controls provided the platform for 
comparative studies of the effects of the MPCIs. Both human liver and intestinal 
microsomes were employed to assess the inhibitory activity of the MPCIs in order to 
assess their potential pharmaceutical utility. 
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4.2. Materials and Methods 
 
4.2.1. Materials 
Pooled mixed gender human intestinal microsomes (HIM) expressing CYP3A4, CYP2C9, 
CYP2J2, CYP4F12, UDT-glucuronosyl transferase and carboxylesterase prepared from 
matured enterocytes of both duodenum and jejunum sections of five donors (1 Male, 4 
Female with non-enteric related pathology and cause of death) and pooled mixed gender 
human liver microsomes (HLM) expressing CYP3A4, CYP2C9, CYP4A11, CYP4F2, 
CYP2E1 and CYP2A6 were purchased from BD Biosciences (Pty) Ltd. (Woburn, MA, 
USA) and stored at -70ºC until used. Methoxy poly(ethylene glycol) (MW=5000g/mol 
[MPEG 5000] and 10000g/mol [MPEG 10000]), poly(ethylene glycol) (PEG, 
MW=2000g/mol [PEG 2000] and 5000g/mol [PEG 5000]), 4-arm-poly(ethylene glycol) 
(MW=10000g/mol [4-arm-PEG 1000] and 20000g/mol [4-arm-PEG 20000]) and 8-arm-
poly(ethylene glycol) (8-arm-PEG) were purchased from Jenkem Technology (Pty) Ltd. 
(Beijing, China). O-(2-aminoethyl)-O-methoxy poly(ethylene glycol) (MW=7500g/mol) 
(MPEG-NH2), poly (L-lysine), poly(methyl methacrylate), and poly(phenylalanine) 
(NADPH, reduced form) were purchased from Sigma-Aldrich (Pty) Ltd. (St Louis, MO, 
USA). Other materials employed for this phase of the study and their respective sources 
can be located in Chapter three, Section 3.4.1. 
 
4.2.2. Computational modeling of Cytochrome P450-inhibitor interactions to 
generate pre-systemic Cytochrome P450 inhibitors  
As an example, a computational comparative study of the structural and three-
dimensional amino acid sequence of CYP3A4 was explored (Figure 4.1). This was 
simultaneously approximated with structural properties, 3D-QSAR of CYP3A4, grapefruit 
flavonoids and verapamil employing Hyperchem 7.5 Professional computational modeling 
software on a non-silicon graphics system (HyperCube Inc. Gainesville, FL, USA) (Figure 
4.2). The templates derived from the known substrates (felodipine) were step-wise 
modified as a single variant within the structure taking into consideration the overall 
electronegativity/total charge density, dipole moment, bond length, bond angle, stereo-
orientation and effective geometry. This provided a deeper molecular understanding of 
substrate specificity, binding affinity and manipulability of CYP3A4. The most stable forms 
of the resulting compounds were determined by estimations of the hydration energy and 
the energy of conformation. Polymer conjugation with known CYP3A4 inhibitors including 
high molecular mass flavonoids and furanocoumarins based on multi-site reactivity of the 
CYP variants was also explored.  
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Arg-Ser-Leu-Leu-Ser-Pro-Thr-Phe-Thr-Ser-Gly-Lys-Leu-Lys-Glu-Met-Val-Pro-Ile-
Ile-Ala-Gln-Tyr-Gly-Asp-Asp-Val-leu-Val-Arg-Asn-Leu-Arg-Arg-Glu-Ala-Glu-Thr-
Gly-Lys-Pro-Val-Thr-leu-Lys-Asp-Val-Phe-Gly-Ala-Tyr-Ser-Met-Asp-Val-Ile-Thr-
Ser-Thr-Ser-Phe-Gly-Val-Asn-Ile-Asp-Ser-Leu-Asn-Asn-Pro-Gln-Asp-Pro-Phe-
Val-Glu-Asn-Thr-Lys-Lys-leu-leu-Arg-PheAsp-Phe-Leu-Asp-Pro-Phe-Phe-Leu-
Ser-Ile-Ile-Phe-Pro-Phe-Leu-Ile-Pro-Ile-Leu-Glu-Val-Leu-Asn-Ile-Cys-Val-Phe-
Pro Arg-Glu-Val-Thr-Asn-Phe-Leu-Arg-Lys-Ser-Val-Lys-Arg-Met-Lys-Glu-Ser-
Arg-Leu-Glu-Asp-Thr-Gln-Lys-His-Arg-Val-Asp-Phe-Leu-Gln-Leu-Met-Ile-Asp-
Ser-Gln-Asn-Ser-Lys-Glu-Thr-Glu-Ser-His-Lys-Ala-Leu-Ser-Asp-Leu-Glu-Leu-
Val-Ala-Gln-Ser-Ile-Ile-Phe-Ile-Phe-Ala-Gly-Tyr-Glu-Thr-Thr-Ser-Ser-Val-Leu-
Ser-Phe-Ile-Met-Tyr-Glu-Leu-Ala-Thr-His-Pro-Asp-Val-Gln-Gln-Lys-Leu-Gln-Glu-
Glu-Ile-Asp-Ala-Val-Leu-Pro-Asn-Lys-Ala-pro-pro-Thr-Tyr-Asp-Thr-Val-Leu-Gln-
Met-Glu-Tyr-Leu-Asp-Met-Val-Val-Asn-Glu-Thr-Leu-Arg-Leu-Phe-Pro-Ile-Ala-
Met-Arg-Leu-Glu-Arg-Val-Cys-Lys-Lys-Asp-Val-Glu-Ile-Asn-Gly-Met-Phe-Ile-Pro-
Lys-Gly-Trp-Val-Val-Met-Ile-Pro-Ser-Tyr-Ala-Leu-His-Arg-Asp-Pro-Lys-Tyr-Thr-
Glu-Pro-Glu-Lys-Phe-Leu-Pro-Glu-Arg-Phe-Ser-Lys-Lys-Asn-Lys-Asp-Asn-Ile-
Asp-Pro-Tyr-Thr-Tyr-Thr-Pro-Phe-Gly-Ser-Gly-Pro-Arg-Asn-Cys-Ile-Gly-Met-Arg-
Phe-Ala-Leu-Met-Asn-Met-Lys-Leu-Ala-Leu-Ile-Arg-Val-Leu-Gln-Asn-Phe-Ser-Phe-
Lys-Pro-Cys-Lys-Glu-Thr-Gln-Ile-Pro-Leu-Lys-Leu-Ser-Leu-Gly-Gly-Leu-Leu-Gln-
Pro-Glu-Lys-Pro-Val-Val-Leu-Lys-Val-Glu-Ser-Arg-Asp-Gly-Thr-Val-Ser-Gly-Ala
 
Key 
Gly-Glycine  Ile-Isoleucine   Trp-Tryptophan  Asn-Asparagine 
Pro-Proline  Met-Methionine   His-Histidine  Glu-Glutamic acid 
Ala-Alanine  Cst-Cysteine   Lys-Lysine  Asp-Aspartic acid 
Val-Valine  Phe-Phenylalanine  Arg-Arginine  Ser-Serine 
Leu-Leucine  Tyr-Tyrosine   Glutamine  Thr-Threonine 
Figure 4.1: Amino acid sequence of CYP3A4 isozyme (Adapted from Nelson, 2009). 
 
The 3D modeling of the polypeptide structure demonstrated the maneuverability of the 
CYP3A4 polypeptide chain for the active site (heme sub-structure, located at the cysteine-
58 residue). The constantly interchanging conformation of the protein chain due to 
physiological conditions inherent or induced by xenobiotic factors and entities as well as 
the distance mapping of the active (heme) site, the different locations of the polypeptide 
chains and the proximity of amino acid residues by way of their conformation variability 
also confirmed the manipulability of the CYP3A4 active sites (Figure 4.2).  
 
The computational simulation performed kept the distance in the range of 2-25Å and 
mapped at three different locations from the N-terminal, middle of the chain and the C-
terminal ending of the polypeptide chain suggesting the approach of the incoming 
molecule to the active site which in its conformation of binding and molecular volume 
would reach the biochemical site of action. The proximity of other sulphur containing 
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residues especially from the methionine residues of the CYP3A4 enzyme may be a 
complimentary location to act as a scavenger (S atom) due to its high valence and ability 
to bind other atoms. Although cysteine-58 placement of the heme sub-structure is 
hypothetical, the link of the heme substructure to any other cysteine residue would not 
have changed the activity except for a negligible change in the resulting loop which itself 
does not alter the activity and approach of the chain and any xenobiotic entity attached to 
it for its interaction by detoxification via biochemical conversion. 
 
 
 
 
Figure 4.2: A three dimensional amino acid sequence of CYP 3A4 as shown by 
Hyperchem 7.5 professional software revealing the a) structural morphology, b) 
manipulable heme substructure, c) expanded view of the C-terminal and d) expanded 
view of the N-terminal. 
 
 
It was therefore reasonable to propose that the versatile activity of the CYP3A4 
polymorph was dependent on numerous factors. The fact that a range of molecules of 
different molecular mass, size, volume and charge as well as diverse classes of 
a) b) 
c) d) 
Lipophilic area 
Lipophilic area 
Fe-S link 
CYP3A4 
CYP3A4 
CYP3A4 
CYP3A4 
Heme OH 
Heme Iron 
Heme Carbon 
Cys 238 
Heme at Cys 58 
Distance between Heme 
and Cys 238, 32.643Å 
Backbone NH 
Backbone CO 
Ser 499 residue 
Ala 500 residue 
Glu 500 residue 
Backbone Carbon 
Carboxyl, Zwitter ionic form, 
C-Terminal, Ala 501 
NH of Backbone 
Met 1 at N-terminal 
Met S-atom 
N atom at N-Terminal 
Backbone 
Carbon 
O of CO bond 
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compounds are substrates and inhibitors of CYP suggested a more flexible approach to 
the bioactivity mechanism involved in interaction with CYP3A4 and its substrates. Thus, 
the binding of both substrates and inhibitors to the CYP3A4 peptide chain is 
complimentary and conjugative to the corresponding active site of the polypeptide chains. 
Therefore, computational modeling of bioactivity was employed to predict and generate 
biodegradable, biocompatible natural and synthetic polymers and their conjugates 
potentially capable of interacting with the CYP3A4 active domain. 
 
4.2.3. Investigation of the inhibitory effects of the MPCIs on felodipine metabolism 
employing CYP-expressed HLM and HIM 
Polymers including derivatives of poly(ethylene glycol), polyacrylates, polyoxyethylene 
and polypeptides were prepared in a 0.01-100mg/ml concentration range and incubated 
with felodipine separately in HLM and HIM solutions in methods as described for the 
grapefruit flavonoids and verapamil in Chapter three, Section 3.5.4. Their inhibitory effects 
were investigated on the microsomal metabolism of felodipine. The potency of the 
inhibitors was measured by their IC50 values that were determined by profiling the 
percentage inhibition of felodipine metabolism against the inhibitor concentration 
employing the Enzyme Kinetic Software (SigmaPlot: Enzyme Kinetic Module, Systat 
Software Inc., Chicago, IL, USA). The total quantity of felodipine metabolized within the 
incubation period was determined from control incubations where metabolism was 
maximal. The concentration of felodipine in incubation mixtures containing the various test 
inhibitors was determined and the extent of metabolism was measured as a percentage of 
the control. The percentage inhibition observed was profiled against concentration of test 
inhibitors added to the incubation mixture. In each case, the inhibitor concentration 
responsible for 50% substrate metabolism inhibition (IC50) was determined. All 
determinations were performed in triplicates (n=3). 
 
4.3. Results and Discussion 
 
4.3.1. Computational molecular and structural modeling of Cytochrome P450 3A4 
inhibitors 
Computational modeling was used to elucidate structural and chemical requirements for 
CYP3A4 binding and activity. From the constituent structural topography for biomimetism, 
the inter-structural cavity shape formation, which may be responsible for activity 
depended on the presence of structural groups and their stereo-electronic factors present 
in specified reactive domains of the protein fiber, which was used as a blueprint for the 
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formation of nearly equivalent cavities within the polymer structural groups (Figure 4.3). 
For a protein structure, the surrounding contribution is less significant due to the 
incompassive and ulta-advanced structural features of the molecule compared to 
polymers with less stereo-electronic and structural features at reactive domains or 
interactive sites.  
 
 
Figure 4.3: Computational models showing the molecular structure of the bio-reactive 
sites of CYP3A4, with a) protein fibril; b) a closer look at protein coiling; c) tertiary 
structural and bioresponsive domain for biomimetic activity; and d) the arrow represents 
hypothetical binding site on the 3-dimensional protein structure (e) with loop and nodes 
formation. 
 
Protein fibril 
A closer look at 
the protein coiling 
Modeled tertiary 
bioresponsive domain 
A hypothetical 
CYP3A4 binding site 
Loop and nodes 
formation 
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Further understanding of the binding of verapamil and flavonoids to active site of CYP 
was derived from computational modeling. Based on the computational biomolecular 
understanding of the inhibitory mechanism of flavonoids-CYP3A4 and verapamil-CYP3A4 
complex formation and subsequent action, computational biomimetism and simulation 
(Figure 4.3) was employed to predict and generate high molecular weight poly(ethylene 
glycol) based polymers and their derivatives, homopeptides, heteropeptides, 
polyoxyethylene and polyacrylate derivatives and conjugations with the potential capacity 
to interact with CYP3A4. 
 
4.3.2. Investigating the effects of MPCIs on in vitro felodipine metabolism by human 
liver microsomes 
The MPCIs inhibited felodipine metabolism to varying degrees (Figure 4.4). The potencies 
of the flavonoids and the MPCIs measured as their IC50 values were compared (Table 
4.1). However, a few of the modeled compounds did not appear to have any significant 
influence on the rate of felodipine metabolism by HLM. PEG 2000, PEG 5000, methoxy 
PEG (MW=1000g/mol and 2000g/mol) and polyoxyethylene (MW=750g/mol) within the test 
concentration range of 0.001-100mg/mL did not have a significant effect on the rate and 
extent of felodipine metabolism by HLM compared to the controls.  
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Figure 4.4: The inhibitory effects of the Modeled Pre-systemic Cytochrome P450 3A4 
Inhibitors on the CYP3A4-catalyzed felodipine metabolism (N=3; S.D.<0.005 in all cases). 
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The concentrations of verapamil and the MPCIs in the incubation mixture were also 
monitored. Although in vitro techniques are often insufficient to prove the mechanism of 
enzymatic metabolism inhibition, the disappearance of the flavonoids, verapamil and the 
MPCIS suggested competitive receptor binding to enzymes as a possible mechanism of 
felodipine inhibition. This was further demonstrated by the direct relationship between the 
inhibitor concentration and the initial extent of inhibition observed (Figure 4.4).  
 
Table 4.1: Comparison of the inhibitory properties of various HLM inhibitors and MPCIs. 
Inhibitor IC50 (mg/ml) IC50 (µM) Highest 
inhibition 
observed (%) 
Conc. (µM) 
at max 
inhibition 
 
Verapamil 
 
0.0530 
 
107.88 
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500 
Naringin 0.1032 177.81 98 1000 
Naringenin 0.0332 121.97 95 500 
Quercetin 0.0631 208.65 98 750 
4-Arm-PEG 10000 0.2379 23.79 95 10000 
4-Arm-PEG 20000 0.6000 30 91 5000 
8-Arm-PEG 10000 0.0722 7.22 96 10000 
Poly (L-lysine) 0.2226 29.68 69 1000 
Poly(methyl 
methacrylate) 10000 
0.1628 16.28 88 26667 
O-(2-aminoethyl)-Oʹ-
methoxy PEG 7500 
0.1029 13.72 77 1000 
 
The ability of the MPCIs modeled based on the chemical structure and binding properties 
of the flavonoids to inhibit the metabolism of felodipine by HLM agrees with other studies 
suggesting that the inhibitory effects of flavonoids are molecularly structure-dependent 
(Miniscalo et al., 1992). This therefore, provided the theoretical avenue for a reliable 
research route and mechanism in computational modeling. The ability of PEG-derivatives 
to inhibit CYP-induced metabolism should also draw attention to pharmaceutical grade 
polymers in the search for oral bioavailability enhancers. Results of this study show 
inhibitory potency for the multi-armed PEGs in this order: 8-arm-PEG >4-arm-PEG 20000 
>4-arm-PEG 10000 (Figure 4.5). This may suggest a trend in the binding and increasing 
substrates affinity of multi-armed PEGs with CYP3A4. 
 
Although enzymatic catabolism has been reported to be responsible for the high intestinal 
first-pass effect of dietary proteins (Stoll et al., 1998), amino acids have not been reported 
to inhibit HLM. The ability of poly (L-lysine) to inhibit CYP3A4-mediated metabolism of 
felodipine however suggests that amino acid derivatives offer potential in the search for 
oral bioavailability enhancers.  
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Figure 4.5: Comparison of the potencies of the investigated MPCIs. 
 
4.3.3. Comparative inhibition of felodipine metabolism by the MPCIs in HLM and 
HIM 
Most in vitro drug metabolism studies for in vivo correlation often employ HLM. Pre-
systemic drug metabolism occurs principally in the intestinal wall and the liver due to the 
presence of metabolic enzymes in both organs (Table 4.2). An HLM inhibitor may not 
necessarily have the same effect in the intestines although cytochromic morphology may 
be similar. In this case, prospective oral bioavailability enhancers must necessarily be 
absorbed to exert hepatic activity. An enzyme inhibitor active against intestinal CYP will 
prevent intestinal pre-systemic metabolism and enhance oral bioavailability. It was 
therefore necessary to investigate intestinal activity of prospective pre-systemic 
metabolism inhibitors especially since they may not survive the physicochemical barriers 
necessary for hepatic absorption. The use of HIM estimates the potential utility of MPCIs 
that may be pre-systemically degradable and whose potency may be lost outside the GIT. 
Thus, HIM was employed to investigate the effects of HLM inhibitors on intestinal 
metabolism for a more reliable extrapolation. 
 
 
 
 
A- Verapamil,  
B- Naringin  
C- Naringenin,  
D- Quercetin,  
E- 4-arm-PEG 10000,  
F- 4-Arm-PEG 20000,  
G- 8-Arm-PEG,  
H- Poly (L-lysine),  
I- Poly(methylmethacrylate)  
J- MPEG-NH2 
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Table 4.2: Intestinal expression and localization of CYP isozymes (Finnstrom et al., 
1998). 
CYP Stomach Duodenum Ascending 
colon 
Transverse 
colon 
Descending 
colon 
 
1B1 
 
+++++ 
 
+ 
 
++++ 
 
+ 
 
+ 
2E1 +++ ++ ++ + +++ 
3A4 +++ ++++ ++ + ++ 
3A5 ++++ +++++ ++++ +++ ++ 
The number of + signs indicates the relative amount of CYP expressed 
 
 
The MPCIs were incubated with felodipine at the pre-determined Km value with CYP3A4 
expressed HIM for in vivo correlational reliability. From the results obtained (Figure 4.6; 
Tables 4.3), the modeled HLM inhibitors demonstrated inhibitory actions against intestinal 
microsomal metabolism of felodipine. Thus, this further confirms the potential utility of 
these intestinal CYP3A4 inhibitors in oral drug delivery. 
 
Table 4.3: Comparison of the inhibitory potencies of MPCIS in HLM and HIM. 
MPCIs IC50 values in 
HLM (µM) 
Inhibition in HIM (%) 
at the HLM IC50 
IC50 in HIM 
(µM) 
 
 
4-Arm-PEG 10000 
 
23.79 
 
33.90 
 
45.18 
 
4-Arm-PEG 20000 30 48.69 41.03  
8-Arm-PEG 10000 7.22 71.03 5.78  
Poly (L-lysine) 29.68 67.45 19.20  
Poly(methyl 
methacrylate) 10000 
16.28 54.51 15.92  
O-(2-aminoethyl)-O´-
methoxy PEG 7500 
13.72 36.16 21.34  
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Figure 4.6: Comparison of the IC50 values of the MPCIs in CYP3A4-expressed HLM and 
HIM: A) 4-arm-PEG 1000, B) 4-arm-PEG 20000, C) 8-arm-PEG, D) poly (L-lysine), E) 
poly(methylmethacrylate) and F) MPEG-NH2. 
 
 
4.4. Concluding Remarks 
 
This phase of the study has shown that the mechanism of drug-drug and drug-food 
interaction can be exploited through the aid of computational modeling to generate 
potential pharmaceutical alternatives in drug delivery and toxicological studies. From the 
results, 8-arm-PEG demonstrated the highest inhibitory potency against felodipine 
metabolism by HLM and HIM. With a satisfactory in vitro result, 8-arm-PEG may be a 
potential oral bioavailability enhancer through the inhibition of pre-systemic CYP-
catalyzed drug metabolism. Further studies including ex vivo and in vivo studies are 
necessary to assess this potential and therefore described in Chapter five. 
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CHAPTER FIVE 
INVESTIGATION OF THE ORAL BIOAVAILABILITY-ENHANCING PROPERTY OF 8-
ARM-POLY(ETHYLENE GLYCOL) 10000 
 
 
5.1. Introduction 
 
In Chapter four, various Modeled Pre-systemic Cytochrome P450 3A4 Inhibitors (MPCIs) 
were generated through computational modeling and were investigated for their inhibitory 
activity against the in vitro metabolism of felodipine employing Human Liver Microsomes 
(HLM) and Human Intestinal Microsomes (HIM). Results showed that 8-arm-poly(ethylene 
glycol) 10000 (8-arm-PEG), a derivative of poly(ethylene glycol) (PEG) possessed the 
highest inhibitory potency.  
 
PEG is an oligomer or polymer of ethylene oxide. It is produced by the interaction of 
ethylene oxide with water, ethylene glycol or ethylene glycol oligomers and has the 
general molecular structure as shown in Figure 5.1 where n represents the number of 
oxyethylene moieties.  
 
 
HO    C     [C     O     C]n     C     OH
H H H H
H H H H
 
Figure 5.1: The molecular structure of poly(ethylene glycol). 
 
PEG has properties that are pharmaceutically desirable (Harris and Chess, 2003). 
Commercially available PEG and most of its derivatives exist as liquid or low-melting 
solids depending on the molecular mass, which varies widely from 300-10,000,000g/mol. 
They are non-toxic, odorless, lubricating, non-volatile, non-irritating, non-antigenic and 
non-immunogenic; and are therefore employed in a variety of pharmaceuticals as 
tableting excipients, coating, ointment and suppository bases, dispensing agents, 
solvents, lubricants, binders and as plasticizers (Veronese and Pasut, 2005). PEG and 
most of its derivatives are freely soluble in water, methanol, benzene and 
dichloromethane but insoluble in diethylether and hexane. PEG is eliminated unchanged 
_ _ _ _ _ _ 
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from the body by either the kidney (MW <30,000g/mol) or in the feces (MW >20,000g/mol) 
(Friman et al., 1993). The United States Food and Drugs Administration (USFDA) has 
approved PEG for use as a vehicle or base in the food, cosmetic and pharmaceutical 
products including oral, injectable, topical, rectal and nasal preparations. PEG is used as 
a laxative base in macrogol-containing products such as Movicol® (Norgine 
Pharmaceutical Ltd. Middlesex, Uxbridge, UK). 
 
Technological advances in the synthetic preparation and modification of PEG has given 
rise to various PEG derivatives with variable physicochemical behavior. Alterations in the 
molecular configuration of PEG has yielded branched PEGs comprising 3-10 PEG chains 
emanating from a central core group, star PEG with 10-100 PEG chains emanating from a 
central core group, while multiple PEG chains are normally grafted to a polymer backbone 
to form a comb PEG (Stowe et al., 2005). Pegylation, often defined as the modification of 
a protein, peptide or non-peptide molecule by the linking of one or more PEG chains, has 
evolved to include conjugation of PEG derivatives with biomolecules to enhance the 
pharmacokinetic and pharmacodynamic properties of protein pharmaceuticals (Hinds and 
Kim, 2002). It is the act of covalently coupling a PEG structure to another larger molecule, 
for example a therapeutic protein in which case the molecule is referred to as being 
pegylated (Veronese and Mero, 2008).  
 
The active terminals of PEG are usually maintained after molecular and structural 
modifications yielding different PEG configurations and derivatives. These alterations 
however can modify the drug delivery and pharmacokinetic behavior of PEG. The most 
popular branched PEGs are 3-10-armed PEGs. 8-arm-PEG has been reported to improve 
the swellability and desirable mechanical properties such as the softness and tenacity of 
poly(L-lactic acid) when conjugated, enhancing the suitability of the co-polymer as an 
implantable soft material (Koji et al., 2006). Partially cholesterol-substituted 8-arm-PEG-
block-poly(L-lactide) has been prepared as a novel star-shaped, biodegradable co-
polymer derivative which has been reported as a potential candidate as an injectable 
cellular scaffold (Nagahama et al., 2008). 
 
PEG-based hydrogels, PEG-modified liposomes and PEG-polypeptide conjugations are 
becoming increasingly important in drug delivery. Many proteins have been linked to one 
or more polymeric chains in order to protect them from rapid enzymatic degradation and 
to increase their half-life. Examples of such conjugates are PEG-asparaginase, PEG-
superoxide dismutase and PEG-α-2a interferon (Guiotto et al., 2002).  
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Liposomal pegylation is also gaining increasing applicability in drug delivery. Pegylated 
liposomes have been demonstrated to show increased half-life, decreased plasma 
clearance and a shift in drug distribution favorable to disease tissues, compared to 
classical liposomes (Chess and Harris, 2003). The pharmacokinetic behavior of 
consensus interferon-α was significantly altered when pegylated with a 40,000g/mol 
branched PEG (Du et al., 2008). The unique nature of the Blood-Brain Barrier (BBB) 
prevents many therapeutic compounds from accessing the central compartment which 
presents a challenge in the pharmacotherapy of neurological and psychiatric disorders. 
There is a high physiological risk in injecting drugs directly into the brain or when the BBB 
is disrupted. Certain drug carriers have shown promising ability to transport drugs across 
the BBB. An example is polymeric nanoparticles such as n-hexadecylcyanoacrylate 
(PHDCA) conjugated with PEG which has been reported to demonstrate enhanced 
penetration into the brain compared to PHDCA alone (Chess and Harris, 2003). This 
conjugation is also reported to have a superior distribution into deep areas of the brain 
including the striatum, the hippocampus and the hypothalamus without damage to the 
brain structures and the BBB (Chess and Harris, 2003). Thus, pegylation is a promising 
drug carrier system for brain drug delivery.  
 
The modeled compound, 8-arm-PEG is a poly-armed derivative of PEG. Its structural 
difference lies in the molecular arrangement of the constituent monomeric units of the 
parent PEG molecule (Figure 5.2). Having demonstrated potent inhibitory activity against 
the in vitro metabolism of felodipine by CYP3A4-expressed HLM and HIM as reported in 
Chapter four, 8-arm-PEG has the potential for further application in oral drug delivery 
aimed at enhancing the oral bioavailability of CYP3A4 substrates in addition to being a 
drug carrier. PEG and most of its derivatives, being pharmacologically inert polymers with 
satisfactory properties as a drug carrier, will be suitable for modifying the drug delivery 
kinetics and possibly enhancing the oral bioavailability of drugs susceptible to CYP3A4-
catalyzed pre-systemic metabolism. 
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Figure 5.2: The molecular structure of 8-arm-PEG. 
 
 
The aim of this phase of the study was therefore, to examine and explore the 
pharmaceutical formulatory capacity, drug release profile and oral bioavailability-
enhancing properties of 8-arm-PEG via ex vivo and in vivo studies. Employing a direct 
compression technique, 8-arm-PEG was assessed for its compactibility, hardness and 
friability. It was included in graded concentrations with hydroxypropylmethyl cellulose 
(HPMC) for formulating a felodipine tablet matrix where its effects on felodipine release 
and oral felodipine bioavailability were investigated. The current study also aimed at 
developing an ex vivo method of felodipine metabolism employing freshly excised pig 
intestinal tissue. The objective was to assess the effect of 8-arm-PEG on the metabolism 
of felodipine by intestinal CYP3A4 after the in vitro study with HIM and HIM (described in 
Chapter four) portrayed 8-arm-PEG as a potent CYP3A4 inhibitor. In addition, the ability 
of 8-arm-PEG to translate its CYP3A4 inhibitory effect for enhanced oral bioavailability 
was investigated in the Large White pig model. 
 
5.2. Materials and Methods 
 
5.2.1. Materials 
Chemically pure D-glucose anhydrous (MW=180.16g/mol, molecular biology grade) was 
purchased from Rochelle Chemicals and Laboratory Equipment (Pty) Ltd. (Johannesburg, 
Gauteng, South Africa). Magnesium sulfate anhydrous (MgSO4, MW=120.415g/mol), 
magnesium chloride (MgCl2.6H20, MW=203.30g/mol), sodium hydroxide pellets (NaOH, 
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MW=40g/mol) and hydroxypropylmethylcellulose (HPMC) were purchased from Merck 
Chemicals (Pty) Ltd. (Darmstadt, Germany). Polysorbate 80 (density at 20°C =1.007g) 
was purchased from Saarchem (Pty) Ltd. (Krugersdorp, Gauteng, South Africa) while 
heparin (1000IU/mL) and normal saline were purchased from Bodene (Pty) Ltd. (PE, 
Eastern Cape, South Africa). Other materials employed in this part of the study and their 
respective sources can be located in Chapter three, Section 3.4.1 and Chapter four, 
Section 4.2.1. 
 
5.2.2. Formulation of the 8-arm-PEG-incorporated tablet matrices 
Employing a mortar and pestle, 8-arm-PEG was manually triturated until a free-flowing 
fine powder was formed. The powdered polymer was then weighed employing a 
calibrated digital analytical balance (Boeco BBL Model Balances, Hamburg, Germany, 
accuracy=±0.05mg) and triturated with 10mg felodipine and HPMC such that the final 
tablet matrix comprised varied quantities of 8-arm-PEG made up to final mass (600mg) 
with HPMC in order to maintain a constant tablet mass. The triturated mixture was directly 
compressed on a Caver® Press (Caver® Laboratory Equipment, Wabash, Indiana, USA) 
under 5 tons of compression force employing a flat-faced punch and die (13mm in 
diameter). Tablet matrices comprising only 8-arm-PEG only were also compressed for 
comparative studies with native HPMC tablets. In-process validation tests were performed 
on randomly selected tablets. 
 
5.2.3. Evaluation of tablet hardness 
In order to assess the suitability of 8-arm-PEG for tableting, hardness testing was 
conducted on the matrices employing a TA.XTplus Texture Analyzer (Stable Micro 
systems, Godalming, Surrey, England, UK)  fitted with a ball probe with a spherical 
indenter of 3.125mm in diameter and a 5kg load cell. The hardness of the tablet matrices 
was determined from Force–Distance profiles obtained by converting the indentation 
hardness to the Brinell Hardness Number (BHN). Equation 5.1 shows the mathematical 
representation of BHN expressing its relationship with the Force (F) generated from 
indentation, the diameter (D) of the spherical probe (3.175mm) and the dept (d) of 
indentation. 
 
BHN =
2F
πD[D− D2−d2 ]1/2
                          Equation 5.1 
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The textural parameter settings employed are summarized in Table 5.1. All tests were 
performed in triplicate and the BHN was computed in each case. 
 
Table 5.1: The textural settings employed for BHN value calculations. 
Test Parameters  Settings 
 
Test mode 
 
Compression 
Pre-test speed (mm/sec) 1 
Test speed (mm/sec) 0.5 
Post-test speed (mm/sec) 1 
Indentation dept (mm) 0.5 
Trigger type Auto (force) 
Trigger force 0.05 
 
5.2.4. Investigation of tablet friability 
Friability tests were conducted employing a Friabilator (Heusenstamm, Germany) set at a 
1% upper limit of friability. This test was performed by weighing 10 tablets each of 8-arm-
PEG and HPMC and subjecting the weighed samples to 4 minutes of rotation in the 
friabilator. The tablets were weighed after friabilation and friability was expressed as the 
percentage loss on the pre-test tablet mass. All determinations were performed in 
triplicate.  
 
5.2.5. Assessment of the effect of compression on the structure and morphology of 
8-arm-PEG 
Tablet matrices of 8-arm-PEG were prepared as described in Section 5.2.2. Fourier 
Transform Infrared Spectrometer (FTIR) was employed to assess infrared spectra of 
powdered and compressed 8-arm-PEG matrices in order to ascertain the integrity of the 
structural backbone of 8-arm-PEG. Quadruple scanning was performed on each sample 
following background spectra collection at wave numbers ranging from 4000-400cm-1. 
Spectra generated from powdered and compressed samples were superimposed for 
comparison to observe possible conformational changes in the polymeric structure as a 
result of compression. 
 
5.2.6. Investigation of the influence of varying concentration of 8-arm-PEG on the in 
vitro felodipine release from tablet matrices 
The effects of graded concentrations of 8-arm-PEG (0, 16.7, 33.3, 50, 66.7, 83.3 and 
100%w/w) on felodipine release from the HPMC tablet matrix was investigated employing a 
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modified USP 32 rotating paddle method in a calibrated six-station dissolution apparatus 
(Caleva Dissolution Apparatus, model 7ST; G.B. Caleva Ltd. Dorset, UK). Tablets were 
immersed at time zero in media containing 1%w/v polysorbate 80 in 900mL phosphate 
buffer (pH 6.8) and agitated at 50rpm after dissolution conditions were equilibrated to 
37ºC. At predetermined intervals, 5mL of release medium was withdrawn and analyzed by 
UPLC for felodipine content. Equal volumes of drug-free medium were replaced after 
sampling to maintain sink conditions. The poor aqueous solubility of felodipine precludes 
the use of plain buffer media in determining its in vitro release pattern. The USP 
dissolution medium for felodipine is 1% polysorbate 80 in phosphate buffer (pH 6.8). 
Polysorbate 80 as a surfactant is expected to facilitate the dissolution of felodipine in the 
medium and enhance even dispersion and distribution of insoluble felodipine molecules 
which are made available for analysis upon sampling. There is limited knowledge of 
intestinal drug dissolution especially for drugs with poor aqueous solubility (Persson et al., 
2005). This could be due to the non-physiological aspects of in vitro systems. The use of 
buffers at intestinal pH for example provides a simulated physicochemical environment for 
dissolution studies. However, the presence of enzymes, lipophic contents and other 
organic components in the intestinal fluid makes in vitro systems lack biochemical 
equivalents. This may lead to over-estimation or under-estimation of actual in vivo 
behavior. 
 
5.2.7. Ex vivo investigation of the inhibitory property of 8-arm-PEG on the intestinal 
tissue metabolism of felodipine 
In an approach similar to a method by de Kanter and co-workers (1999, 2002 and 2005), 
felodipine was co-incubated with precision-cut slices of small intestinal tissue obtained 
from a Large White pig for ex vivo metabolism. The method was optimized and repeated 
with the separate addition of graded concentrations of naringenin (62.5, 125, 250, 500, 
1000 and 2000µM) (as the control inhibitor) and 8-arm-PEG. The effect of 8-arm-PEG on 
felodipine metabolism was determined and compared to that of naringenin. 
 
5.2.7.1. Preparation of intestinal tissue slices 
A healthy female Large White pig (55kg) was euthanized with 200mg/mL intravenous 
sodium pentobarbitone (0.48mL/kg body weight). This was followed by dissection of the 
GIT where intestinal slices were excised from the jejunum with a 4mm biopsy core. After 
coring, the mucosa was carefully separated from the muscle layer. The mucosa was 
sliced using a tissue slicer into equal slices (1mm thickness) and the slices were 
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incubated immediately in Kreb-Heinseleit Buffer (KHB) employing a humidified Galaxy 
Standard incubator (RS Biotech Laboratory Equipment (Pty) Ltd. Ayrshire, Scotland, UK). 
5.2.7.2. Preparation of Kreb-Heinseleit Buffer 
KHB, a modification of Ringer’s solution used to maintain physiological activity during in 
vitro investigations involving liver and other living tissues was developed in the early 
1930’s by Hans Krebs and Kurt Henseleit (Nickelsen and Graβhoff, 2008). The powdered 
salt contents of KHB listed in Table 5.2, were weighed, triturated and added to 900mL 
double deionized water at 20°C under agitation. This was followed by the addition of 
0.373g of CaCl2.2H2O (calcium chloride dehydrate) and 28mL of 7.5%
w/v Na2CO3 (sodium 
bicarbonate). The solution was agitated until dissolved while the pH was adjusted with 1N 
hydrochloric acid to 6.8. The final buffer was made up to 1L volume with double deionized 
water, sterilized by filtration through a 0.22µm filter system and utilized immediately. 
 
Table 5.2: Components of Krebs-Henseleit Buffer (Sigma-Aldrich Product Information, 
2009). 
Components g/L 
 
D-Glucose 
 
2.000 
Magnesium sulphate (anhydrous) 0.141 
Potassium phosphate (monobasic) 0.160 
Potassium chloride 0.350 
Sodium chloride 6.900 
 
5.2.7.3. Investigation of the effect of 8-arm-PEG on felodipine metabolism using the 
excised intestinal tissues 
Freshly excised and precision-cut intestinal tissue was incubated with freshly prepared 
KHB employing a six-well culture plates in a humidified incubator (Galaxy Incubators, RS 
Biotech Laboratory Equipment (Pty) Ltd. Ayrshire, Scotland, UK) circulated with 95:5 
O2/CO2 (Afrox (Pty), Alrode, Gauteng, South Africa) and set at 37ºC). Each well contained 
2mL KHB, 4mm cored intestinal tissue and 500µM felodipine. The felodipine metabolic 
rate was determined between 0 and 3 hours of control incubations while graded 
concentrations of naringenin and 8-arm-PEG (62.5, 125, 250, 500, 1000 and 2000µM) 
were added. The tests were performed such that tissue slices lasted for ˂4 hours after the 
source pig was euthanized. This was necessary in order to maintain tissue survival and 
enhance the maximum physiologic activity of the tissue enzymes. All determinations were 
performed in triplicate. The rate and extent of felodipine metabolism in 8-arm-PEG co-
incubated well plates were compared to controls (8-arm-PEG-free as a negative control) 
and naringenin co-incubated metabolism (as a positive control). 
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5.2.7.4. Analysis of the effects of naringenin and 8-arm-PEG on intestinal tissue 
metabolism of felodipine 
At 3 hours, the metabolic activity of the excised intestinal tissues were halted by the 
addition of 1mL ice-cold acetonitrile (-20ºC) into each well. The fluid contents of the 
incubation system were transferred by pipeting into a separate labeled six-well plate. The 
excised intestinal tissues were further rinsed in 1mL acetonitrile to extract felodipine and 
its metabolites. The transferred fluid content was centrifuged at 4000g at 4ºC for 30 
minutes in a refrigerated centrifuge (Xiang Yi L-535RTM Centrifuge, Changsha, China) to 
precipitate the protein content. The supernatants were then filtered through a 0.22µm 
Cameo Acetate membrane filter (Millipore, Billerica, MA, USA) and subjected to UPLC 
analysis to identify and quantify felodipine content.  
 
5.2.8. In vivo animal studies to investigate the oral bioavailability-enhancing 
property of 8-arm-PEG 
With the initial results from in vitro and ex vivo studies demonstrating the inhibitory 
property of 8-arm-PEG on CYP3A4, the ability of 8-arm-PEG to inhibit in vivo CYP3A4 
activity and translate such inhibition to an increase in oral bioavailability was investigated 
in the Large White pig model. 
 
5.2.8.1. Procurement and habituation of pig specimens 
Four Large White female pigs weighing 29.2±0.8kg were purchased from Animal Nutrition 
and Products Institute of the Agricultural Research Council (Pretoria, Gauteng, South 
Africa) and housed in standard animal rooms (Central Animal Service Unit, University of 
the Witwatersrand, Johannesburg, South Africa) where they were maintained in a 12-hour 
light/darkness cycle. The pigs were ascertained healthy by veterinary experts, fed with 
commercial pig feed and monitored for adaptation to the new environment. They were 
allowed a 10-day habituation period during which they were domesticated through feeding 
and frequent visiting (Figure 5.3). This was done to acculturate the pigs to subsequent 
processes of catheter flushing and plasma sampling. 
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Figure 5.3: Typical habituation process of the procured Large White female pigs. 
 
5.2.8.2. Surgical catheterization for long-term repetitive blood sampling 
The four pigs weighing 28.5kg, 28.8kg, 29.4kg and 30kg, respectively were anaesthetized 
with ketamine (11mg/kg) and midazolam (0.3mg/kg) administered intramuscularly. 
Analgesia was maintained by intramuscular administration of buprenorphine (0.05mg/kg) 
and carprofen (4mg/kg). The pigs were then intubated under anesthesia with 2% 
isoflurane in 100% oxygen. A 7 french gauge double lumen 35cm catheter (CS-28702) 
(Arrow Deutschland GmdH, Erding, Germany) was surgically inserted into the jugular vein 
of each pig under aseptic conditions. An incision, dorsal to the jugular groove on the left 
lateral side of the neck was made to expose the jugular vein. The vein was isolated and 
the catheter inserted 10cm into the lumen of the vein via a blunt dissection. The lumen of 
the catheter was fastened to the wall of the vein employing a purse suture procedure. 
With the use of trocar, the remaining 25cm length of the catheter was tunneled 
subcutaneously to an exit point cranial to the dorsal aspect of the scapular. In order to 
limit excessive movement and kinking, the externalized injection ports of the catheter 
were sutured to the skin of the pig. The catheter was cleaned by withdrawal of blood 
through it, followed by flushing with heparinized saline (1000 IU/Liter of 0.9% saline). The 
surgical catheterization procedure is depicted in Figure 5.4. The animals were observed 
over a period of 1 hour for recovery from anesthesia and then allowed further 8 days to 
recover from the surgical procedure before the commencement of dosing and sampling. 
During this period, the catheter was flushed with heparinized saline (1000IU/L normal 
saline) every 12 hours to prevent blood coagulation and to maintain aseptic conditions. 
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 Figure 5.4: The surgical procedure for the jugular vein catheterization of experimental 
pigs depicting a) anesthesia and skin preparation for surgery, b)surgical incision into the 
jugular area, c) transverse catheterization through the neck tissue, d) isolation and 
catheterization of the jugular vein, e) subcutaneous tunneling of the catheter and skin 
suturing and f) recovery after 2 hours. 
 
5.2.8.3. Oral dosing of the pigs with the felodipine tablet matrix containing graded 
concentrations of 8-arm-PEG 
Dosing of the pigs was commenced after 10 post-surgery days. The jugular catheters 
were flushed with heparinized normal saline followed by blood sampling to obtain a pre-
dosing baseline sample for control analysis. The pigs were anesthetized with intravenous 
ketamine (4mg/kg) and midazolam (0.3mg/kg). Anesthesia was maintained by gaseous 
administration of 2% isoflurane in 100% oxygen via facemask inhalation. The pigs were 
then held in an upright position and intubated with a bore gastric tube via the mouth 
a
) 
b) 
c) d) 
e) f) 
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through the esophagus into the stomach. The felodipine tablet was then introduced via 
the tube and flushed down the stomach with 20mL of water. All intravenous felodipine 
dosing were performed through the jugular catheter. A minimum wash-out period of 96 
hours was allowed between felodipine administrations. With an average half-life of 8.16 
hours (Takanaga et al., 2000), this wash-out period allowed for the satisfactory plasma 
elimination of felodipine. A schematic detailing the dosing and the contents of the 
felodipine formulation is presented in Figure 5.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: A schematic illustrating the study design for the in vivo experimentation in the 
Large White pig model. 
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5.2.8.4. Blood sampling for quantitative analysis of felodipine 
Blood sampling from the pigs was preceded by catheter flushing with heparinized normal 
saline. For intravenous administration, samples were drawn after 0.1, 0.5, 1, 2, 3, 4, 5, 6, 
8, 10, 12, 16, 20 and 24 hours while sampling after oral dosing was performed at similar 
intervals but starting at 1 hour after dosing. All blood samples were immediately 
transferred into heparinized vacutainers (BD Vacutainers®, Franklin Lakes, NJ, USA) and 
stored at (4°C) when necessary but not for longer than 2 hours. The samples were 
thereafter centrifuged at 2000g for 20 minutes yielding a clear plasma supernatant which 
was pipetted with an adjustable calibrated micropipette (Boeco GmbH, Hamburg, 
Germany). All clear plasma samples were stored at -70°C until further analysis.  
 
5.2.8.5. Development of an Ultra Performance Liquid Chromatographic (UPLC) 
method for the quantitative determination of felodipine in plasma 
A method of quantitative determination of felodipine was developed employing Ultra 
Performance Liquid Chromatography (UPLC) (Waters® Acquity UPLC™ System, Milford, 
MA, USA). Isocratic baseline separation was achieved with the instrumental settings listed 
in Table 5.3. All solutions and solvents were filtered through a 0.22µm pore size Cameo 
Acetate membrane filter (Millipore Co., Billerica, MA, USA). Complete separation of 
felodipine and the internal standard were confirmed by three-dimensional 
chromatographic separation. 
 
Table 5.3: UPLC instrumental settings for the determination of felodipine in plasma 
samples. 
Parameters Values/Conditions 
 
Strong wash 
 
90%v/v acetonitrile : 10%
v/v water 
Weak wash 10%v/v water : 90%
v/v acetonitrile 
Mobile phase 0.025M potassium dihydrogen phosphate, 
pH 2.5 and acetonitrile (40:60) 
Flow-rate 0.2mL/min 
Column specification BEC C18 1.7µM, 2.1x50mm 
Injection volume 2µL 
Run time 
Internal Standard 
Column temperature 
Sample temperature 
Pump pressure 
Delta value 
Wavelength of absorption 
3 minutes 
10µg/mL phenacetin 
25°C 
25°C 
6000±500psi 
˂20 
200nm 
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5.2.8.6. Extraction of felodipine from plasma samples 
A procedure of extracting felodipine from plasma similar to that of Miglioranca and co-
workers (2005) was developed for further quantitative analysis. The procedure combined 
liquid-liquid and solid-phase extraction techniques for optimal results. Aliquots (0.5mL) of 
felodipine-containing pig plasma was transferred into polypropylene tubes followed by the 
addition of 2mL diethyl ether:hexane mixture (80:20v/v). The samples were then vortexed 
for 1 minute and centrifuged at 2000g for 5 minutes. The supernatant was transferred to 
clean propylene tubes. A further addition of 2mL diethyl ether:hexane mixture was 
performed on the lower layer, vortexed and centrifuged for further felodipine extraction. 
The supernatants were combined in clean propylene tubes and loaded onto acetonitrile-
conditioned Oasis® HLB cartridges enabled with the a Visiprep Vacuum Manifold (Waters 
Milford, MA, USA) followed by a further wash with 1mL diethyl ether:hexane mixture and 
collected in clean test tubes. The collected felodipine extracts were evaporated under 
nitrogen at 40°C. The dry residue was dissolved with 500µL acetonitrile and filtered 
through 0.22µm Cameo Acetate membrane filters. Equal volumes of the filtrate and the 
internal standard (phenacetin) were then transferred into UPLC vials, capped and placed 
in the autosampling compartment of the UPLC for analysis.  
 
5.2.8.7. Calibration standards and limits of quantification for plasma felodipine 
Stock solution of felodipine was prepared in acetonitrile at concentrations of 1mg/mL. The 
internal standard (phenacetin) solution of 10µg/mL was similarly prepared. Blank (drug-
free) pig plasma samples were spiked with serially diluted felodipine solution yielding final 
theoretical plasma felodipine concentrations of 0.2441 0.9760, 3.90625, 15.625, 31.25, 
62.5, 125, 250, 500 and 1000nmol/L. The spiked plasma samples were subjected to the 
extraction method described in Section 5.2.8.6. The ratio of the AUC (of the 
chromatogram) of felodipine/internal standard was profiled against the corresponding 
felodipine concentrations expressed in ng/mL. Linear regression and correlation 
coefficients were obtained by means of the least square method. The sensitivity of the 
method was assessed by employing a large number of serial dilutions and low felodipine 
concentrations were employed to estimate the lower limit of quantification. The limit of 
quantification according to Mandrioli and co-workers (2006) is the analyte concentration 
which produced chromatographic peaks with heights at least 3 times that of the baseline 
noise. 
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5.2.8.8. Validation of the extraction method 
Standard solutions of felodipine at three different concentrations were separately added to 
0.5mL blank plasma in order to obtain plasma felodipine concentrations of 100mmol/L, 
1µmol/L and 0.25nmol/L. The prepared mixtures were subjected to the described 
extraction procedure and analyzed by UPLC. By comparing the chromatogram AUC of 
the felodipine obtained employing the extraction method with those obtained from 
standard solutions at the same theoretical concentrations, the extraction yield (%) for the 
samples was calculated. Intra-day reproducibility was determined by multiple injections 
(N=3) during a 24-hour period while the inter-day uniformity was assessed by multiple 
injections of samples over 3 consecutive days (N=3) for each day. The within- and 
between-run precisions were determined as the Relative Standard Deviation (RSD) using 
Equation 5.4 where M is the mean. 
 
𝑅𝑆𝐷  % =
100𝑆𝐷
𝑀
              Equation 5.4 
 
The accuracy was assessed as the percentage Relative Error (RE) using Equation 5.5. 
 
𝑅𝐸  % =  𝐸 − 𝑇 (
100
𝑇
)             Equation 5.5 
 
where E is the experimentally determined felodipine concentration and T the theoretical 
concentration. 
 
5.3. Results and Discussion 
5.3.1. Assessment of the tablet formulatory properties of 8-arm-PEG 
The routine tableting formulation properties investigated with 8-arm-PEG indicated that 
the polymer has satisfactory tableting characteristics. Its possible inclusion in a tablet 
matrix may not negatively impact on the tablet features. The specific outcomes of the 
investigations are discussed in the following sub-sections. 
 
5.3.1.1. Formulation of the 8-arm-PEG tablet matrix by direct compression 
The triturated 8-arm-PEG powder was free-flowing and when compressed yielded 
uniform-sized and smooth-surfaced tablets. Compared to the brittle-textured powder, the 
tablets were sufficiently compact and robust. The ability of 8-arm-PEG to be easily 
compressed without the need for pre-compression granulation indicated its suitability as 
90 
 
an effective excipient in direct compression tableting. The tablets formed were free of 
tableting flaws such as capping, chipping and sticking. This was observed despite the 
non-inclusion of a lubricant, binder and/or anti-adherents. Due to the superior 
compactibility, capability of self-lubrication and non-adherence to the punch or the die 
wall, 8-arm-PEG possessed desirable properties for effective tableting. This is consistent 
with the pharmaceutical application of PEG as a lubricant, binder and/or a diluent to 
improve the rheological properties of tablet formulations and granules (Larhrib and Wells, 
1998). These observed properties confirmed the retention of the tablet-formulation 
properties of PEG in 8-arm-PEG as a derivative of PEG. 
 
5.3.1.2. Investigation of mass uniformity of the 8-arm-PEG tablet matrix   
The mass of 10 randomly selected 8-arm-PEG tablet matrices are listed in Table 5.4. 
Results show that the tablets had relatively uniform weights within the USP permitted 
range of 1%. This further confirmed the desirable tableting properties of 8-arm-PEG. The 
absence of capping and chipping in the compression process due to the free-flowing 
nature of 8-arm-PEG enhanced the mass uniformity of the tablets. 
 
Table 5.4: Evaluation of mass uniformity of 10 randomly selected 8-arm-PEG tablet 
matrices. 
Tablet Weight Weight 
deviation (%) 
 
1 
 
597.55 
 
0.02 
2 596.71 0.16 
3 599.83 0.35 
4 595.35 0.39 
5 598.11 0.07 
6 599.30 0.27 
7 597.56 0.02 
8 596.99 0.12 
9 598.17 0.08 
10 597.37 0.05 
 
 
5.3.1.3. Matrix Indentation Hardness 
The BHN values of equal mass (600mg) 8-arm-PEG and HMPC tablet matrices were 
compared. Results indicated that HPMC tablet matrices were slightly harder than 8-arm-
PEG tablet matrices although both compare favorably (Table 5.5). 
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Table 5.5: The comparative hardness of compressed 8-arm-PEG and HPMC. 
Tablets 8-arm-PEG  HPMC  
 Indentation Force (N) BHN Indentation Force (N) BHN 
 
1 
 
2.830 
 
1.460 
 
2.962 
 
1.526 
2 2.827 1.459 2.961 1.528 
3 2.829 1.460 2.959 1.527 
 
5.3.1.4. Comparative friability tests on 8-arm-PEG and HPMC tablet matrices 
The result of the friability tests is summarized in Table 5.6. The fact that the tests yielded 
results within the 1% limit with only 0.73% of the tablet mass lost after four minutes of 
friabilator rotation is another indication that 8-arm-PEG as an excipients can be employed 
to produce tablets with pharmaceutically acceptable hardness.  
 
Table 5.6: Instrumental settings and results of friability tests on 8-arm-PEG tablet 
matrices. 
Parameters for Friability Test Values  
 8-arm-PEG HPMC 
 
Number of Tablets used  
 
10 
 
10 
Test Duration (minutes) 4 4 
Weight of tablets before test 5937.32 5980.33 
Weight of tablets after test 5894.15 5951.74 
The difference (weight of dust) 43.17 28.59 
Friability (weight loss, %) 0.73 0.48 
 
The results thus depicted 8-arm-PEG as a potential multi-purposed pharmaceutical 
excipient with physicochemical and formulation properties compatible with tablet 
formulation requirements. 
 
5.3.1.5. Assessment of chemical structural changes of 8-arm-PEG due to direct 
compression 
Possible change to the structural and morphological configuration of 8-arm-PEG was 
verified. Polymeric materials often undergo complex stress under compression leading to 
successive and simultaneous molecular and atomic rearrangement, elastic and plastic 
deformation, fracture, formation and/or breakage of inter-particulate bonds, cold sintering, 
structural deformation among others (Baker et al., 2000). The response of individual 
pharmaceutical materials to compression depends on the physicochemical properties of 
the material. Crystalline materials may exhibit different responses compared to polymers 
and amorphous substances. Possible deformation to the molecular and structural 
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arrangement of 8-arm-PEG was therefore verified employing FTIR. The spectrum of 
powdered samples of 8-arm-PEG served as a control for comparing with the directly 
compressed 8-arm-PEG. As seen in Figure 5.6, the superimposed spectra exhibited 
visual similarity with a 99.98% spectral similarity between the powdered and directly 
compressed 8-arm-PEG samples. This suggested that 8-arm-PEG was structurally stable 
to direct compression within the limit of pressure applied (5 metric tons).  
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Figure 5.6: FTIR spectra of powdered and compressed 8-arm-PEG generated. 
 
5.3.2. The influence of 8-arm-PEG on in vitro felodipine release 
In vitro release profiles of felodipine from graded concentrations (0-100%w/w) of 8-arm-
PEG in HPMC is presented in Figure 5.7. The release pattern from HPMC (0% 8-arm-
PEG) was fairly consistent over 10 hours. In the 100% 8-arm-PEG matrix, there was an 
initial burst-release of 65% of felodipine in 1 hour. This may be attributed to the free 
aqueous solubility of 8-arm-PEG and deposition of surface drug on the tablet matrix. The 
subsequent phase of drug release was gradual over 3 hours suggesting dissolution rate-
dependent release of felodipine due to its poor water-solubility. In the other tablet 
matrices containing graded concentrations of 8-arm-PEG, felodipine release was 
generally faster with increasing concentration of 8-arm-PEG. 
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Figure 5.7: The influence of graded concentrations of 8-arm-PEG on in vitro felodipine 
release (N=3; S.D.<0.003 in all cases). 
 
5.3.3. The influence of 8-arm-PEG on the intestinal tissue metabolism of felodipine 
An ex vivo method for felodipine metabolism was developed employing pig intestinal 
tissue in order to assess the effects of 8-arm-PEG on intestinal tissue metabolism of 
felodipine. Results obtained from the ex vivo studies are shown in Figure 5.8. There was 
concentration-dependent inhibition of felodipine metabolism by naringenin such that at 
1mM concentration, complete inhibition of felodipine metabolism was observed. With the 
aid of Enzyme Kinetic Module software (SigmaPlot: Enzyme Kinetic Module, Systat 
Software Inc., Chicago, IL, USA), the IC50 was determined to be 179.88µM. When 
compared with results from the in vitro study where the IC50 value was 0.0332µM, 
naringenin appeared less potent. Several factors can be responsible for this. The 
incubation of felodipine and naringenin in HLM mixtures in the in vitro study provided 
direct contact with the enzyme, confining binding interactions between naringenin, 
felodipine and the enzyme. However, in the ex vivo studies, other enzymes and non-
enzyme protein entities were potentially capable of binding these substrates. Efflux 
proteins and cellular transporters such as p-glycoproteins are capable of interacting with 
chemical molecules (Cong et al., 2001). Although the binding affinities at different 
receptor sites vary, the existence of multiple binding sites in intestinal tissues would make 
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naringenin appear less potent at CYP3A4 sites just as higher felodipine concentrations 
are required for maximal metabolic activity. This can be said to account for the wide 
difference in the IC50 values of the in vitro and ex vivo felodipine metabolism inhibition by 
naringenin. 
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Figure 5.8: The influence of naringenin and 8-arm-PEG on intestinal tissue metabolism of 
felodipine (N=3; S.D.<0.01 in all cases). 
 
Results also show that 8-arm-PEG exerted inhibitory effects on felodipine metabolism by 
intestinal CYP3A4. Its IC50 value was 487.75µM. With an IC50 value of 7.22µM, the in vitro 
result demonstrated >50 times potency of 8-arm-PEG against felodipine metabolism. 
Similar factors may be responsible for the differences in the in vitro and ex vivo potencies 
of 8-arm-PEG. At a concentration corresponding to the ex vivo IC50, the pharmaceutical 
implication is that at a 0.5mM concentration, 8-arm-PEG has the potential of inhibiting the 
first-pass metabolism of felodipine by 50%. Given that the oral systemic bioavailability of 
felodipine is 15-20% with 80-85% metabolized by pre-systemic CYP3A4, 0.5mM 8-arm-
PEG thus has the potential of reducing this loss to 40-42.5% leading to 58.5-60% oral 
felodipine bioavailability. 
 
The European Centre for the Validation of Alternative Methods (ECVAM) promotes the 
scientific and regulatory acceptance of alternative methods which are of importance to the 
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biosciences and which reduce, refine or replace the use of laboratory animals (Eric et al., 
2001). The need to use co-factors at high concentrations for the in vitro functionality of 
HLM implies a physiologically disproportional condition for enzyme activity. This variation 
in physiological and biochemical environment may pose a significant challenge in 
extrapolating in vitro metabolic results for in vivo correlation. Metabolic studies employing 
intestinal tissues presents a closer in vivo behavior than the use of HLM because of the 
presence of an operable cell membrane and physiological and biochemical environment 
for intestinal enzyme activity. The use of caco-2 cell layer has also been promoted as a 
suitable alternative to in vitro HLM use. This however could also be challenging. 
According to Sun and co-workers (2002), inter-laboratory reproducibility of caco-2 cells is 
difficult. These cell layers also lack metabolic enzymes such as CYP3A4 at 
concentrations comparable to physiological values (Sun et al., 2002).  
 
The intestinal epithelium serves as the gatekeeper, controlling the passage of nutrients 
and xenobiotics out of the intestinal compartment into the system circulation (Masaoka et 
al., 2006). The rich expression of metabolic enzymes in intestinal tissues makes it a 
suitable model for drug metabolism studies (Kanter et al., 2005). The study of the 
intestinal enzyme development has revealed a higher level of similarity between human 
and pig CYP450 than other commonly used experimental animals including rat, mouse 
and rabbit (Shulman et al., 1998). Apart from the well-known similarity between pig and 
human gastrointestinal anatomy and physiology compared to other non-primate 
mammals, Shulman and co-workers (1998) concluded that the degree of small intestinal 
maturation and the similar intestinal enzyme distribution compared with that of the human 
infant suggest that the pig is an excellent model for studies of intestinal enzyme 
development, regulation and physiological functions. In a similar study, Anzenbacher and 
co-workers (1998) employed nifedipine oxidation and testosterone 6β-hydroxylation which 
are specific CYP3A4 markers to identify the presence of CYP3A4 in pigs with similar 
anatomical distribution as in humans.  
 
The present study was able to develop and apply a method for the preparation of slices 
from the intestines that retain adequate viability and activity. It was expected that a closer 
in vivo correlation would be obtainable through ex vivo tissue studies. It was also 
envisaged that in vivo metabolic activity will be replicated in freshly excised and cultured 
metabolic enzyme-expressed tissues in simulated physiologic fluids. Although all ex vivo 
activity including metabolism inhibition by test compounds may not necessarily be similar 
in magnitude in vivo, it was reasoned that a test inhibitor that failed ex vivo investigation 
may likely lack in vivo effectiveness (Kanter et al., 2002; 2005). This is important for 
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exclusion of unnecessary utilization of laboratory animals except where confirmatory 
studies are prompted by positive ex vivo results. 
 
5.3.4. The influence of 8-arm-PEG on the oral bioavailability of felodipine in the pig 
model 
5.3.4.1. Recovery of felodipine from pig plasma 
The developed extraction technique was applied for plasma felodipine extraction in order 
to remove plasma constituent interference and isolate felodipine from the plasma 
samples. Diethyl ether has poor aqueous solubility and is immiscible with water. Hexane 
with similar properties dissolves most non-polar organic compounds. Both compounds are 
volatile. Liquid-liquid extraction of felodipine from human and dog plasma through the 
application of a diethyl ether: hexane mixture has been reported to be effective for 
accurate analytical purposes (Kim et al., 2003; Miglioranca et al., 2005). In addition, the 
employment of Oasis HLB cartridges for the extraction provided an added advantage of 
impurity removal. The passage of the dissolved felodipine residue through 0.22µm Cameo 
Acetate membranes filter prepared the sample for UPLC analysis. 
 
5.3.4.2. Quantitative UPLC analysis of plasma felodipine 
A typical chromatogram depicting the retention of felodipine and phenacetin (internal 
standard) at 1.795±0.01 and 0.590±0.01 minutes respectively is displayed in Figure 5.9. 
This indicates that the extraction procedure was effective in isolating and eluting 
felodipine. A positive control for the extraction method containing blank plasma was also 
subjected to UPLC analysis yielding a chromatogram displayed in Figure 5.10. Complete 
separation of felodipine and the internal standard devoid of interference was confirmed 
through three-dimentional chromatography (Figure 5.11). 
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Figure 5.9: A typical UPLC chromatogram indicating the separation and retention time of 
felodipine (1.795) and the internal standard (0.590 minutes). 
 
 
Figure 5.10: A typical UPLC chromatogram obtained from felodipine-free pig plasma. 
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Figure 5.11: A three-dimensional chromatogram depicting a complete separation of 
felodipine and the internal standard and the absence of interference. 
 
5.3.4.3. Calibration curve and the limit of quantification of plasma felodipine 
Figure 5.12 shows the calibration curve for the quantitative determination of plasma 
felodipine. Plasma felodipine concentration range of 0.25-1000nmol/L offered satisfactory 
linearity (R2=0.99) with a lower limit of quantification of 0.244nmol/L. 
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Figure 5.12: A standard calibration curve generated for quantifying felodipine 
concentration from plasma samples employing UPLC (N=3; S.D.<0.002 in all cases). 
 
5.3.4.4. Method validation for plasma felodipine extraction and UPLC analysis 
The recovery of felodipine from plasma samples employing three sample concentrations 
of 0.25nmol/L, 1µmol/L and 1mmol/L evaluated over 3 consecutive days ranged from 
96.71 to 101.06%. The method validation data depicting the extraction efficiency, intra- 
and inter-day variation/uniformity are summarized in Table 5.7. 
 
Table 5.7: Data for assessing the extraction efficiency of plasma felodipine. 
Theoretical plasma 
felodipine concentration 
Intra-day  
 
Extraction yield 
(%) 
 
 
CV (%) 
Inter-day 
 
Extraction yield 
(%) 
 
 
 
 
 
CV (%) 
 
0.25nmol/L 
 
96.71±0.00008 
 
0.017 
 
96.67±0.00018 
  
0.0051 
1µmol/L 98.93±0.0006 0.015 98.90±0.00071  0.021 
1mmol/L 101.06±0.0031 0.0053 0.053±0.0041  0.047 
CV = Coefficient of Variation 
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5.3.4.5. The influence of graded concentrations of 8-arm-PEG on the oral 
bioavailability of felodipine in Large White pig model 
Figures 5.13 and 5.14 depict the influence of graded concentrations (2.5mg/kg, 5mg/kg 
and 10mg/kg) of 8-arm-PEG on the mean plasma concentration of felodipine following 
oral administration in pig models. Theoretical 100% absolute bioavailability which was 
equivalent to a peak plasma felodipine concentration (Cmax) of 33.137nmol/L was yielded 
following intravenous administration of 10mg felodipine. This served as the reference 
bioavailability measurement. The control inhibitor-free formulation produced a Cmax of 
6.310nmol/L which was equivalent to 19.04% absolute bioavailability. This agrees with 
literature values of oral felodipine bioavailability independent of the formulation to be 15-
20% (Dorne et al., 2003). Table 5.8 summarizes the effects of the enzyme inhibitors on 
the oral bioavailability of felodipine. 
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Figure 5.13: Plasma felodipine concentration- time profiles demonstrating the influence of 
graded concentrations of 8-arm-PEG and naringenin on oral felodipine bioavailability 
(N=5; S.D.<0.006 in all cases). 
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Figure 14: The effects of 8-arm-PEG on the oral bioavailability of felodipine in pigs 
(indicating peak plasma felodipine concentrations in nmol/L) 
 
 
As displayed in Figure 5.13, only the Cmax was significantly affected by the presence of the 
enzyme inhibitors while the time required for the orally administered felodipine to reach 
peak plasma concentration (tmax) and elimination profile were relatively unchanged. This 
suggested that the enzyme inhibition was limited to the pre-systemic sites allowing 
systemic felodipine clearance. This has a desirable drug delivery implication as the 
enzyme inhibition poses no toxicological significance at a reduced therapeutic dose. From 
Table 5.8, 8-arm-PEG caused a dose-dependent increase in the oral bioavailability of 
felodipine. Thus, with the inclusion of 10mg/kg of 8-arm-PEG in felodipine oral 
formulations, a 55.5% reduction in the conventional dose can achieve similar oral 
bioavailability. This implies that 4.5mg, in the presence of 10mg/kg 8-arm-PEG can 
achieve a Cmax of 10mg felodipine in conventional formulations. The required frequency of 
administration of the felodipine may, however, not be affected since the elimination profile 
was not altered by the presence of the enzyme inhibitor. 
 
  
A - Intravenous injection 
B - 10mg/kg 8-arm-PEG 
C - 0.1mg/kg Naringenin 
D - 5mg/kg 8-arm-PEG 
E - 2.5mg/kg 8-arm-PEG 
F - Control (Inhibitor- free) 
33.137 
13.340 
12.410 
 
10.880 
9.350 
6.310 
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Table 5.8: The effects of 8-arm-PEG on oral bioavailability of felodipine in pigs. 
Formulation content  Increase in oral felodipine 
bioavailability (%) 
 
2.5mg/kg 8-arm-PEG 
  
48.21 
5mg/kg 8-arm-PEG  72.48 
10mg/kg 8-arm-PEG  111.40 
 
 
Although alternative methods for routine drug absorption metabolism and other 
investigations are desirable to replace the use of laboratory animals, the use of 
experimental animals is necessary in certain cases where biochemical and physiological 
conditions closely resembling that in humans are desired. The use of pigs offers ease of 
breeding and handling advantages compared to non-human primates. This, in addition to 
anatomomical and morphological similarities in absorption physiology as mentioned 
earlier (Section 5.3.3), makes pigs the preferable models for drug absorption and 
metabolism studies. 
 
In a study of the effects of PEG 400 on p-glycoprotein efflux and enterocyte-based 
metabolism utilizing rat jejunal tissue mounted in diffusion chambers, Johnson and co-
workers (2002) reported that the presence of PEG 400 from a concentration between 1-
20%w/v exerted an inhibitory effect on p-glycoprotein efflux regardless of whether the 
polymer was added to the mucosal side, the serosal side or both sides of the intestinal 
tissue. Molecular interaction of PEG derivatives at such molecular level could only have 
suggested further investigations for enzymatic modulation since p-glycoprotein and 
intestinal CYP are closely related and synergistic in activities leading to first pass effects. 
 
5.4. Concluding Remarks 
 
This phase of the study investigated and demonstrated that 8-arm-PEG possesses multi-
purpose tableting features including self-lubricating, disintegrant and binding properties 
which are desirable in tableting. The ex vivo tissue metabolism studies also demonstrated 
that 8-arm-PEG is capable of inhibiting intestinal CYP3A4 significantly inhibiting the 
CYP3A4-dependent metabolism of felodipine. Employing pig models, the CYP3A4-
inhibiting features of 8-arm-PEG was successfully translated into improved oral felodipine 
bioavailability. The systemic elimination profiles of felodipine appeared unaltered by the 
presence of 8-arm-PEG suggesting that 8-arm-PEG exerts its inhibitory properties at pre-
systemic sites of drug absorption, thus allaying toxicological fears. This study, therefore, 
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proposes that 8-arm-PEG possesses the potential of significantly reducing the required 
oral dose of felodipine in clinical practice with no influence on the required frequency of 
drug administration. 
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CHAPTER SIX 
CONCLUSIONS AND RECOMMENDATIONS 
 
 
6.1. Conclusions 
 
The various biochemical, anatomical and physiological barriers to oral drug absorption 
and bioavailability have received considerable attention in drug delivery studies. The 
various approaches aimed at enhancing oral drug delivery were presented in this study. 
Being responsible for the metabolism and pre-systemic metabolism of greater than 50% 
of all administered drugs, the CYP enzyme family was identified as the single most 
important factor influencing oral drug delivery for enhanced bioavailability. Various oral 
drug delivery systems designed to enhance trans-mucosal permeation and afford 
modified drug release including site-targeting were described in this study. This study also 
noted that while these drug delivery systems significantly enhance oral drug absorption, 
only minimal effects were reported on absolute bioavailability. An effective inhibition of 
pre-systemic CYP presents a potentially effectual means of improving the oral 
bioavailability of the many poorly bioavailable drugs. 
 
The phenomena of food-drug and drug-drug interactions, often considered in clinical 
pharmacotherapy for toxicological purposes, have been known to occur via interferences 
with CYP activity. The principles involved in these interactions leading to altered plasma 
drug levels and modified pharmacokinetic profiles was explored with the intention of 
preventing pre-systemic CYP-induced drug loss. 
 
In this research, methods for in vitro utilization of human liver microsomes were validated 
through in vitro metabolism of felodipine and production of acetaminophen from CYP1A2-
catalyzed phenacetin o-deethylation.The study also confirmed that the component 
flavonoids, the major phytochemicals found in grapefruit juice are responsible for 
grapefruit-drug interactions. Specific flavonoids investigated including quercetin, 
naringenin and its glycoside, naringin did inhibit CYP-induced felodipine metabolism to 
varying degrees.  
 
Computational modeling and biomimetism was employed through a multi-disciplinary 
biochemical approach to simulate flavonoid-CYP3A4 reactions and consequently to 
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generate biocompatible and biodegradable pharmaceutical grade polymers with the 
potential of interacting with CYP3A4 metabolic activity. A number of the generated 
polymers demonstrated potent inhibitory ability against felodipine metabolism through in 
vitro and ex vivo studies with 8-arm-PEG being the most potent. The successful 
development and validation of an ex vivo technique employing pig intestinal tissue for 
drug metabolism also confirmed the in vitro results prompting animal studies. 
 
White Pig models, widely accepted to possess an acceptable level of similarity with 
human gastrointestinal physiology and anatomy, and closer biochemical similarities in 
cytochromal proteins, were employed to investigate the ability of 8-arm-PEG to translate 
CYP-3A4-inhibiting property to enhanced oral bioavailability of felodipine. A two-fold 
increase in peak plasma felodipine after 10mg/Kg 8-arm-PEG administration confirmed 8-
arm-PEG as a promising oral bioavailabilty enhancer. 
 
6.2. Recommendations 
 
Due to the widely held fear of toxicological consequences of CYP inhibition more 
extensive research is required to confirm that prospective oral bioavailability enhancers 
are not absorbed thus localizing enzyme inhibition to pre-systemic sites alone. The roles 
of gastrointestinal CYP also need to be further studied in order to establish its roles in 
detoxification and the safety in its activity inhibition. 
 
The association of intestinal CYP with other enzymes and efflux proteins may also arouse 
research curiosity. It may be necessary to investigate the effects of 8-arm-PEG on other 
physiologic enzymes and proteins in order to ascertain its absolute safety. Further studies 
may also be advisable employing primates for a closer clinical extrapolation. Importantly, 
studies with human subjects are recommended to ascertain the ultimate pharmaceutical 
applicability of 8-arm-PEG in improving the oral bioavailability of drugs. 
 
This study presents the potential utility of 8-arm-PEG in enhancing the oral bioavailability 
of CYP3A4 substrates. The cost-effectiveness of its use and the pharmaco-economic 
considerations are worth further research. The results of this study are however novel and 
very promising. It is believed that the outcome of this study will be of significant value to 
the polymer scientist, drug delivery expert and the toxicologist. 
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